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Abstract: The majority of critically ill intensive care unit (ICU) patients with severe sepsis develop
ICU-acquired weakness (ICUAW) characterized by loss of muscle mass, reduction in myofiber size
and decreased muscle strength leading to persisting physical impairment. This phenotype results
from a dysregulated protein homeostasis with increased protein degradation and decreased protein
synthesis, eventually causing a decrease in muscle structural proteins. The ubiquitin proteasome
system (UPS) is the predominant protein-degrading system in muscle that is activated during
diverse muscle atrophy conditions, e.g., inflammation. The specificity of UPS-mediated protein
degradation is assured by E3 ubiquitin ligases, such as atrogin-1 and MuRF1, which target structural
and contractile proteins, proteins involved in energy metabolism and transcription factors for UPS-
dependent degradation. Although the regulation of activity and function of E3 ubiquitin ligases
in inflammation-induced muscle atrophy is well perceived, the contribution of the proteasome to
muscle atrophy during inflammation is still elusive. During inflammation, a shift from standard-
to immunoproteasome was described; however, to which extent this contributes to muscle wasting
and whether this changes targeting of specific muscular proteins is not well described. This review
summarizes the function of the main proinflammatory cytokines and acute phase response proteins
and their signaling pathways in inflammation-induced muscle atrophy with a focus on UPS-mediated
protein degradation in muscle during sepsis. The regulation and target-specificity of the main E3
ubiquitin ligases in muscle atrophy and their mode of action on myofibrillar proteins will be reported.
The function of the standard- and immunoproteasome in inflammation-induced muscle atrophy will
be described and the effects of proteasome-inhibitors as treatment strategies will be discussed.
Keywords: ubiquitin-proteasome system; proteostasis in skeletal muscle; muscle wasting;
ICUAW; autoinflammation
1. Introduction
The skeletal muscle contributes approximately 40% of our body weight and is one of
the biggest organs of our body in terms of mass and protein content. Nevertheless, the
mass of skeletal muscle is highly dynamic and depends on physiological and pathological
conditions such as postnatal and adolescent growth, exercise, nutrition, aging, cancer or
inflammation. Physiological homeostasis of skeletal muscle is determined by anabolic
and catabolic protein metabolism controlled by extracellular and intracellular signals.
Protein homeostasis (proteostasis), in general, represents the critical balance of protein syn-
thesis, quality control and degradation. In any cell, two major intracellular protein degra-
dation systems exist: the ubiquitin proteasome system (UPS) and the autophagy-lysosomal
pathway (ALP). Whereas ALP engages lysosomal proteolytic enzymes to degrade mem-
brane proteins and protein aggregates, the UPS represents a cytosolic and nuclear machin-
ery involved in the targeted degradation of cytosolic and nuclear proteins. Muscle contrac-
tile proteins are degraded by the UPS, the ALP, and proteases such as calpains and cas-
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pases [1]. These pathways are also coordinately activated during physiological and patho-
logical muscle atrophy. Physiological muscle atrophy mainly occurs due to unloading, such
as in athletes with training breaks, people with low physical activity, those having a seden-
tary life style or those with reduced gravitational load such as astronauts during space flight.
It is also observed during intentional short- and long-term [2,3] head-down-tilt bed rest,
used as space flight analogs to investigate mechanisms and counter measures of muscle at-
rophy caused by zero gravity. Pathological atrophy is caused by fasting, loss of innervation,
due to neurological diseases such as stroke, and in many diseases (e.g., cancer [4], end-stage
renal disease [5] and sepsis [6]). Whether or not age-related muscle atrophy can be classi-
fied as a physiological or a pathological condition warrants a detailed clinical assessment.
Normal ageing of muscle is thought to begin around 25 years of age and to accelerate
thereafter. Age-related muscle atrophy can be caused by numerous conditions, including
a decline in physical activity, low-grade systemic inflammation, a reduction in anabolic
hormones and a decrease in appetite and/or food intake [7,8]. To what extent these factors
are related to normal ageing and are therefore physiological is not well defined. This sit-
uation is aggravated by a higher incidence of comorbidities and chronic medication in
aged people. In light of population ageing and associated health risks, a clear distinction
between physiological and pathological age-related muscle atrophy is needed.
Cellular organelles, large protein aggregates or proteins of the plasma membrane
are transported to lysosomes for degradation by ALP in skeletal muscle under normal
conditions as well as in response to stress stimuli [9]. The critical role of the ALP in skeletal
muscle homeostasis and function is supported by the observation that several muscle
diseases that are accompanied by atrophy or dystrophy show an increase in autophago-
somes within myofibers promoting disruption of myofibril organization. A well-balanced
autophagic flux is of great importance to prevent the loss of muscle mass since both ALP
activation and inhibition exhibit a similar atrophic phenotype with only varying speed
of onset [10,11]. Loss or impairment of muscle mass due to atrophy by perturbed pro-
teostasis causes severe pathologies. Maintenance of muscle homeostasis is thus of utmost
importance to human health, and the clinical burden caused by muscle wasting is high.
However, our understanding of these processes is limited. One of the most devastating con-
sequences during inflammation and critical illness is muscle wasting and long persisting
weakness. The role of the UPS aside from its key E3 ubiquitin ligases is not well understood.
In this review, we will address the current knowledge on the role of the proteasome in
inflammation-induced muscle wasting.
1.1. Intensive Care Unit-Acquired Weakness (ICUAW)
Weakness and muscle atrophy have long been recognized as bystanders in patients
with severe life-threatening infections and cancer. Many critically ill patients at the intensive
care unit (ICU) suffer from muscle weakness. This syndrome is called intensive care unit-
acquired weakness (ICUAW) and is defined as clinically detected weakness in critically ill
patients where the only plausible etiology is the critical illness itself, which may persist
long after ICU discharge [12]. In addition, the occurrence of ICUAW must follow the onset
of critical illness to exclude other causes of weakness. The reduced muscle strength is
typically observed after the acute phase of the disease, e.g., when sedation of the patients
is stopped [13]. Affected patients reveal a pronounced lack of movement, which is in
contrast to their level of consciousness and cooperativity. Physical examination shows
diffuse, symmetric weakness involving all extremities and the diaphragm. ICUAW occurs
in approximately 40% of critically ill patients [14], which prolongs ICU and hospital stay,
and, due to weakness of the diaphragm and the auxiliary respiratory muscles, increases
the duration of mechanical ventilation and ventilator weaning. ICUAW also increases
ICU and hospital mortality [15–17]. Sustained weakness results in functional limitations
as well as decreased employment rates and quality of life [18,19]. Post-ICU treatment,
these patients often experience limitations even in simple daily activities such as getting
out of bed, getting out of a chair and going up and down stairs. Muscle atrophy is the
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major contributor of ICUAW. Critically ill patients lose as much as 20% of muscle mass
in the first 10 days of ICU stay [20]. Whereas physiological muscle atrophy or atrophy
conditions under which unloading is the predominant cause are usually reversible and
respond well to physiotherapy and exercise, sequelae of ICUAW may persist for years
after ICU or hospital discharge [19]. The cause of ICUAW is currently unknown. A recent
meta-analysis of 14 prospective cohort studies revealed that disease severity (i.e., Acute
Physiology and Chronic Health Evaluation II score), female sex, sepsis, multiple organ
failure, hyperglycemia, electrolyte disturbances, parenteral nutrition, medication (e.g.,
neuromuscular blocking agents, aminoglycoside antibiotics and norepinephrine) and
long-lasting mechanical ventilation are risk factors for ICUAW [21]. For example, during
ICU stay, 25% to 75% of mechanically ventilated, critically ill patients developed severe
skeletal muscle atrophy and weakness [12]. Nutrition is a further important issue for
critically ill patients because adequate feeding and outcome are associated with each other.
Both underfeeding and overfeeding appear to be harmful to critically ill patients suggesting
that caloric goals need to be correctly estimated [22]. Whether protein intake or absorption
contribute to ICUAW is not well defined. Observational studies have shown that feeding
higher as opposed to lower amounts of protein was associated with reductions in morbidity
and mortality [22–24]. However, only few randomized controlled trials on enhanced
protein administration are available, and those studies show only limited or no effects on
functional and clinical outcomes [25–27]. Further studies are needed to clarify the relation
between nutrition, protein intake and ICUAW. During ICU treatment, many critically ill
patients have ionized calcium levels outside the reference range. These abnormal values are
likely a marker of disease severity in critical illness. For example, ionized calcium values
are often low in critically ill patients, especially those with sepsis, but often normalize
with recovery [28,29]. Although early studies found that hypocalcemia is a risk factor
for mortality in ICU patients [28,29], later studies that used more sophisticated statistical
methods showed that ionized calcium concentration is not associated with hospital or ICU
mortality [30]. Whether or not calcium levels should be corrected to target values warrants
further investigation.
As 60–100% of patients with sepsis, which is defined as a life-threatening organ dys-
function caused by a dysregulated host response to an infection, develop ICUAW, this
risk factor appears to be of utmost importance [31,32]. Sepsis is the most frequent cause
of admission to an ICU and the most common cause of death in ICU [33]. Data from
the Intensive Care over Nations audit (ICON) and the Sepsis Occurrence in Acutely ill
Patients study (SOAP) revealed that approximately 30% of critically ill patients are either
admitted with or develop sepsis during ICU treatment [34,35]. The association between
infection, host response and ICUAW is supported by clinical observations obtained from
critically ill patients affected with corona virus disease 2019 (COVID-19). In approxi-
mately 70% of COVID-19 patients, muscle weakness occurred during ICU treatment [36,37].
Because systemic inflammation in sepsis causes ICUAW and muscle atrophy in almost all
affected patients, it is important to better understand the involved pathomechanisms to
prevent or stop the disease and its progression. In this review, we mainly focus on ICUAW
of skeletal muscle and the effects sepsis and inflammation have on it. How ICUAW affects
the respiratory muscle and which animal models exist to investigate this pathology have
been reviewed recently [38]. It is important to note that ICUAW is a multifactorial disease
that cannot only be related to inflammation. Some of the most important causes of muscle
atrophy, i.e., immobilization, a dysfunctioning nervous system, and inadequate nutrition
have also been shown to contribute to ICUAW. Knowledge about central pathways mediat-
ing these disease mechanisms even if they have not been directly associated with ICUAW
is important and will also be addressed.
Skeletal muscle is a great reservoir for amino acids that support the function of
vital organs, including brain, heart and liver. Muscle breakdown may therefore protect
the organism especially during the early phase of life-threatening diseases, especially
sepsis. However, during sustained muscle wasting, as occurring in long-term critical
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illness, the negative effects of muscle atrophy and weakness will most certainly outweigh
any beneficial effects of muscle protein breakdown. This also argues for an immediate
initiation of therapies that aim to maintain muscle homeostasis. However, at this early time
point, many patients are still mechanically ventilated and are not accessible for standard
diagnostic procedures, which may delay the diagnosis of ICUAW and therefore specific
therapies or even inclusion into clinical trials.
The decline in muscle mass of critically ill patients can be attributed to a reduction in
the cross-sectional area of myofibers (MCSA). As shown by analyses of biopsies from the
vastus lateralis muscle of ICU patients, a reduction in the MCSA of all fiber types can be
found, and this reduction is more pronounced in fast twitch/type II-myofibers as compared
with slow twitch/type I-myofibers. This was accompanied by a reduction in fast and
slow myosin heavy chain (MyHC) protein and mRNA expression [39]. Myofiber atrophy
leads to a reduction in muscle function with decreased specific force and endurance [40].
A disturbed protein homeostasis with increased degradation of structural proteins, such
as MyHC, and reduced protein synthesis contribute to muscle wasting in critical illness.
These disease mechanisms occur very early during the disease process [39,41–43], which
is at least partially explained by the observation that infection-induced sepsis leads to an
immediate and systemic increase in proinflammatory cytokines and acute phase response
proteins. Since both proinflammatory cytokines and acute phase response proteins directly
act on muscle homeostasis, early muscle pathologies are also expected.
The primary cause of muscle loss in atrophy is the strongly increased proteolysis
of myofibrils, since more than 70% of muscle protein consists of myofibrillar proteins.
The UPS and particularly E3 ubiquitin ligases play an important role in this process [44,45].
Myofibrils are highly organized structures consisting of thin and thick filaments that repeat
in the contractile units called sarcomeres [46]. Because of that, their disassembly and
breakdown is a complex and coordinated process comprising many different pathways,
which will be discussed in the following paragraphs; however, we will mainly focus on
the UPS.
1.2. The Ubiquitin Proteasome System
The majority of misfolded or otherwise damaged proteins in cells are targeted for
degradation by the UPS. In addition, the abundance of myriads of regulator molecules
including cyclins, transcription factors or kinases involved in signal transduction are under
its control. The UPS generates peptides for major histocompatibility complex (MHC) class
I antigen presentation and is thus also an integral part of our immune system [47].
For degradation by proteasomes, proteins need to be post-translationally labeled
with the small modifier ubiquitin. Ubiquitin modification is a sophisticated three-step
enzymatic cascade involving ubiquitin activation, conjugation and ligation to a protein
substrate. The ubiquitin-activating enzyme E1 activates ubiquitin in an ATP-dependent
manner to form a thioester and transfers the so modified ubiquitin to an E2 ubiquitin-
conjugating enzyme. The E2 enzyme in turn interacts with its cognate E3 ubiquitin ligase
to transfer the ubiquitin moiety covalently on a substrate protein via an isopeptide bond.
This process is run several times to generate ubiquitin chains of at least four ubiquitin
moieties on substrates, which are often linked at lysine 48 (K48) of the ubiquitin amino
acid sequence to be recognized by the proteasome. Substrate specificity is assured by more
than 600 E3 ubiquitin ligases that are encoded in the human genome. This process can be
counteracted by deubiquitinating enzymes (DUBs) that may preserve the substrate from
degradation (Figure 1) [48].
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covalently on a protein substrate. This thioester cascade has to run several times to form ubiquitin
chains. Deubiquitinating enzymes (DUBs) can counteract this process to control protein degradation
and recycle ubiquitin. Protein substrates modified by lysine 48 (K48)-linked ubiquitin chains are
marked for degradation by different proteasome isoforms, such as standard proteasomes, immuno-
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Protein substrates with K48-linke l i iti i rec nized for degra-
dation by t t e. This multi-subunit enzyme complex is generally built
of two subcomplexes: the 20S proteasom c re complex containing the active site sub-
units (standard proteasome) and the 19S regulatory complex consisting of subunits for
substrate recognition, deubiquitination, unfolding and translocation into the proteolytic
cavity. The attached ubiquitin is recognized by ubiquitin-binding domain proteins that
function as ubiquitin receptors and decode the signal into various cellular responses [49].
Here, different ubiquitin acceptors recognize ubiquitin-modified protein substrates for
degradation by proteasomes either as part of the 19S complex (subunits Rpn1, Rpn10,
Rpn13 and Rpt5) or as shuttle proteins by the Dsk2, Rad23 or DDI family members [50].
The architecture of the 20S core complex is conserved from yeast to men with four staggered
rings of seven subunits each. The two outer rings comprise seven different α-subunits,
and the two inner rings consist of seven different β-subunits with the three active sites
β1, β2 and β5 conferring the trypsin-like, the caspase-like and the chymotrypsin-like
activities, respectively. Depending on cell type and tissue, proteasomes display a modular
composition with isoforms that have either alternative active sites or regulator complexes
or both (Figure 1). Immunoproteasomes incorporate the alternative catalytic subunits
β1i (LMP2, PSMB9), β2i (MECL-1, PSMB10) and β5i (LMP7, PSMB8). In comparison to
standard proteasomes, the assembly of immunoproteasome is significantly accelerated
since β5i binds directly to the proteasome maturation protein (POMP), enabling the cell to
rapidly adjust the proteolytic capacity and dynamically adapt the immune response [51].
Furthermore, the cleavage occurs more specifically after basic and hydrophobic residues,
which enhances the processing of MHC class I antigens [52,53]. The altered cleavage site
preference results additionally in the improvement of specific epitope amounts [54]. It was
proposed that a major source for MHC class I epitopes are so-called defective ribosomal
products (DRiPs), newly translated polypeptides that are immediately polyubiquitinated
and allow for a very fast peptide presentation irrespective of the cellular localization of the
proteins [55,56]. Nevertheless, antigenic peptides for MHC class I antigen presentation can
be generated from functional proteins as well [57].
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Besides that, intermediate- or mixed-type-proteasomes exist, which only contain one
or two inducible catalytic subunits. They are predominantly found in tissues with high
protein turnover such as tumoral tissue or the liver [58–60]. Different proteasome isoforms
may coexist in cells and tissues. In muscle cells, standard proteasomes represent the typical
proteasome population; however, the distribution of other proteasome isoforms in muscle
is poorly understood.
Furthermore, the activity of the proteasome can be adjusted by association of different
regulatory particles apart from 19S (PA700), namely PA28αβ, PA28γ and PA200, to one
or both ends of the 20S core complex [61]. Out of those, only the activator PA28αβ is
induced by proinflammatory signals and therefore often linked to immunoproteasomes in
the literature, but it is found ubiquitously in all tissues [54]. Association of PA28 at one
side of a proteasome complex results in so-called hybrid proteasomes (Figure 1).
Proteasome isoforms such as immunoproteasomes or hybrid proteasomes have been
shown to confer altered proteolytic activities, to be involved in antigen presentation as well
as in clearance of damaged proteins in the course of inflammatory signaling [47,52,62,63].
By the altered breakdown of all polyubiquitinated proteins, immunoproteasomes also
affect various signaling pathways via modifying the turnover rate of regulators [47,62].
2. Regulation of UPS Expression by NRF1 and Other Transcription Factors
Proteasome formation occurs upon de novo synthesis via sophisticated assembly
programs dependent on different signaling pathways and transcriptional programs [64,65].
Cellular requirements for proteolytic capacities can be adapted by these programs for UPS
factors as well as proteasome isoforms. One of these transcriptional programs is controlled
by the transcription factor nuclear factor erythroid 2-related factor 1 (NRF1), encoded
by the NFE2L1 gene, through a bidirectional regulatory feedback loop. NRF1 belongs
to the Cap’n’Collar basic leucine zipper (CNC-bZIP) family and is a master regulator of
adapted standard proteasome gene expression upon proteasome impairment as well as the
antioxidant response and proteostasis in mammalian cells [52,66]. This so-called bounce
back response of proteasomal gene activation following diminished proteasome activity is
a convergent evolutionary strategy with RPN4 in yeast [67], SKN-1A in C. elegans [68] and
Cnc-C in drosophila [69]. The two best described isoforms of NRF1 are human TCF11 (772
amino acids) and NRF1a in mice missing one exon (742 amino acids). Similar to all CNC-
bZIP transcription factors, NRF1 forms dimeric complexes predominantly with small Maf
(musculoaponeurotic fibrosarcoma) proteins and binds to antioxidant-response elements
(ARE) in the promoter regions of its cytoprotective target genes [70]. Deletion of Nrf1 in
mice is embryonic lethal due to defects in erythropoiesis and fetal liver hematopoiesis [71].
With its hydrophobic N-terminal domain (NTD), TCF11/NRF1 is tethered to the
membrane of the endoplasmic reticulum (ER) [72,73]. The bulk of TCF11/NRF1 includ-
ing the C-terminal DNA-binding site is located in the ER lumen [74], and some of the
luminal domains are extensively N-glycosylated [75]. Due to its permanent removal by
the ER-associated degradation (ERAD) system, TCF11/NRF1 has a short half-life under
unstressed conditions [76]. Here, it is ubiquitinated by the ER-associated E3 ubiquitin ligase
HMG-CoA (β-Hydroxy β-methylglutaryl-CoA) reductase degradation protein 1 (HRD1),
extracted from the membrane by the AAA ATPase (ATPases associated with diverse cellu-
lar activities) p97/valosin containing protein (VCP) and translocated to the cytosol, where
it is finally degraded by proteasomes [74,76]. When the proteasomal activity is impaired or
when cells face other proteotoxic insults leading to oxidative stress [77], TCF11/NRF1 is
stabilized and processed to its active form, which translocates to the nucleus and increases
the expression of its target genes. Therefore, it is deglycosylated by N-glycanase 1 (NGLY1)
in the cytosol [78,79]. For a long time, it was unclear which protease was responsible for
the subsequent TCF11/NRF1 cleavage and activation, with calpain-1 and the proteasome
being the most discussed and promising candidates [80,81]. However, Vangala and col-
leagues demonstrated that TCF11/NRF1 can be activated independently from proteasome
activity [82], and we showed that calpain-1/2 is involved in TCF11/NRF1 degradation, but
Biomolecules 2021, 11, 1327 7 of 42
not activation under standard conditions [83]. The puzzle was solved when the aspartic
protease DNA-damage inducible 1 homolog 2 (DDI2) was found to cleave TCF11/NRF1
between Trp-103 and Leu-104 at the N-terminal transmembrane domain (TMD) [74,84].
By now, it is also known that polyubiquitination is a prerequisite for proteolytic cleavage
to define DDI2 as an ubiquitin-directed endoprotease [85,86].
Two other CNC-bZIP transcription factors closely related to NRF1 are NRF2 and
NRF3. NRF2 is a master regulator of the antioxidative response that plays a key role in the
maintenance of cellular redox homeostasis. Although both proteins have unique biological
functions, NRF2 has also been shown to induce the expression of several proteasomal
subunits, for example, in mice treated with high doses of antioxidants [87] or in colon cancer
cells [88]. However, it is well known that NRF1 is the main regulator of adapted proteasome
expression in response to proteasome impairment. In denervation-induced muscle atrophy
in mice, an increased amount and activity of all catalytic standard proteasome subunits
was observed, which can be attributed to elevated NRF1 protein levels in muscle tissue
lysates [89–91].
NRF3 function has been implicated in tumorigenesis and cancer malignancy by up-
regulation of POMP and proteasome assembly. NRF1 and NRF3 bind complementarily to
promoters of proteasome genes; however, NRF3 can suppress translation of NRF1 by the
NRF3-CPEB3-NRF1 translational repression axis (for review, see [92]).
Besides the three discussed NRF transcription factor family members, other transcrip-
tion factors were reported to control constitutive proteasome gene expression including
nuclear transcription factor Y (NF-Y) [93], forkhead box class O family members of tran-
scription factors (FOXO 1-4) [94,95] and signal transducer and activator of transcription 3
(STAT3) [96]. However, those transcription factors regulate the expression of only a specific
set of proteasome subunits and depend on the cellular condition and the cell type [97].
Since all proteasomal subunits except RPN10 (PSMD4) are thought to only exist within
their respective complex in cells and unassembled subunits are degraded, it is not clear how
the upregulation of single subunits contributes to the number of complete proteasomes.
These data indicate that subunit homeostasis is eventually sensed by transcriptional control
circuits, as described above [92,98].
Apart from transcriptional regulation, proteasome abundance is regulated by au-
tophagy in dependence of carbon and nitrogen sources most likely via mTOR and NRF1 [99].
However, the current knowledge about these regulatory mechanisms is limited and more
studies have to be conducted in the future.
Immunoproteasomes are commonly expressed in cells of the immune system, but
they can also be induced in non-immune cells upon exposure to proinflammatory cy-
tokines such as interferons (IFN) [100] or tumor necrosis factor (TNF) [101,102], environ-
mental stress (e.g., heat shock [103]), aging [104] or neurodegenerative diseases [105,106].
Additionally, exogenous IFN-α and IFN-β as well as endogenous virus-induced type I IFNs
were also shown to increase immunoproteasome formation in cells and in vivo [107,108].
The genes of β1i (PSMB9) and β5i (PSMB8) are encoded within the MHC class II region
and are continuously activated in immune cells by binding of a STAT1-IRF1-dimer to their
promoter regions [60,109]. By the accelerated breakdown of polyubiquitinated proteins,
immunoproteasomes may in turn affect various signaling pathways via modifying the
turnover rate of regulators [47,62].
3. Protein Turnover in Muscle Is Regulated by a Precisely Acting Protein
Degradation Pathway
In vertebrates, skeletal muscles are attached to bones by tendons, and they assure
motion of body parts relative to each other, stability and protection of internal organs.
Skeletal muscles are composed of bundled long multinuclear myocytes that contain a
precisely aligned filamentous system called myofibrils. These myofibrils are responsible
for force generation [110]. The smallest functional unit in myofibrils is the sarcomere,
which is a repetitive unit between two Z-lines. It mainly contains thick filaments, such as
myosin, and thin filaments, such as actin (Figure 2). Myosin is composed of two heavy
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chains (MyHC) and two pairs of regulatory (MyLC2) and essential (MyLC1) light chains,
and contains an N-terminal head domain, the neck domain and a C-terminal α-helical tail
domain. The myosin head contains the motor domain that binds actin and hydrolyzes
adenosine triphosphate (ATP) to generate force, and its neck domain links the head and tail
domains and facilitates binding with MyLCs to MyHC [110]. At the center of the sarcomere,
additional structural and regulatory proteins, such as MyLCs, and myosin-binding protein
C (MyBP-C), which periodically bind to the thick filaments and are required for myofibril
stability and normal contractility [111,112], stabilize myosin thick filaments. The thin
filaments actin, titin and nebulin are anchored to the sarcomere at the Z-band. The protein
tropomyosin covers the myosin-binding sites of actin. The myosin head can only bind
to actin when tropomyosin is removed from its binding site. This is realized by troponin
that is aligned at intervals along the actin filaments. Troponin is composed of the three
components troponin-T, troponin-I and troponin-C, and represents the on-off switch of
muscle contraction [110]. Muscle contraction is activated by calcium-influx into the cytosol.
Calcium ions in turn bind troponin-C and cause displacement of troponin-T and troponin-I
from tropomyosin, which exposes myosin-binding sites on actin. When myosin heads bind
to actin, ATP is hydrolyzed causing cross-bridge cycling with sliding of the thick over the
thin filaments. This causes shortening of the sarcomeres and therefore myofibers, which
results in movement. The thin filaments bind desmin via cross-linking proteins, such as
α-actinin at the Z-bands. The muscle-specific type III intermediate filament (IF) desmin is
essential for a proper muscular structure and function. Because desmin IF connects adjacent
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3.1. The Role of Calpains and the UPS in Muscle Protein Degradation
The complex structure and function of myofibrils implies that pathways involved
in sarcomere disassembly and degradation are equally complicated. Because myofiber
atrophy occurs while the muscle is still contracting, it appears important for the organism
that the muscle keeps its functionality. Therefore, the process of myofiber degradation
needs to be tightly controlled. Groundbreaking work from the groups of Goldberg, Glass
and Cohen has shown that muscle atrophy is a very well-organized step-wise process.
Solomon and Goldberg had already shown in 1996 that the proteasome efficiently de-
grades monomeric myosin, actin, troponin and tropomyosin, but that it does not break
down actomyosin complexes or intact myofibrils. This observation implicates that proteins
contained in multiprotein complexes or myofibrils need to be disassembled first before
they can be targeted by the proteasome [44]. This disassembly is realized by proteases
such as calpains or caspases that have been demonstrated to accelerate the disassembly
of myofibrills [115,116]. This in turn allows proteases, E3 ubiquitin ligases and the pro-
teasome to access monomeric actin, myosin and other associated proteins [117] (Figure 2).
Although calpain [118] or caspase-3 [116] are thought to initiate myofibril breakdown,
this assumption has not been proven in vivo, to date. Since the calpain- and caspase-
system interact with each other, it is likely that both systems cooperate in muscle atrophy
and that the impact of the one or the other may differ in individual conditions [119].
Several studies implicate that these proteases predominantly degrade desmin filaments
and that the subsequent myofibril breakdown is mediated by the UPS [117]. For example,
in vitro studies revealed that calpain-1 specifically cleaves isolated desmin, but not actin
or myosin. Once phosphorylated and ubiquitinated, desmin is preferentially and more
rapidly degraded. However, since calpain-1 does not contain a ubiquitin-binding domain,
this is probably due to conformational changes [114,117,120]. Besides that, glycogen syn-
thase kinase-3β (GSK-3β)-mediated desmin phosphorylation was shown to be required
for its calpain-1-mediated depolymerization, and the subsequent myofibril destruction.
Accordingly, GSK-3β inhibition in mice prevented desmin phosphorylation and depolymer-
ization, and blocked atrophy upon fasting or denervation. GSK-3β activation is therefore
an early step in muscle atrophy [120]. However, whether GSK-3β plays a role in ICUAW
has not been reported.
Calpains are non-lysosomal cysteine proteases activated by calcium binding.
Almost sixty years ago, they were first isolated from rat brains [121]. Besides the two
ubiquitously expressed isoforms of calpain proteases, µ- and m-calpain (or calpain-1 and
-2), the calpain proteolytic system comprises the small regulatory subunit CAPNS1 and the
endogenous inhibitor calpastatin [122]. However, 15 other calpain isoforms with multiple
splice variants and different tissue specificity exist [123]. Calpain-3 (CAPN3) is specifi-
cally expressed in skeletal muscle, and its dysfunction is linked to limb-girdle muscular
dystrophy type 2A [124,125]. In addition, several studies revealed that calpain-3 levels
are decreased in different atrophy conditions suggesting a unique or even contrary role of
calpain-3 as compared to that of calpain-1/2, whose expression is increased in various atro-
phy conditions [119,126]. Calpains are modulatory proteases with little cleavage sequence
specificity and limited proteolysis of their substrates; therefore, they are thought to mainly
fulfill regulatory functions in physiological and pathological cellular processes [127,128].
The function of calpains in muscle wasting remains controversial. Shenkman et al. observed
that inhibition of calpain-1 leads to muscle sparing and reduced protein ubiquitination
in unloading-induced muscle atrophy in rats [129]. Similar observations were made after
downregulation of calpain-1 by shRNA in fasting- or denervation-induced muscle atrophy,
which also attenuates desmin loss and myofibril breakdown, but results in accumulation
of phosphorylated desmin IF [120]. Ex vivo experiments using rat diaphragm muscle
revealed that activation of calpain increased the total protein degradation rate, which was
prevented by proteasome inhibition. Besides that, calpain activation suppresses the Akt
pathway that promotes protein synthesis and inhibits protein degradation, probably due
to proteolysis of the chaperone heat shock protein 90 (HSP 90), which enables normal
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Akt function. This might lead to increased expression of UPS factors in particular E3
ubiquitin ligases [130]. On the other hand, Fareed and colleagues reported that calpain
inhibition also prevented sepsis- and glucocorticoid-induced muscle wasting, but did not
decrease proteasomal degradation of myofibrillar proteins during sepsis. In addition, total
proteasomal protein degradation and overall proteasomal activity as well as MuRF1 and
atrogin-1/Muscle Atrophy F-box (MAFbx encoded by Fbxo32) mRNA expression were
not reduced in response to calpain inhibition. These data indicate that calpain activity is
not required for proteasomal degradation of muscular proteins, and the UPS is regulated
independently [131].
The most important modulator of calpain activity is the amount of calcium ions.
Besides that, calcium regulates the binding of the calpain inhibitor calpastatin, and ac-
tive calpain degrades itself [122]. Numerous studies suggest an indirect linkage between
increased intracellular calcium levels and diseases and conditions that cause muscle wast-
ing [132]. Treatment of muscles ex vivo and myotubes in vitro with calcium or the calcium
ionophore A23187 was described to increase proteasomal activity and protein degrada-
tion [133–135]. Notably, the depolymerization of desmin IF catalyzed by calpain-1 occurs
several days after the induction of atrophy, when cytosolic calcium levels rise [120,136].
In conclusion, calpains act upstream of proteasome-dependent protein degradation
during muscle atrophy. Whether or not the proteasome isoforms differentially contribute
to myofibrillar protein degradation is currently unknown.
3.2. E3 Ubiquitin Ligases and Other UPS Factors in Skeletal Muscle
In order to identify universal markers of atrophy, two genes encoding E3 ubiquitin
ligases with restricted expression to striated muscles were found to be significantly up-
regulated in multiple early stage models of skeletal muscle atrophy: Muscle RING (really
interesting new gene) finger 1 (MuRF1 encoded by Trim63) and atrogin-1/MAFbx [137–141].
Deletion of those genes in mice partially attenuated muscle loss in denervation-induced
atrophy [137]. Interestingly, Baehr et al. reported that the loss of muscle mass caused by 14
days of administration of the synthetic glucocorticoid (GC) dexamethasone is reduced in
MuRF1, but not atrogin-1/MAFbx knockout mice indicative for a distinct role of both E3
ubiquitin ligases in different atrophy conditions. Since the observed partial atrophy resis-
tance in MuRF1-deficient mice was connected to the maintenance of protein synthesis and
not increasing protein degradation, another role of MuRF1 beyond the UPS is likely [142].
Furthermore, deletion of MuRF1 promotes the preservation of muscle mass in conditions
of amino acid starvation [143], hindlimb unloading [144] and cardiac cachexia [145] in mice.
To date, at least 120 genes named “atrogenes” have been identified with altered expression
in various muscle-wasting conditions [45,141]. However, since the majority of studies
employed rodent atrophy models, further investigation of the atrogene transcriptional
program in human diseases is necessary.
As mentioned, myofibrillar disassembly appears to be important for proteasome-
mediated degradation of structural proteins. However, since E3 ubiquitin ligases have
been shown to be localized to the sarcomere, the ubiquitination of myofibrillar proteins
is likely to occur independently of their disassembly. For example, MuRF1 and MuRF2
interact with the C-terminus of titin leading to their association with the M-band [146,147].
MuRF1 and MuRF3 have been shown to be localized to the Z-band [146,148]. In addition,
upon denervation and fasting, MuRF1 interacts with and ubiquitinates various structural
and contractile proteins such as MyBP-C, MLC1 and MLC2, even when they are organized
in myofibrils, eventually leading to disassembly of thick filaments [149,150]. MyHC is
also degraded in an MuRF1-dependent manner [151], but is protected in myofibrils by
connected proteins [149]. These findings further support the fact that E3 ubiquitin ligases
can ubiquitinate proteins contained in intact myofibrils and that the loss of myofibrillar
proteins is a highly ordered process (Figure 2).
Another MuRF1 target discovered in vitro and in vivo in cultured cardiomyocytes is
cardiac troponin I [152]. MuRF1 was also found to interact with titin and nebulin, and
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it may modulate the titin kinase activity [146,150]. Since experiments with wildtype and
MuRF1 knockout mice revealed similar ubiquitination levels of some myofibrillar pro-
teins such as titin and nebulin, it was hypothesized that they are not primary MuRF1
targets in vivo, suggesting the involvement of other E3 ubiquitin ligases [150]. In this
regard, it is important to know that MuRF1 and MuRF3 physically interact with each
other [146,153] and that their combined absence causes accumulations of fast- and slow-
twitch MyHC in striated muscles leading to a myosin storage myopathy of the heart
and skeletal muscle [151]. Likewise, the combined absence of MuRF2 and MuRF3 also
leads to a protein storage myopathy in mice, in vivo [153]. However, the composition of
these protein aggregates is less well defined. Nevertheless, these results imply that the
MuRF family of E3 ubiquitin ligases function cooperatively and may have similar targets.
Several studies showed that MuRF1 and possibly MuRF2, but not MuRF3, are linked to
muscle atrophy [145,154]. A MuRF1 yeast two-hybrid screen performed by Witt and col-
leagues identified 11 interacting enzymes involved in ATP generation, pointing to a role as
regulator of energy metabolism [150]. Beyond that, experiments with mice overexpressing
MuRF1 specifically in skeletal muscle uncovered its interaction with enzymes involved in
glycolysis and glycogen metabolism [155].
MuRF1 was long thought to act as a monomeric RING E3 ubiquitin ligase, but cur-
rent work suggests that it may function as a component of a Cullin-type ubiquitin ligase
encompassing Cullin 4A (Cul4A), DDB1, Rbx1 and DCAF8 [156]. Cullin ubiquitin lig-
ases represent modular and versatile multi-protein complexes that are built around one of
several Cullin proteins. These scaffolds bind a RING-type ubiquitin ligase and different sub-
strate receptors, which integrate the protein complexes into diverse cellular processes [157].
In Cul4-type ligases, DDB1 and selected “DDB1-Associated Factor” (DCAF) proteins form
such substrate recruiting modules [158]. Similar to MuRF1, the knockdown of DCAF8
prevented atrophy of cultured C2C12 myotubes. This finding and results from protein–
protein interaction studies imply that MuRF1 and DCAF8 form an operational unit in a
Cul4A ligase complex that drives myocyte atrophy [156]. Still, the detailed functions of the
Cul4A-MuRF1-DCAF8-DDB1 complex in muscle biology in vivo warrant further studies.
In contrast to MuRF1, the identified substrates of atrogin-1/MAFbx are predominantly
regulators of muscle protein synthesis and regeneration. The most prominent targets
are the myogenic factor MyoD1 and eukaryotic translation initiation factor 3 subunit f
(eIF3-f) [159,160]. Additionally, atrogin-1/MAFbx was found to interact with the desmin
and vimentin IF, sarcomeric proteins and a number of other proteins in coimmunopre-
cipitation experiments of C2C12 myocytes treated with human myostatin, an inhibitor of
myogenesis [161]. However, the interactions still need to be confirmed in vivo [154].
Whether all the identified atrogin-1/MAFbx and MuRF1-interacting proteins are also
ubiquitinated by them and whether this leads to UPS-dependent degradation warrants
further investigation. It is also not known which of the atrogin-1/MAFbx and MuRF1-
interacting proteins are ubiquitinated and degraded during sepsis-induced muscle atrophy,
and whether these substrates change with different atrophy causing conditions.
Various pathologies in and even treatments of critically ill patients can increase
the activity of the UPS [162]. Importantly, an increased atrogin-1/MAFbx and MuRF1
mRNA and protein expression as well as an increased expression of the 20S proteasome
was found in vastus lateralis biopsy specimens from critically ill patients at risk of de-
veloping ICUAW [39,163,164]. However, the literature is not consistent in this regard as
the ubiquitin ligases are not always found to be differentially expressed in the muscle
of critically ill patients [165]. The discrepancies between these studies may be related to
their experimental design, timing and site of biopsy collection, and the type of analysis
performed. For example, atrogin-1/MAFbx and MuRF1 are rapidly increased during
atrophy conditions, which levels off in the later disease phases [39,166]. Therefore, timing
of analyses is important to uncover differences in gene expression and protein contents of
atrophy-related pathways; for human patients, this is not at all trivial.
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3.3. Tripartite Motif Containing 32 (Trim32)
The E3 ubiquitin ligase tripartite motif containing (Trim) 32 is a ubiquitously expressed
multifunctional protein that plays a role in differentiation, tumor suppression, muscle phys-
iology and regeneration [167]. Similar to MuRF1, it belongs to the TRIM family of proteins,
which contain three zinc binding domains composed of a RING-finger, a coiled-coil region
and a B-box type 1 and 2 [168]. In contrast to MuRF1 and atrogin-1/MAFbx, TRIM32 is
found in many different cell types throughout the body and is not restricted to striated
muscles [154]. TRIM32 directly acts on cytoskeletal networks and insoluble myofibrils
in vitro. In this regard, TRIM32 was shown to be critically linked to the breakdown of
desmin IF during fasting-induced muscle atrophy, which is initiated by phosphorylation of
the desmin head domain by GSK3-β or maybe other kinases, initiating the destruction of Z-
bands and thin filaments [114,120]. Downregulation of TRIM32 attenuated fasting-induced
breakdown of contractile and cytoskeletal proteins and subsequent muscle atrophy in
hindlimb muscles. Furthermore, downregulation of TRIM32 in skeletal muscle increased
PI3K/Akt/FoxO signaling, enhanced glucose uptake and induced myofiber growth [169].
The importance of TRIM32 for muscle homeostasis is supported by data from human
patients. For example, TRIM32 mutations were shown to cause limb-girdle muscular
dystrophy type 2H (LGMD2H) [170]. TRIM32 was also shown to be increased in skeletal
muscle of patients with Becker and Duchenne muscular dystrophy [171], whereas the
latter describes a progressive neuromuscular condition designated by a long-term muscle
deterioration significantly affecting pulmonary and cardiac function and leading to prema-
ture death. However, whether TRIM32 plays a role in muscle wasting in sepsis needs to
be shown.
Beyond that, a study by Volodin et al. showed that the paired box 4 (PAX4) transcrip-
tion factor regulates the expression of enzymes that are required for myofibril degradation
in later phases of denervation-induced atrophy [136]. All PAX family transcription factors
play crucial roles in embryonic development and organogenesis. PAX4 in particular is
essential for the differentiation of pancreatic β cells in mice, and mutations can lead to type
2 diabetes in humans [172–174]. PAX4 increases the expression of the p97/VCP ATPase
complex in muscle [136]. p97/VCP extracts proteins from immobile cellular structures for
proteasomal degradation [175] and catalyzes myofibril disassembly by release of ubiquiti-
nated proteins to the cytosol [176]. The disassembled structure of myofibrils may in turn
enhance the substrate availability for E3 ubiquitin ligases such as TRIM32, accelerating
the degradation of thin filaments (Figure 2). Accordingly, downregulation of PAX4 is
paralleled by a decreased expression of p97/VCP and a reduced myofibrillar breakdown
in denervated mouse muscles [136].
3.4. Neural Precursor Cell Expressed Developmentally Down-Regulated Protein 4 (NEDD4)
The role of the ubiquitously expressed E3 ubiquitin ligase neural precursor cell ex-
pressed developmentally down-regulated 4 (NEDD4) in skeletal muscle atrophy is not
well defined. NEDD4 is a HECT (Homologous to the E6-AP Carboxyl Terminus) domain
ubiquitin ligase that is increased in skeletal muscles after denervation and unloading [177].
Increased NEDD4 expression was described in muscles in response to hindlimb unload-
ing [177–179] and long-term denervation [180], but not in fasting or diabetes [177]. The ac-
tivity of NEDD4 is regulated by posttranslational modifications including tyrosine phos-
phorylation by SRC [181], which activates NEDD4 activity, and by auto-ubiquitination,
which causes NEDD4 oligomerization and inhibits its activity [182]. NEDD4 is localized
to the sarcolemmal region of muscle fibers. Its first discovered target, Notch1, mediates
satellite cell proliferation after muscle injury [177]. NEDD4 expression is also induced
by PAX4 [136]. Nedd4 knockout mice showed a reduction of IGF-1 and insulin signaling,
delayed embryonic development, reduced growth and body weight as well as neona-
tal lethality [183]. Skeletal muscle-specific Nedd4 knockout mice were protected against
denervation-induced muscle atrophy [184]. Whether NEDD4 plays a role in muscle atrophy
in sepsis or ICUAW is not known.
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3.5. TNF Receptor-Associated Factor 6 (TRAF6)
TNF receptor-associated factor 6 (TRAF6) is a member of the TRAF family of adaptor
proteins, possesses E3 ubiquitin ligase activity and predominantly promotes lysine 63 (K63)-
linked polyubiquitin chains [185]. TRAF6 is upregulated in skeletal muscle in response
to denervation, starvation and cancer cachexia. Skeletal muscle-specific deletion of Traf6
protects against denervation-induced muscle atrophy in mice. This is attributable to a
downregulation of atrogin-1/MAFbx and MuRF1 as well as a reduction of NF-κB, JNK, p38
MAPK and AMPK signaling pathways in the Traf 6 knockout mice. Besides that, TRAF6
inhibition was shown to inhibit cancer cachexia [186].
3.6. Muscle Ubiquitin Ligase of the SCF Complex in Atrophy-1 (MUSA1) and Others
Other E3 ubiquitin ligases have also been shown to be involved in skeletal muscle
protein breakdown. Milan et al. found that a group of E3 ubiquitin ligases were upregulated
in skeletal muscle of denervated or fasted mice, and were blunted in mice with a skeletal
muscle-specific deletion of FoxO1, -3 and -4 [187]. These E3 ubiquitin ligases include
MUSA1 (muscle ubiquitin ligase of the SCF complex in atrophy-1), Fbxo31 and SMART
(Specific of Muscle Atrophy and Regulated by Transcription, Fbxo21). In addition, other
factors of the ubiquitin conjugation/deconjugation machinery, proteasome subunits as
well as ALP-related genes, were reduced in theses triple knockout mice [187]. These data
suggest a complex regulation of protein degradation and protein synthesis by FoxO1, -3 and
-4, and therefore by IGF-1, which mediates its effects through these transcription factors.
Because the individual FoxO-transcription factors have specific targets, this regulation is
even more complex. For example, FoxO3 overexpression was shown to induce MUSA1 but
no other E3 ubiquitin ligase in myotubes. FoxO1 and FoxO3 were shown to bind to the
promoter regions of MUSA1 and SMART, and deletion FoxO3 attenuated the induction
of SMART, but not other E3 ubiquitin ligases. Because IGF-1 signaling is reduced by
inflammatory cytokines and in sepsis, it is tempting to speculate that this mechanism
contributes to muscle atrophy in sepsis. However, this hypothesis needs to be proven.
The role of DUBs in muscle wasting is less defined; however, due to the general
function of DUBs, it can be assumed that DUB action may counteract muscle protein
breakdown (reviewed in [188]). Further details on the regulation of activity and function
of E3 ubiquitin ligases and related pathways in muscle atrophy in general have recently
been reviewed elsewhere [189].
4. Role of Proinflammatory Cytokines in Inflammation-Induced Muscle Wasting
Meta-analysis revealed that higher levels of circulating inflammatory markers are
associated with a marked decrease in skeletal muscle strength and mass [190]. Among the
best-studied proinflammatory cytokines promoting muscle atrophy are tumor necrosis
factor (TNF), interleukin-6 (IL-6), interleukin-1 (IL-1), IFN-γ and TNF-like weak inducer of
apoptosis (TWEAK). These cytokines are elevated in sepsis and may together cause muscle
wasting, probably by increasing NF-κB or by causing the release of other cytokines [191,192].
In addition, skeletal muscle acts as a secretory immunogenic organ, producing and releas-
ing numerous cytokines and other proteins referred to as myokines. Myokines mediate
cross talk to several organs, such as the brain, adipose tissue and liver, and may influ-
ence their function [193]. IL-6 is the founding member of the myokine class of proteins.
However, in systemic inflammation, skeletal muscle not only synthesizes and releases
IL-6 [194] but also other cytokines, such as IL-1β [195,196], and acute phase proteins, such
as serum amyloid A1 (SAA1) [43,194]. Interestingly, the levels of circulating cytokines are
not necessarily associated with their tissue levels. The significance of this observation and
the question if differences exist between systemic and local effects of cytokines warrants
further investigation. In the following paragraph, the role of key inflammatory cytokines
and their signaling pathways in inflammation-induced muscle wasting will be described.
The main pathways are illustrated in Figure 3.
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4.1. Tumor Necrosis Factor (TNF)
TNF, initially named cachectin [197], promotes skeletal muscle wasting in various
pathological conditions, such as immobilization [138] and cachexia [198,199]. Early studies
sh wed that TNF treatment of culture myotubes caused a reduction in total protein
content and a decrease in the myotube diameter indicative of atrophy [200]. Rats treated
with recombinant TNF or IL-1β showed a significant reduction in total muscle protein
content a d a reduced expression of myofibrillar proteins [201,202]. ICU patients displayed
increased TNF serum levels [203], and maximal TNF plasma levels were found to be higher
in patients who developed ICUAW as compared with control subjects [204]. Importantly,
the admi istration of an anti-TNF antibody i hibited the sepsis-induced increase in muscle
proteolysis in rats, indicating that TNF is an important regulator of muscle protein break-
down during sepsis [205]. The atrophic effects of TNF are closely related to NF-κB and
its downstream targets atrogin-1/MAFbx and MuRF1. TNF increases the expression of
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atrogin-1/MAFbx and MuRF1 in mouse skeletal muscle in vivo and in C2C12 myotubes
in vitro, which is accompanied by myotube atrophy [206]. Likewise, TNF-induced at-
rophy was shown to be accompanied by an increase in atrogin-1/MAFbx and decrease
the translation initiation factor eIF3f abundance in rat L6 and mouse C2C12 myotubes.
These data suggest that TNF not only increases proteolysis but also decreases protein
synthesis in myocytes [207].
TNF binds to the sarcolemmal TNF receptor 1 (TNFR1) or TNFR2, which in turn
activates the NF-κB and PI3K/Akt signaling pathways as well as ubiquitin mediated
proteolysis [208]. TNFR1 was shown to stimulate apoptosis via interaction with the
TRADD (tumor necrosis factor receptor type 1-associated DEATH domain protein), TRAF2
(TNF receptor associated factor 2) and RIP1 (receptor interacting serine/threonine kinase
1) complex [209]. Activation of this complex further leads to the activation of FADD
protein (Fas associated via death domain) resulting in apoptosis. The activated TRADD
complex also activates JNK (c-Jun N-terminal kinase) and the transcription factor AP-1.
The activated complex promotes phosphorylation and subsequent proteasomal degradation
of the IκBα protein, which leads to an activation of NF-κB (for further details on this
pathway, please see below). Moreover, TNFR2 also activates NF-κB by stimulating the
PI3K/Akt signaling pathway [210]. Importantly, the IGF1/Akt pathway controls myofibril
growth and maintenance via the GSK-3β/nebulin/N-WASP pathway. GSK-3β-mediated
inhibition of eukaryotic translation initiation factor 2b (eIF2B) leads to decreased protein
synthesis. In general, Akt inactivates GSK-3β, which releases inhibition of eIF2B and
promotes protein synthesis. GSK-3β was found to be required for skeletal muscle atrophy
and muscle wasting [211]. GSK-3β also suppresses NFAT activity (Nuclear factor of
activated T-cells), which inhibits myogenic differentiation [212]. In addition, it results
in decreased formation of actin filaments by inhibition of nebulin and neuronal Wiskott–
Aldrich syndrome protein (N-WASP) [211]. In summary, these data show that TNF perturbs
protein homeostasis at different levels involving an increase in proteasome-mediated
protein degradation and decreased protein synthesis.
4.2. Interleukin 6
IL-6 has pleiotropic functions in different tissues and regulates protein homeostasis in
the skeletal muscle [212,213]. While an acute increase in systemic IL-6 promotes muscle
growth and hypertrophy, its sustained elevation, as occurring in catabolic conditions such
as cancer or sepsis, causes muscle atrophy [214]. However, the role of IL-6 signaling in
sepsis-induced muscle atrophy is not well understood. IL-6 production is stimulated by
other cytokines, such as TNF, and IL-1β. IL-6 contributes to systemic inflammation in
critical illness and sepsis [215], and it increases protein breakdown and skeletal muscle
atrophy [216]. It was also reported to increase the activities of the 26S proteasome as well
as cathepsin B and L, which decreased the half-life of proteins in murine myotubes [217].
These data indicate that chronic elevation of circulating IL-6 is sufficient to cause muscle
wasting. In addition, intra-peritoneal IL-6 injections were found to cause muscle atrophy
in rats possibly due to an increased proteolysis [216]. Local IL-6 infusion into the tibialis
anterior muscle was associated with a reduction in the total and myofibrillar protein
content in rats [218]. These data suggest that IL-6 directly acts on skeletal muscle to cause
atrophy. In support of this, IL-6 treated C2C12 myotubes showed a lower mTOR and
4EBP-1 phosphorylation and an increased STAT3 phosphorylation and atrogin-1/MAFbx
expression, which was paralleled by a reduced myotube diameter. This indicates that IL-6
increases atrogene gene expression and diminishes mTOR signaling and thereby protein
synthesis in muscle [219]. However, other authors show only little effects of IL-6 on skeletal
muscle both in vivo and in vitro [220], which may be explained by differences in IL-6 levels,
shorter treatment durations or the pleiotropic nature of IL-6 in skeletal muscle. These data
suggest that IL-6 increases protein degradation in muscle by activation of the proteasome
and the lysosomal (cathepsin) pathway and decreases protein synthesis to cause atrophy.
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IL-6 signaling is mediated either through binding to a membrane bound IL-6 receptor
that facilitates homodimerization with the signal transducing receptor glycoprotein 130
(gp130, encoded by Il6st) [221] or through binding to a soluble IL-6 receptor, which then
associates with gp130 [222]. Because other IL-6 cytokine family members such as IL-11,
ciliary neurotrophic factor, leukemia inhibitory factor (LIF), oncostatin M, cardiotrophin 1,
cardiotrophin-like cytokine and IL-27 also signal through gp130, they might as well play
a role in sepsis-induced muscle wasting, but this needs to be proven [223]. Nevertheless,
LIF has been reported to activate the JAK2/STAT3 signaling pathway to mediate skeletal
muscle atrophy in a mouse model of cancer cachexia [224]. The activated IL-6R-gp130 com-
plex binds and activates the Janus kinase (JAK) family of tyrosine kinases, primarily JAK1,
JAK2 and tyrosine kinase 2 (TYK2), which phosphorylate the cytoplasmic tail of gp130,
enabling the association of the STAT proteins, mainly STAT1 and STAT3. Phosphorylated
STAT proteins dimerize and translocate to the nucleus where they control the expression of
STAT target genes, such as Suppressor of Cytokine Signaling 3 (SOCS3) [225,226]. SOCS3
in turn acts as a negative feedback inhibitor of cytokine signaling by inhibition of JAK1,
JAK2 and TYK2 [227]. SOCS3 also inhibits the Insulin/PI3K/Akt pathway as a substrate
recognition component of an ubiquitin-protein ligase complex, degrading insulin receptor
substrate 1 (IRS-1), which is essential for insulin signaling [228]. Insulin increases protein
synthesis and decreases atrogene expression and protein degradation via the PI3K/Akt
pathway [229,230]. This promotes muscle growth, and, inversely, perturbations of insulin
signaling can aggravate muscle atrophy as frequently seen in critically ill patients [42].
Activated STAT3 also activates C/EBPδ (CCAAT-enhancer-binding protein d) causing an
increased expression of myostatin (for further details, please see below), which conse-
quently activates atrogin-1/MAFbx and MuRF1, and increases protein degradation [231].
Based on these data and together with the observation that increased IL-6 plasma level
are a risk factor for Critical Illness Myopathy (CIM) correlated with peripheral nerve
dysfunction [232], it is feasible that the IL-6/gp130/JAK/STAT pathway plays a role in
sepsis-induced muscle atrophy. This, however, needs to be proven.
In this context, it is interesting to note that mouse models for denervation-induced
muscle atrophy revealed the induction of standard- and immunoproteasomes indicating
induction of inflammatory signaling. Here, immunoproteasome-deficient mice exhibited
an altered activity and content of the remaining catalytic subunits, but the muscle loss was
not attenuated [91].
4.3. Interleukin 1β
The interleukin (IL)-1 family comprises prototypic proinflammatory cytokines in-
volved in the immune response to infection and injury, which consists of 11 family mem-
bers. Interleukin-1α (IL-1α) and IL-1β are the best described and investigated cytokines of
the IL-1 family. One of the most activated cytokines in sepsis is IL-1β [233–235]. Evidence
for its role in muscle atrophy comes from in vitro and in vivo studies. For example, IL-1β
treatment caused atrophy of differentiated C2C12 myotubes in a concentration-dependent
manner, in vitro [195]. Treatment of rats with recombinant IL-1α resulted in an increased
breakdown of myofibrillar proteins [236]. Chronic IL-1 infusion was reported to reduce
muscle weight, which was associated with a decrease in protein content and protein syn-
thesis in rat gastrocnemius muscle [237]. By contrast, when a IL-1 receptor antagonist
was administered to septic or with endotoxin treated rats, muscle breakdown was attenu-
ated [238]. Administration of an IL-1 antagonist also preserved muscle mass in a chronic
abdominal sepsis rat model [239].
The expression, cleavage and secretion of IL-1β is tightly controlled. Inflammatory
cytokines increase the expression of pro-IL-1β, which is the inactive proform of IL-1β.
The conversion of pro-IL-1β to IL-1β and IL-1β secretion are mediated by caspase-1 ac-
tivating inflammasomes [233,240]. Inflammasomes are multi-protein complexes of the
innate immune system that have been shown to be involved in the pathogenesis of sep-
sis [241,242]. The nucleotide-binding domain (NOD)-like receptor (NLR) family are central
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components of the inflammasome. One of the best characterized NLR is NLRP3 [243,244].
The NLRP3 inflammasome comprises the sensor molecule NLRP3, the adaptor protein
ASC and pro-caspase-1. In general, activation of the NLRP3 inflammasome requires two
steps: priming and activation. The priming step occurs in response to inflammatory stim-
uli such as TLR4 agonists, which increases the expression of NLRP3 and pro-IL-1β via
NF-κB. The activation step is mediated by pathogen-associated molecular patterns (PAMP)
and damage-associated molecular pattern (DAMP). Upon activation, the NLRP3 protein
interacts with ASC, which recruits pro-caspase-1 to form the NLRP3–ASC–pro-caspase-1
complex [245]. Proximity-induced autocatalytic activation of pro-caspase-1 to caspase-1
occurs upon its recruitment to this complex. In turn, active caspase-1 cleaves the cytokines
pro-interleukin-1β (pro-IL-1β) and pro-IL-18 into their mature and biologically active
forms [244]. NLRP3 is contained in muscle, and its activity is increased in myopathies [246].
NLRP3 knockout mice are incapable of activating IL-1β and therefore show reduced IL-1β
serum levels at baseline as well as in sepsis. In accordance with the observation that IL-1β
causes myocyte atrophy, Nlrp3-deficient mice are protected against sepsis-induced muscle
atrophy. This was accompanied by an increased survival of septic Nlrp3 knockout mice
when compared with septic wildtype littermate controls [195]. IL-1β signal transduction is
mediated by the IL-1 receptor, which is associated with IL-1 receptor associated kinase1
(IRAK1) that activates NF-κB [247]. This in turn increases atrogin-1/MAFbx and MuRF1
expression in myocytes [248,249]. Accordingly, septic Nlrp3-deficient mice showed a re-
duced activation of NF-κB, which was accompanied by a decrease in atrogin-1/MAFbx and
MuRF1 expression when compared with wildtype littermate controls. Because Nlrp3 dele-
tion reduces mortality and sepsis-induced end-organ damage, such as muscle failure [195],
cardiomyopathy [250,251] and acute lung injury, pharmacological NLRP3 inhibition might
be beneficial in sepsis. Indeed, positive effects were reported for the NLRP3-inhibitors
hemin, which protected against cecal ligation and puncture (CLP)-induced acute lung
injury in mice [252], and scutellarin as well as glyburide, which improved survival of mice
with bacterial sepsis [253,254]. Whether such an approach is applicable to critically ill
human patients awaits further investigation. In addition, a reanalysis of a phase III ran-
domized controlled trial that investigated the role of the IL-1 antagonist anakinra showed
significant survival benefits in patients with sepsis [255]. However, whether this was
related to a preservation in muscle mass and function is unknown.
4.4. Serum Amyloid A1 (SAA1)
The acute-phase response protein serum amyloid A1 (SAA1) is associated with inflam-
mation during sepsis [43]. While the main source of SAA1 is the liver [256], inflammatory
cytokines such as IL-6 increase SAA1 expression and secretion also in muscle [43,257,258].
SAA1 expression significantly increases and accumulates in the sarcolemma and intersti-
tium of muscle from ICUAW patients, which was not observed in control subjects [43].
However, the role of SAA1 in ICUAW is not well defined [259]. Various tumors produce
SAA1 [260,261], and it is associated with muscle wasting in cancer cachexia in mice [262].
SAA1 and IL-6 cooperate with each other to mediate angiotensin II-induced muscle atrophy,
which is important for muscle wasting in heart failure patients [263]. In immune cells, SAA1
binds to several different receptors such as the purinergic receptor P2X7 (P2RX7), the scav-
enger receptor class b member 1 (SCARB1), the CD36 receptor (CD36), the VCP interacting
membrane seleno-protein (VIMP) and Toll-like receptors (TLR) 2 and 4 [264–266]. SAA1 ac-
tivates the NLRP3 inflammasome via P2RX7 causing an activation and release of IL-1β from
mouse and human macrophages [264]. When SAA1 binds to the CD36 receptor, it increases
IL6 and TNF expression in rat macrophages and human embryonic kidney cells [265].
SAA1 was also shown to increase the pro-inflammatory cytokines IL-23α and TNF via
TLR2, and to increase nitric oxide via TLR4 in mouse macrophages [267]. Recently, Hahn
et al. identified the receptors and signaling pathway that mediate SAA1-induced muscle
atrophy. They showed that SAA1 via the TLR2/TLR4/NF-κB signaling pathway medi-
ates C2C12 myotube atrophy in vitro and sepsis-induced muscle atrophy in mice in vivo.
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They reported that SAA1 participates in a positive feedback loop of self-perpetuating
inflammation in muscle during sepsis. Importantly, they reported that the IκB kinase-2
(IKK-2) inhibitor BMS-345541 that causes an inhibition of NF-κB reduces atrogin-1/MAFbx
and MuRF1 expression, diminishes skeletal muscle atrophy and increases survival in sep-
tic mice [194]. It is therefore likely that SAA1 via activation of the TLR2/TLR4/NF-κB
atrophy pathway is mechanistically important for ICUAW. However, the improved sur-
vival of BMS-345541 treated septic mice is possibly related to a systemic NF-κB inhibition.
Further, experiments with myocyte-specific deletions of TLR2 and or TLR4 are needed to
state that these receptors mediate sepsis-induced muscle atrophy in vivo. Whether SAA1
affects the proteasome function in muscle during sepsis is unknown.
4.5. TNF-Related Weak Inducer of Apoptosis (TWEAK)
The proinflammatory cytokine TNF-related weak inducer of apoptosis (TWEAK)
also mediates skeletal muscle wasting. TWEAK binds to the cell surface receptor Fn14
(Fibroblast growth factor inducible 14), which activates TAK1 (Transforming growth factor
beta activated kinase-1) and Akt. This results in phosphorylation and activation of IKKβ
followed by NF-κB activation. Activated TAK1 also stimulates JNK-1 and p38 MAPK,
which in turn activates AP-1. TWEAK increases the degradation of muscle proteins
and leads to a reduction in the diameter of C2C12 cells and primary myotubes [268].
Similarly, chronic administration of TWEAK in vivo or muscle-specific overexpression of
TWEAK in mice resulted in a loss of skeletal muscle mass. The TWEAK-mediated loss of
muscle mass is mediated by several mechanisms, such as an activation of NF-κB or the
UPS as well as an inhibition of the Akt pathway. For example, TWEAK caused a rapid and
sustained increase in both DNA binding and transcriptional activity of NF-κB in myotubes
and activated NF-κB in skeletal muscle of mice in vivo. In addition, treatment of myotubes
with TWEAK reduced the phosphorylation of Akt, which was paralleled by a reduced
phosphorylation of GSK-3β, mTOR, p70S6K and FOXO1. These data suggest that TWEAK
inhibits the activity of the PI3K/Akt pathway [269]. Finally, TWEAK-induced MyHC-
degradation and myotube atrophy was attenuated by inhibition of MuRF1, autophagy or
caspase-3 [270], suggesting that these factors are involved in TWEAK-mediated muscle
atrophy. In summary, these data suggest that TWEAK mediates muscle atrophy by an
increased protein degradation and a reduced protein synthesis, resulting in a perturbed
protein homeostasis and muscle wasting. The role of TWEAK in ICUAW is uncertain.
4.6. Transforming Growth Factor (TGFs) and Its Signaling Pathways
The precise function of the transforming growth factor (TGF) cytokine family in
inflammation-induced muscle wasting is not well understood. However, evidence sug-
gests a role of TGF family in sepsis-induced muscle wasting, i.e., TGF-β1 serum levels
are increased in sepsis [271,272]. Because TGF-β1 inhibits the release of proinflammatory
cytokines, such as IL-1 and TNF from monocytes and macrophages, it may be important
for immunosuppression often seen in sepsis [273,274]. TGF-β1 also increases the produc-
tion of immunosuppressive factors, such as the soluble TNF receptors (sTNFRs) and the
IL-1 receptor antagonist (IL-1Ra) [275]. In addition, TGF-β1 is involved in muscle atro-
phy. For example, overexpression of TGF-β1 in muscle causes skeletal muscle atrophy in
mice [276]. TGF-β1 preferentially mediates atrophy of fast twitch/type II myofibers [277].
Moreover, myostatin, which is a TGF-β family member, induces atrophy of fast twitch/type
II myofibers [278]. Because type II myofibers are mainly affected in ICUAW, TGF-β1 might
be involved in this pathology. By contrast, clinical studies showed that TGF-β1 inhibitors
reduce muscle atrophy. For example, a TGF-β1 neutralizing antibody attenuated muscle
atrophy and improved muscle regeneration [279]. The TGF-β receptor I (TβRI) antagonist
Ki26894 increased muscle weight and strength in wildtype mice and diminished mus-
cle atrophy in a transgenic mouse model of muscle dystrophy [280]. A role of TGF-β1
in skeletal muscle atrophy is further supported by the observation that increased TGF-
β1 expression is associated with muscle atrophy in muscular dystrophy patients [281].
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Together, these data suggest that TGF-β1 may be involved in inflammation-induced skeletal
muscle atrophy.
The TGF family is mainly divided into two subfamilies with opposing effects on
muscle mass. In general, TGF-β/myostatin/activin are seen as negative regulators, and
BMPs (Bone Morphogenic Proteins)/GDF (Growth and Differentiation Factors) are judged
as positive regulators of muscle mass [282]. TGF-β binds to the TβRI and TβRII complex
to activate both canonical SMAD-dependent and non-canonical signaling pathways, such
as PI3K/Akt, MAPK pathways (ERK, JNK and p38 MAPK) that activate protein synthesis
and muscle growth [283,284]. TGF-β/myostatin/activin mainly activates SMAD2 and
SMAD3 that are pro-catabolic. By contrast, BMP ligands predominantly recruit the SMAD1,
SMAD5 and SMAD8 that elicit an anabolic transcriptional program. SMAD4 is shared
by both pro-anabolic and pro-catabolic SMADs and can be a limiting factor for SMADs’
downstream effects. In terms of muscle mass control, Myostatin/GDF8 is the best described
TGF-family member [285], next to GDF11 and Activin A [286,287]. Myostatin is a myokine,
and its autocrine and paracrine effects limit skeletal muscle growth. It is involved in muscle
mass regulation during embryonic development and plays a key role in (patho-)physiologic
adaptations of skeletal muscle mass. Myostatin is highly conserved across species, and loss
of myostatin function leads to skeletal muscle hypertrophy, hyperplasia and eventually a
massive increase in muscle mass in humans, mice and cattle [288]. By contrast, myostatin
overexpression has been shown to be involved in muscle atrophy during different diseases
such as chronic heart failure or chronic obstructive pulmonary disease [289]. Upon myo-
statin binding, atrogin-1/MAFbx and genes involved in the degradation of several anabolic
factors (ribosomal proteins, translation initiation factors, MyoD, desmin and vimentin)
are upregulated [290] and the Akt/mTORC1 pathway is inhibited [291]. Furthermore,
myostatin has been found to be associated with cancer cachexia, and its expression is
stimulated through the JAK/STAT pathway [192]. Binding of myostatin to ActRIIB results
in the phosphorylation of SMAD2/3 and activation of SMAD signaling [292], which re-
duces levels of Akt phosphorylation [287], consequently activating caspase-3 and FoxO
and resulting in increased protein degradation [192]. Myostatin administration is sufficient
to induce cachexia in mice through ActRIIB signaling [293]. However, whether or not
myostatin is involved in inflammation-induced muscle atrophy has not been investigated
so far. The activity of the TGF-β-, BMP- and activin A-signaling pathways is also regulated
by the HECT E3 ubiquitin ligase SMURF1 (Smad ubiquitination regulatory factor 1) via
interaction and proteasomal degradation of the signal transducing SMAD1, SMAD5 and
SMAD4 proteins in vitro [294]. SMURF1 also indirectly interacts with TβRI via SMAD7
and thereby facilitates the degradation of TβRI [295]. As a key downstream effector of
activin-mediated ActRII signaling, SMURF1 increases proteasome-dependent degradation
of sarcoplasmic reticulum calcium ATPase (SERCA2a), which is a critical determinant of
cardiomyocyte function [296]. Because the TGF-β family significantly affects muscle mass
and function, it can be assumed that modulation of TGF-β signaling by SMURF1 also
affects muscle atrophy in sepsis. However, this has not been proven so far.
TGF-β via the synergistic action of FOXO3a and SMAD3 increases the expression of
MuRF1/Trim63 in vitro [297]. Similarly, Activin A negatively regulates muscle mass [298].
Interestingly, the non-canonical TGF-β pathway involving TAK1-p38 MAP kinase can
also be activated by Activin A treatment in cells and in vivo, leading to atrogin-1/MAFbx-
mediated myotube atrophy [299]. Recent reports showed that the canonical NF-κB and an-
giotensin II pathways mediate the TGF-β effects in cells and in vivo [300].
Conversely, the BMP pathway regulates hypertrophy by repressing the E3 ubiquitin ligases
atrogin-1/Fbxo32, MuRF1/Trim63, MUSA1/Fbxo30 and through activation of mTORC1
consequently protein synthesis [301–303]. Altogether, these data implicate that the net
balance between the pro-anabolic and pro-catabolic TGF-β/BMP pathways are important
for determination of skeletal muscle mass. However, the multitude of ligands and receptors
as well as the downstream canonical and non-canonical signaling pathways warrant further
analyses to state their individual contribution in sepsis-induced muscle wasting.
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4.7. Signaling Pathways That Mediate Inflammation-Induced Muscle Wasting
4.7.1. Nuclear Factor-κB (NF-κB)-Signaling
The transcription factor NF-κB (nuclear factor ‘kappa-light-chain-enhancer’ of acti-
vated B-cells) is a central component in septic shock. It is a key regulator of inflamma-
tory responses, and its activation is an important step in inflammation-induced muscle
wasting [304–306]. NF-κB represents a family of inducible transcription factors, which
regulates a large array of genes involved in different processes of the immune and inflam-
matory responses [307]. Inhibition of NF-κB alleviates cytokine-induced muscle atrophy,
indicating that NF-κB is directly involved in inflammatory muscle wasting [308]. As stated
above, the properties of the inflammatory cytokines TNF, IL-1β and IL-6 and acute phase
response proteins such as SAA1, which cause muscle wasting, have mainly been attributed
to receptor-mediated activation of NF-κB. In turn, NF-κB increases the expression of several
proinflammatory cytokines, which initiates a self-augmenting positive feedback loop, and
enhances protein degradation [309].
The NF-κB family is composed of five structurally related members, including NF-
κB1 (also named p50), NF-κB2 (also named p52), RelA (also named p65), RelB and c-Rel.
Transcriptionally active NF-κB dimers are formed by combinatorial association of these
five subunits. The NF-κB subunits p50 and p52 are generated by proteasomal cleavage of
the p105 and p100 precursor proteins, respectively [310–312]. Although the proteasome is
involved in cleavage of both p105 and p100, the processing of p105 is primarily constitutive,
whereas the processing of p100 is primarily inducible [313]. The NF-κB family mediates
transcription of target genes by binding to a specific DNA element, κB enhancer, as various
hetero- or homo-dimers [314]. Whether there is a specific role for the different NF-κB
family members or particular hetero- or homo-dimers in ICUAW is unknown. In the
majority of cells, NF-κB exists in an inactive form in the cytoplasm bound to the inhibitory
protein IκB with IκBα being the best-studied IκB family member [315]. In response to
inflammatory cytokines (e.g., TNF, IL-1β, IL-6), IκB kinase is activated and phosphorylates
IκB, which leads to its ubiquitination and degradation by the proteasome [316]. Especially,
K48- and K63-linked ubiquitin chains play a role on several levels in NF-κB activation [317].
Importantly, transgenic mice expressing a mutant isoform of ubiquitin that interferes
with ubiquitin chain assembly in a dominant negative manner (K48R mutant ubiquitin)
displayed a disrupted NF-κB activation and improved survival in response to lipopolysac-
charide (LPS)-induced toxic shock [318]. Once activated, NF-κB translocates to the nucleus
and stimulates the expression of its target genes, especially atrogin-1/MAFbx and MuRF1,
which in turn mediate muscle atrophy [194,319]. Therefore, many approaches were un-
dertaken to reduce the NF-κB activity in various disease models, e.g., miss-expression of
IκB in muscle that inhibits NF-κB attenuated denervation-induced atrophy in mice [304].
The absence of IκB kinase-β also reduced atrophy in response to denervation in mice [305].
Synthetic double-stranded oligodeoxynucleotides, which block NF-κB binding to its pro-
moter elements, have been shown to inhibit tumor cachexia in a mouse model [320].
Activation of NF-κB, through muscle-specific transgenic expression of activated IκB kinase
beta (MIKK), causes profound muscle wasting mainly due to increased UPS-mediated
protein degradation. Indeed, MIKK mice showed an increased expression of MuRF1.
By contrast, no overt phenotype was seen upon muscle-specific inhibition of NF-κB through
expression of IκBα super-repressor (MISR). However, denervation- and tumor-induced
muscle loss were substantially reduced and survival rates improved by NF-κB inhibition
in MISR mice [304]. Importantly, Hahn et al. reported that the IκB kinase-2 (IKK-2) in-
hibitor BMS-345541 that in turn inhibits NF-κB reduces atrogin-1/MAFbx and MuRF1
expression, diminishes skeletal muscle atrophy and increases survival in septic mice [194].
Finally, because proteasome inhibitors suppress IκB degradation, they interfere with the
NF-κB pathway, this in turn prevents NF-κB activation [321]. Since atrogin-1/MAFbx
and MuRF1 are NF-κB target genes, proteasome inhibition is expected to prevent muscle
atrophy by maintaining NF-κB in an inactive state and thus preventing upregulation of
atrogin-1/MAFbx and MuRF1. Indeed, the proteasome inhibitor MG132 was shown to
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attenuate immobilization-induced atrophy. Likewise, the proteasome inhibitor bortezomib
has been shown to reduce atrophy in response to denervation [322]. For more information
about the effects of proteasome inhibitors on muscle atrophy, please see below.
4.7.2. JAK/STAT-Signaling
The role of the JAK/STAT signaling pathway in muscle pathophysiology has recently
been reviewed in detail and was described with the IL-6 pathway [323].
The JAK/STAT pathway is activated by type I (IFN-α/β), type II (IFN-γ), IL-2, and
IL-6 receptor stimulation [324]. IL-6 binding to the IL-6r-gp130 receptor complex results in
the recruitment to the intracellular domain of the receptor, and subsequent activation of
the JAK tyrosine kinase. After binding, JAK proteins undergo a conformational change,
dimerize and activate the STAT proteins through phosphorylation. Subsequently homo-
or hetero-dimerization of STAT proteins is followed by translocation to the nucleus [323].
STAT transcriptional activation contributes to muscle wasting through various mecha-
nisms. It stimulates C/EBPδ expression and activity, which in turn increases myostatin,
atrogin-1/MAFbx1, MuRF1 and caspase-3 expression in myofibers, therefore enhancing
muscle proteolysis [192,218,325]. Moreover, increased myostatin expression resulting from
STAT/C/EBPδ activation suppresses postnatal myogenesis, which in turn may negatively
affect muscle mass maintenance [192]. Furthermore, STAT3 was documented to regulate
gene transcription by interaction with FoxO and NF-κB [326,327].
4.7.3. MAPK Signaling
The MAPK pathway controls growth and stress responses in a wide variety of different
cell types, including skeletal muscle. MAPK signaling is activated by cellular stress, growth
factors, and pro-inflammatory cytokines (e.g., IL-1 and TNF) [328]. The MAPK family of
proteins consists of four distinct signaling pathways, namely, extracellular signal-regulated
kinases 1 and 2 (ERK1/2), p38 MAPK, c-Jun NH2-terminal kinases (JNK), and ERK5 [329].
p38 MAPK mediates upregulation of atrogin-1/MAFbx and MuRF1 in response to TNF by
an unknown mechanism [206]. IL-1 signaling has also been shown to stimulate phosphory-
lation of p38 MAPK, leading to increased atrogin-1/MAFbx expression, independent of
Akt/FoxO signaling [248]. Furthermore, p38 phosphorylates MRF4 (myogenic regulatory
factor 4), thus inhibiting the expression of selective myogenic genes in late myogenesis, and
antagonizes the JNK proliferation-promoting pathway [330]. JNK mediates AP-1 activation,
which has been implicated in muscle atrophy responses [331]. TNF treatment caused an
increase in p-ERK in differentiating myoblasts, which was accompanied with reduced
MyoD and MyoG levels, as well as reduced MyHC protein content. Administration of the
ERK inhibitor PD98059 to C2C12 cells prevented this inhibitory effect of TNF on myogenic
differentiation [332].
4.7.4. TFEB/TFE3-Signaling
As already mentioned, TRIM63/MuRF1 mRNA and protein expression are rapidly
and strongly increased in various physiological and pathological atrophy conditions [137].
The strong transcriptional regulation during atrophy together with the multitude of its
target proteins highlights the importance of MuRF1 in muscle homeostasis. The expression
of MuRF1/TRIM63 is regulated by several signaling pathways converging onto multiple
transcription factors, such as the FoxO protein family [333,334], myogenin, and NF-κB [335].
Recently, the basic helix-loop-helix leucine zipper (bHLH-LZ) transcription factor EB (TFEB)
and its microphthalmia/transcription factor E (MiT/TFE) family member TFE3 were shown
to regulate Trim63/MuRF1 expression in vitro [336,337]. Importantly, TFEB- and TFE3-
induced TRIM63 expression was shown to be tightly regulated by a transcriptional network
comprised of the class IIa histone deacetylases (HDAC) 4, HDAC5 and HDAC7 and the
protein kinase D-family members PKD1, PKD2 and PKD3. In this pathway, the class IIa
HDACs physically interact with and inhibit the activity of TFEB and TFE3, whereas the
PKDs associate with and phosphorylate these HDACs, resulting in their nuclear export
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and derepression of TFEB and TFE3 followed by an increase in Trim63/MuRF1 expression.
This pathway may at least partially be involved in heart failure-induced muscle wasting
(cardiac cachexia) [336]. Whether it plays a role in inflammation-induced muscle atrophy
warrants further investigation.
4.7.5. IGF/PI3K/AKT Signaling
The insulin-like growth factor-1(IGF-1)/phosphatidylinositol 3-kinase (PI3K)/Akt/
mammalian target of rapamycin (mTOR) pathway is one of the best characterized pathways,
which regulates protein turnover. Evidence suggests that the serine/threonine kinase Akt
(also called Akt1 and PKB, for protein kinase B) increases skeletal muscle mass by activating
anabolic and suppressing catabolic pathways. IGF-1 induces hypertrophy of differentiated
myotubes in vitro [229] and skeletal muscle in vivo since transgenic mice that overexpress
IGF-1 in the skeletal muscle display an increased muscle size [338,339]. IGF-1 via its recep-
tor activates PI3K. PI3K phosphorylates the membrane phospholipid phosphatidylinositol
4,5-bisphosphate to produce phosphatidylinositol 3,4,5-trisphosphate [340], creating a
lipid binding site on the cell membrane for Akt [341]. The subsequent translocation of
Akt to the membrane facilitates its phosphorylation and activation by the kinase PDK-
1 [342]. Direct and indirect targets downstream of Akt include mTOR, ribosomal S6 kinase
(p70S6K) and PHAS-1 (4EBP-1), key regulatory proteins involved in translation and protein
synthesis [229]. Akt-mediated phosphorylation of GSK-3β leads to its inhibition, which
relieves the inhibitory effect of GSK-3β on the eukaryotic translation initiation factor 2B
(eIF2B) [343]. Eukaryotic initiation factors (eIFs) and p70S6K regulate the translational
capacity in skeletal muscle. The formation of the eIF4F complex is a rate-limiting step in
initiation of mRNA translation [344], whereas phosphorylation of p70S6K promotes riboso-
mal biogenesis and translation [345]. Akt also phosphorylates and activates mTOR [346],
which causes phosphorylation of p70S6K and PHAS-1/4E-BP1, activating protein synthesis
and translation initiation, respectively [347]. In addition, Akt is known to prevent mus-
cle loss by phosphorylating FoxO1 and FoxO3a, which prevents their translocation from
the cytosol to the nucleus [333,348]. Recent studies have shown that FoxO transcription
factors are necessary for both atrogin-1/MAFbx and MuRF1 gene expression [140,333].
Thus, activation of the PI3K/Akt signaling pathway in skeletal muscle inhibits the ex-
pression of atrogin-1/MAFbx and MuRF1 by inhibiting the activity of FoxO1 and FoxO3a
transcription factors [333,349]. The activity of the PI3K/Akt/FoxO pathway has been
shown to be suppressed by the deubiquitinating enzyme ubiquitin-specific protease 1
(USP1) in muscle. Specifically, USP1 removes K63-linked polyubiquitin chains on Akt,
which reduces Akt phosphorylation at theonine 308 and suppresses PI3K/Akt signaling
when cellular energy levels are low. USP1-mediated inhibition of the PI3K/Akt pathway
may contribute to muscle wasting, but whether it plays a role in ICUAW needs to be inves-
tigated [350]. Proinflammatory cytokines such as TWEAK have been shown to decrease
Akt activity, which ultimately reduces protein synthesis and increases atrogin-1/MAFbx
and MuRF1 expression via FoxO transcription factors [269].
In addition, insulin via insulin receptor increases phosphorylation of IRS-1, which is
the predominant signaling mediator of this pathway. IRS-1 in turn activates Akt, GSK-3β
and Akt substrate 160 (AS160) to induce translocation of GLUT4, the most important
glucose transporter in muscle cells, to the cell membrane facilitating glucose uptake and
energy production. In critically ill septic patients, insulin resistance is frequently observed,
leading to a perturbed PI3K/Akt/GLUT4 pathway with decreased availability of glucose
and energy, a decreased protein synthesis and an increased protein degradation [42].
The precise mechanism of how proinflammatory cytokines mediate insulin resistance
is not well understood. However, IL-6 has been shown to increase the expression of
SOCS3, which in turn interacts with IRS-1 and mediates its proteasomal degradation [228].
This mechanism might in part explain insulin resistance in septic patients occurring at the
post-receptor level.
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4.8. Involvement of Myogenic Regeneration in Muscle Atrophy of Critically Ill Patients
Skeletal muscle has a remarkable regenerative capacity. However, long-term sequelae
of ICUAW persist for up to 5 years after ICU or hospital discharge, which indicates a
significant defect in myogenic regeneration [17,19]. Previously, a diminished regenerative
capacity was shown in muscle of ICUAW patients and septic mice. This was accompanied
by a reduced number and a defective activation of adult muscle stem cells called satel-
lite cells as well as an impaired myogenic regeneration [351–353]. Satellite cells are the
tissue-residing stem cells of skeletal muscle, providing myonuclei for postnatal muscle
growth and for maintenance and regeneration in adults [354]. They are located between
the basal lamina and the plasmalemma of myofibers [355]. Once activated, satellite cells
proliferate, differentiate and fuse to multinucleated myofibers [354]. This well-regulated
process of myogenesis requires the sequential expression of myogenic transcription fac-
tors [356], proteins involved in myoblast fusion [357,358] and contractile proteins [359].
The role of myogenesis in maintaining skeletal muscle size is well described [360], but
its importance in critical illness is uncertain. Importantly, TGF-β superfamily members,
such as TGF-β, myostatin and activin, were shown to inhibit myogenic differentiation
in vitro and in vivo [361–363]. By contrast, studies using the TβRI specific inhibitor SB-
431542 or overexpression of a dominant negative TβRII in myoblasts revealed that TGF-β
receptors are essential for myogenesis [364,365]. Recently, an increased TGF-β signaling
and elevated TβRII levels were reported in muscle of critically ill patients suggesting their
involvement in muscle atrophy [366,367]. TGF-β binds to the TβRI and TβRII complex to
activate both canonical SMAD-dependent and non-canonical signaling pathways, such
as Akt, which activates protein synthesis and muscle growth [283]. Additionally, and
important for this review, is a study by Kitajima et al., who investigated the function of
the proteasome in satellite cells using mice lacking the crucial proteasomal 19S component,
Rpt3. A satellite cell-specific ablation of Rpt3 resulted in a decreased proteasome activity.
Proteasome dysfunction in Rpt3-deficient satellite cells impaired their ability to prolifer-
ate, survive and differentiate, resulting in defective muscle regeneration. Mechanistically,
they found that the proteasome dysfunction caused an activation of the p53 pathway,
which caused cell-cycle arrest [368]. However, whether or not muscle regeneration plays
a role in sepsis-induced muscle wasting and whether satellite cells and their contribu-
tion to myogenic differentiation and regeneration are involved in this phenotype need
further analyses.
4.9. Is the Ubiquitin Proteasome System a Suitable Target to Prevent Inflammation-Induced
Muscle Wasting?
Given the role of UPS-dependent protein degradation in skeletal muscle atrophy [369],
several groups tested if proteasome inhibitors are effective in this pathology [370–373].
For example, the proteasome inhibitors MG132 and N-acetylleucyl-leucyl-norleucinal
(LLN) suppressed proteolysis in isolated rat skeletal muscles [370]. At baseline, these
proteasome inhibitors inhibited protein breakdown by up to 50%, which was even more
pronounced in atrophying muscles. Importantly, MG132 significantly reduced the increase
in hind limb and diaphragm muscle proteolysis in CLP-operated septic rats [370,374].
Likewise, the proteasome inhibitors N-acetyl-L-leucinyl-L-leucinal-L-norleucinal (LLnL)
and lactacystin also inhibited protein breakdown in muscles from septic rats in vitro [372],
and systemic MG132 treatment decreased the inflammatory response and prolonged
survival in CLP-induced sepsis in mice in vivo [375]. These studies support the hypoth-
esis that the proteasome system is largely responsible for inflammation-induced muscle
proteolysis. However, these studies did not measure muscle force generation or deter-
mine if proteasome inhibitors had any effect on preserving muscle strength in sepsis.
Further analyses by Supinski et al. tested if the proteasome inhibitors MG132, epoxomicin
and bortezomib prevent endotoxin-induced proteolysis in the diaphragm muscle of rats
and if this has favorable effects on muscle strength. Although all of these proteasome
inhibitors attenuated endotoxin-induced proteolysis in the diaphragm muscle, they did not
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prevent the reduction in diaphragm force production [376]. Therefore, these proteasome
inhibitors are unlikely to preserve muscle function in toxic shock patients. However, when
the proteasome inhibitor bortezomib was administered 1 hour before CLP-surgery, it not
only reduced serum levels of inflammatory cytokines but also increased the survival of
septic mice [377]. The proteasome inhibitors MG132 and lactacystin also decreased the
inflammatory response and prolonged survival in CLP-operated mice [375,378]. This sur-
vival benefit is probably related to systemic anti-inflammatory effects as opposed to direct
effects on muscle proteolysis. In this regard, proteasome inhibitors were found to be
effective in chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory
bowel disease [379–381], and the anti-inflammatory effects are again thought to be related
to an inhibition of NF-κB [311,382]. In general, bortezomib is well tolerated by patients,
but it is also associated with toxicity, such as thrombocytopenia, nausea, diarrhea, fatigue,
peripheral neuropathy and generalized weakness [383]. Prevention and treatment of mus-
cle atrophy is often a long-term approach; therefore, side effects of any therapy are likely to
occur. Because the proteasome mediates degradation of a multitude of proteins involved in
critical biological processes, its inhibition may promote the formation of protein aggregates
that may cause proteotoxic and adverse effects (see next chapter). Indeed, proteasome
inhibition by MG132 was shown to cause an accumulation of ubiquitin-conjugated proteins
in rat skeletal muscle [370]. Occurrence of protein aggregates have also been described in
patients with inclusion body myopathy associated with Paget disease of the bone and fron-
totemporal dementia (IBMPFD), which is an autosomal dominant disorder attributed to
mutations in p97/VCP [384]. Several missense mutations in p97/VCP have been identified
in IBMPFD patients, and most of them caused accumulations of ERAD substrates [385].
These accumulations are associated with the IBMPFD phenotype that is characterized by
adult-onset proximal and distal muscle weakness and premature frontotemporal dementia
manifesting in muscle, brain and bone. Additionally, most studies used a preventive rather
than a therapeutic approach to investigate effects of proteasome inhibitors, such as borte-
zomib, which is impossible to be translated into the clinical setting. Taken all these findings
together, the application of pan-reactive proteasome inhibitors to treat ICUAW appears
questionable. However, immunoproteasome-specific inhibitors that have been shown to be
immunosuppressive in mouse models are in phase I trials and may be clinically approved
for treatment of hematopoietic malignancies soon. Their possible benefit in muscle wasting
has to be evaluated very carefully in the future [370,386].
Due to the ubiquitous distribution of the proteasome and its involvement in multiple
cellular processes that are not restricted to striated muscles, its unselected inhibition in
patients may cause more harm than good. One way around this would be to inhibit a
specific UPS-related factor that is restricted to striated muscles and plays a central role in
muscle atrophy. Because the role of the muscle-restricted E3 ubiquitin ligase MuRF1 in
muscle atrophy is well described and many of its interaction partners are known, a MuRF1
inhibitor could be useful to prevent muscle atrophy. Indeed, the groups of S. Labeit and
V. Adams performed an alpha-screen to search for small molecules that block the recog-
nition of titin by MuRF1. This compound prevented dexamethasone-induced myotube
atrophy in vitro and attenuated myofiber atrophy and contractile dysfunction in mouse
muscle during cardiac cachexia in vivo by inhibition of UPS-dependent proteolysis and
protection of de novo protein synthesis [387]. Further studies by the same groups showed
that this MuRF1 inhibitor attenuated diaphragm dysfunction in chronic heart failure in
mice [388], skeletal muscle atrophy and dysfunction in cancer cachexia in mice and skeletal
muscle dysfunction in a rat model of heart failure with preserved ejection fraction [389].
Whether this inhibitor also prevents muscle wasting in sepsis is not known.
Nevertheless, the inhibition of even tissue-restricted E3 ubiquitin ligases also needs to be as-
sessed with caution. For example, the germ line deletion of Trim54/MuRF3 predisposed the
heart for failure and rupture during acute myocardial infarction in mice [390]. In addition,
it has been shown that a homozygous TRIM63/MuRF1 null mutation in combination with
the heterozygous TRIM54/MuRF3 mutation leads to a myosin storage myopathy associ-
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ated with skeletal muscle hypertrophy and hypertrophic cardiomyopathy in patients [391].
Likewise, the combined germ line deletion of Trim63/MuRF1 and Trim54/MuRF3 [151] as
well as the deletion of Trim55/MuRF2 and Trim54/MuRF3 [153] caused a myosin storage
myopathy of the heart and skeletal muscle in mice.
4.10. Proteasome Dysfunction and CANDLE/PRAAS Patients
While activation and upregulation of the UPS contributes essentially to skeletal muscle
atrophy as discussed in the previous paragraphs, proteasome dysfunction also promotes
muscle weakness in contrast to that. Muscle atrophy, myositis, lipodystrophy, arthritis,
recurrent episodes of fever and skin eruptions in patients are typical features in all forms
of Proteasome-Associated Autoinflammatory Syndrome (PRAAS), which is represented by
sterile inflammation [392]. Several names were used by different groups to describe this
disease spectrum [393]. The first direct linkage between impaired proteasome activity and
chronic inflammation was discovered by Agarwal and colleagues in patients suffering from
joint contractures, muscle atrophy, microcytic anemia and panniculitis-induced lipodys-
trophy, and they called this disease JMP (Joint contractures-muscular atrophy-microcytic
anemia-panniculitis-associated lipodystrophy syndrome) syndrome. They found a homozy-
gous missense mutation in the PSMB8 gene encoding the immunoproteasome catalytic
subunit β5i/LMP7 and detected highly increased serum levels of IL-6 and IFN-γ in the
affected patients [394]. Further mutations in the same gene were then found in patients
diagnosed with Japanese autoinflammatory syndrome with lipodystrophy (JASL) [395],
Nakajo-Nishimura syndrome (NNS) [396], and Chronic atypical neutrophilic dermatosis
with lipodystrophy and elevated temperature (CANDLE) [397] who were suffering from
very similar symptoms which lead to the hypothesis that defective immunoproteasomes
are the cause of the disorders. A few years later, this assumption was proven wrong when
Brehm et al. described mutations in four additional proteasome genes (PSMA3, PSMB4,
PSMB9 and POMP) associated with PRAAS, which manifest as well in decreased protea-
some activity and strong type I IFN signature. Therefore, they suggested that a global
proteasome dysfunction is responsible for the chronic activation of a type I IFN response
since all patients displayed decreased expression or hindered proteasome assembly and
accumulation of ubiquitinated proteins [65]. Furthermore, subjects with alterations in the
proteasome chaperone PSMG2 and the remaining immunoproteasome subunit PSMB10
(β2i/MECL-1) also developed PRAAS symptoms [398,399]. Another form of PRAAS,
namely POMP-related autoinflammation and immune dysregulation disease (PRAID),
was described in patients with POMP frameshift variants that escape nonsense-mediated
decay (NMD) and interfere with proper proteasome assembly. They exhibited a severe
neonatal-onset phenotype with pronounced ER stress, activation of the unfolded protein
response and type I IFN response [400]. By now, it is clear that not all discovered protea-
some loss-of-function mutations cause severe autoinflammation. Genomic alterations in
genes of 19S subunits (PSMD12 [401], PSMC3 [402]) or in PSMB1 encoding β6 [403] are
predominantly characterized by neurodevelopmental disorders and do not present with
pronounced autoinflammation [47,392]. In addition to type I IFN, PRAAS patients present
with moderate-to-strongly increased serum levels of IL-6 [393,404]. Moreover, activation
of p38 MAPK was shown in subjects with a mutated version of PSMB8 due to reduced
proteasome activity, which might further contribute to IL-6 elevation [396]. IFN-γ was
only elevated in JMP and JASL syndrome, while TNF levels were increased in NNS [393].
The treatment options for PRAAS patients are limited. Many of them do not respond
well to biologic disease-modifying antirheumatic drugs that target proinflammatory cy-
tokines [65,405]. The application of baricitinib, an orally available inhibitor of JAK1 and
JAK2, which decreases the phosphorylation of STAT1 and blocks type I IFN signaling, has a
very promising outcome and is well tolerated in patients with interferonopathies. The treat-
ment normalized serum levels of inflammatory markers and showed significant clinical
improvement [393,405]. Two recently published studies described successful treatment of
PRAAS patients by hematopoietic stem cell transplant (HSCT), providing strong evidence
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that immunodeficiency and autoinflammation can be traced back to defective proteasomes
in hematopoietic cells [406,407].
It is still under debate what molecular mechanisms are responsible for type I IFN
production following proteasome dysfunction in PRAAS patients. We and others hy-
pothesized an involvement of increased ER stress and activation of the unfolded protein
response (UPR), since it is well established that proteasome impairment affects the ERAD
pathway and leads in turn to the accumulation of damaged and misfolded proteins at
the ER [400,408,409]. There are various pathways that may induce sterile inflammation in
response to persistent ER stress such as mechanisms including the ER-membrane sensors
Activating Transcription Factor 6 (ATF6), protein kinase RNA-like endoplasmic reticulum
kinase (PERK) and inositol-requiring enzyme 1-alpha (IRE1-α) as well as crosstalk with the
integrated stress response (ISR) and mTORC1 activity [410–412].
To date, it was not formally clarified what mechanism exactly triggers the pronounced
muscle atrophy in extremities of PRAAS patients. Whether or not type I IFNs play a direct
role in proteasome dysfunction-induced muscle wasting remains to be determined. One can
speculate that the chronic inflammation, possibly also in the muscle, and increased cytokine
levels in the serum induce the severe loss of muscle mass via the previously discussed
mechanisms. In addition to that, cytokines induce radical production, therefore increasing
the burden of oxidant-damaged proteins and leading to more cellular stress, which cannot
be counteracted by upregulation of proteasomal activity. This in turn reinforces the type I
IFN response and closes the inflammation circle [413].
5. Conclusions
ICUAW is a devastating sequela for critically ill septic patients and inflammatory
cytokines, and acute phase response proteins are involved in its pathogenesis. While the
contribution of E3 ubiquitin ligases, especially atrogin-1/MAFbx and MuRF1, received
much attention, the role of the proteasome in ICUAW and particular inflammation-induced
skeletal muscle atrophy is less well defined. However, data from biopsy specimens of
critically ill human patients, PRAAS patients, animal models of sepsis and toxic shock as
well as proteasome inhibitor studies unequivocally suggest a role of the proteasome itself
in ICUAW. Further studies are needed to decipher the differential role of the proteasome
isoforms in muscle in ICUAW. For example, it would be interesting to know if the com-
position of the muscular proteasomes changes during sepsis; whether this affects their
substrate specificity and which substrates are then degraded; which upstream regulators
are involved in this process; to what extent this affects muscle wasting; and whether this is
related to fiber types and certain muscle groups. Much of our knowledge is based on short-
term animal models ranging from a few hours until four to seven days after the induction
of sepsis or toxic shock. During this time frame, many septic patients have not even seen
a physician. The dynamics of sepsis and inflammation as well as possible long-term side
effects suggest that there is a window of opportunity to administer drugs, but this has
not been sufficiently addressed so far. Proteasome dysfunction in PRAAS patients leads
to muscle wasting indicating the requirement of tightly controlled and balanced protein
homeostasis rather than general proteasome inhibition. If this holds true, biological or
small molecules interfering with inflammatory signaling represent promising treatment
options also for ICUAW patients. A new way to rebalance protein homeostasis and to
control muscle wasting lies in inhibitors of E3 ubiquitin ligases involved muscle protein
breakdown. It is currently uncertain if this leads to a preservation of muscle mass and
function, as these are, together with survival, the most important outcomes for patients.
Much emphasis has been put on molecular mechanisms and treatment options to prevent
or treat ICUAW in human patients, animal models and cell culture with exciting results.
Now is the time for translational approaches.
Author Contributions: All authors contributed to data collection and writing of this review. E.K.
and J.F. conceptualized the work, wrote parts of it, designed figures and reviewed and edited. S.H.-M.
Biomolecules 2021, 11, 1327 27 of 42
wrote substantial parts of the work, designed figures, screened literature, reviewed and edited.
All authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by the German Research Foundation (SFBTR186 TP A13, GRK
2719 B4) to E.K. and (FI 965/5-2, FI 965/9-1, GRK 2719 B5) to J.F., and the German Centre for
Cardiovascular Research, partner site Greifswald (DZHK 81Z5400153) to J.F.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Acknowledgments: We acknowledge support for the Article Processing Charge from the DFG
(German Research Foundation, 393148499) and the Open Access Publication Fund of the University
of Greifswald.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Webster, J.M.; Kempen, L.J.A.P.; Hardy, R.S.; Langen, R.C.J. Inflammation and Skeletal Muscle Wasting During Cachexia. Front.
Physiol. 2020, 11, 11. [CrossRef]
2. Arc-Chagnaud, C.; Py, G.; Fovet, T.; Roumanille, R.; Demangel, R.; Pagano, A.F.; Delobel, P.; Blanc, S.; Jasmin, B.J.;
Blottner, D.; et al. Evaluation of an Antioxidant and Anti-inflammatory Cocktail Against Human Hypoactivity-Induced Skeletal
Muscle Deconditioning. Front. Physiol. 2020, 11, 71. [CrossRef] [PubMed]
3. Traon, A.P.-L.; Heer, M.; Narici, M.V.; Rittweger, J.; Vernikos, J. From space to Earth: Advances in human physiology from 20
years of bed rest studies (1986–2006). Graefe’s Arch. Clin. Exp. Ophthalmol. 2007, 101, 143–194. [CrossRef]
4. Dolly, A.; Dumas, J.; Servais, S. Cancer cachexia and skeletal muscle atrophy in clinical studies: What do we really know?
J. Cachex- Sarcopenia Muscle 2020, 11, 1413–1428. [CrossRef] [PubMed]
5. Watanabe, H.; Enoki, Y.; Maruyama, T. Sarcopenia in Chronic Kidney Disease: Factors, Mechanisms, and Therapeutic Interven-
tions. Biol. Pharm. Bull. 2019, 42, 1437–1445. [CrossRef]
6. Mankowski, R.; Laitano, O.; Clanton, T.; Brakenridge, S. Pathophysiology and Treatment Strategies of Acute Myopathy and
Muscle Wasting after Sepsis. J. Clin. Med. 2021, 10, 1874. [CrossRef] [PubMed]
7. Lexell, J. Ageing and Human Muscle: Observations From Sweden. Can. J. Appl. Physiol. 1993, 18, 2–18. [CrossRef]
8. Bauer, J.; Morley, J.E.; Schols, A.M.W.J.; Ferrucci, L.; Cruz-Jentoft, A.J.; Dent, E.; Baracos, V.E.; Crawford, J.A.; Doehner, W.;
Heymsfield, S.B.; et al. Sarcopenia: A Time for Action. An SCWD Position Paper. J. Cachexia Sarcopenia Muscle 2019, 10, 956–961.
[CrossRef]
9. Sandri, M. Protein breakdown in muscle wasting: Role of autophagy-lysosome and ubiquitin-proteasome. Int. J. Biochem. Cell
Biol. 2013, 45, 2121–2129. [CrossRef]
10. Neel, B.A.; Lin, Y.; Pessin, J.E. Skeletal muscle autophagy: A new metabolic regulator. Trends Endocrinol. Metab. 2013, 24, 635–643.
[CrossRef]
11. Masiero, E.; Sandri, M. Autophagy inhibition induces atrophy and myopathy in adult skeletal muscles. Autophagy 2010,
6, 307–309. [CrossRef] [PubMed]
12. Fan, E.; Cheek, F.; Chlan, L.; Gosselink, R.; Hart, N.; Herridge, M.; Hopkins, R.O.; Hough, C.L.; Kress, J.P.; Latronico, N.; et al.
An Official American Thoracic Society Clinical Practice Guideline: The Diagnosis of Intensive Care Unit–acquired Weakness in
Adults. Am. J. Respir. Crit. Care Med. 2014, 190, 1437–1446. [CrossRef]
13. Schweickert, W.D.; Hall, J. ICU-Acquired Weakness. Chest 2007, 131, 1541–1549. [CrossRef] [PubMed]
14. Appleton, R.T.; Kinsella, J.; Quasim, T. The incidence of intensive care unit-acquired weakness syndromes: A systematic review.
J. Intensiv. Care Soc. 2014, 16, 126–136. [CrossRef]
15. Sharshar, T.; Bastuji-Garin, S.; Stevens, R.D.; Durand, M.-C.; Malissin, I.; Rodriguez, P.; Cerf, C.; Outin, H.; De Jonghe, B.
Presence and severity of intensive care unit-acquired paresis at time of awakening are associated with increased intensive care
unit and hospital mortality*. Crit. Care Med. 2009, 37, 3047–3053. [CrossRef]
16. De Jonghe, B.; Bastuji-Garin, S.; Durand, M.-C.; Malissin, I.; Rodrigues, P.; Cerf, C.; Outin, H.; Sharshar, T. Respiratory weakness is
associated with limb weakness and delayed weaning in critical illness. Crit. Care Med. 2007, 35, 2007–2015. [CrossRef] [PubMed]
17. Van Aerde, N.; Meersseman, P.; Debaveye, Y.; Wilmer, A.; Gunst, J.; Casaer, M.P.; Bruyninckx, F.; Wouters, P.J.; Gosselink, R.;
Berghe, G.V.D.; et al. Five-year impact of ICU-acquired neuromuscular complications: A prospective, observational study.
Intensiv. Care Med. 2020, 46, 1184–1193. [CrossRef]
18. Koch, S.; Wollersheim, T.; Bierbrauer, J.; Haas, K.; Mörgeli, R.; Deja, M.; Spies, C.; Spuler, S.; Krebs, M.;
Weber-Carstens, S. Long-term recovery In critical illness myopathy is complete, contrary to polyneuropathy. Muscle
Nerve 2014, 50, 431–436. [CrossRef]
19. Herridge, M.S.; Tansey, C.M.; Matté, A.; Tomlinson, G.; Diaz-Granados, N.; Cooper, A.; Guest, C.B.; Mazer, C.D.; Mehta, S.;
Stewart, T.E.; et al. Functional Disability 5 Years after Acute Respiratory Distress Syndrome. N. Engl. J. Med. 2011, 364, 1293–1304.
[CrossRef]
Biomolecules 2021, 11, 1327 28 of 42
20. Puthucheary, Z.A.; Rawal, J.; McPhail, M.; Connolly, B.; Ratnayake, G.; Chan, P.; Hopkinson, N.S.; Padhke, R.; Dew, T.;
Sidhu, P.S.; et al. Acute Skeletal Muscle Wasting in Critical Illness. JAMA 2013, 310, 1591–1600. [CrossRef]
21. Yang, T.; Li, Z.; Jiang, L.; Wang, Y.; Xi, X. Risk factors for intensive care unit-acquired weakness: A systematic review and
meta-analysis. Acta Neurol. Scand. 2018, 138, 104–114. [CrossRef]
22. Zusman, O.; Theilla, M.; Cohen, J.; Kagan, I.; Bendavid, I.; Singer, P. Resting energy expenditure, calorie and protein consumption
in critically ill patients: A retrospective cohort study. Crit. Care 2016, 20, 1–8. [CrossRef]
23. Weijs, P.J.M.; Stapel, S.N.; De Groot, S.D.W.; Driessen, R.H.; De Jong, E.; Girbes, A.R.J.; Van Schijndel, R.J.M.S.; Beishuizen, A.
Optimal Protein and Energy Nutrition Decreases Mortality in Mechanically Ventilated, Critically Ill Patients. J. Parenter. Enter.
Nutr. 2011, 36, 60–68. [CrossRef]
24. Compher, C.; Chittams, J.; Sammarco, T.; Nicolo, M.; Heyland, D.K. Greater Protein and Energy Intake May Be Associated With
Improved Mortality in Higher Risk Critically Ill Patients. Crit. Care Med. 2017, 45, 156–163. [CrossRef]
25. Allingstrup, M.J.; Kondrup, J.; Wiis, J.; Claudius, C.; Pedersen, U.G.; Hein-Rasmussen, R.; Bjerregaard, M.R.; Steensen, M.; Jensen,
T.H.; Lange, T.; et al. Early goal-directed nutrition versus standard of care in adult intensive care patients: The single-centre,
randomised, outcome assessor-blinded EAT-ICU trial. Intensiv. Care Med. 2017, 43, 1637–1647. [CrossRef] [PubMed]
26. Caparrós, T.; Lopez, J.; Grau, T. Early Enteral Nutrition in Critically III Patients With a High-Protein Diet Enriched with Arginine,
Fiber, and Antioxidants Compared With a Standard High-Protein Diet. The Effect on Nosocomial Infections and Outcome. J.
Parenter. Enter. Nutr. 2001, 25, 299–309. [CrossRef] [PubMed]
27. Rugeles, S.; Villarraga-Angulo, L.G.; Ariza-Gutiérrez, A.; Chaverra-Kornerup, S.; Lasalvia, P.; Rosselli, D. High-protein hypocaloric
vs normocaloric enteral nutrition in critically ill patients: A randomized clinical trial. J. Crit. Care 2016, 35, 110–114. [CrossRef]
28. Desai, T.K.; Carlson, R.W.; Geheb, M.A. Prevalence and clinical implications of hypocalcemia in acutely III patients in a medical
intensive care setting. Am. J. Med. 1988, 84, 209–214. [CrossRef]
29. Burchard, K.W.; Gann, D.S.; Colliton, J.; Forster, J. Ionized Calcium, Parathormone, and Mortality in Critically 111 Surgical
Patients. Ann. Surg. 1990, 212, 543–550. [CrossRef]
30. Egi, M.; Kim, I.; Nichol, A.; Stachowski, E.; French, C.J.; Hart, G.K.; Hegarty, C.; Bailey, M.; Bellomo, R. Ionized calcium
concentration and outcome in critical illness. Crit. Care Med. 2011, 39, 314–321. [CrossRef]
31. Berek, K.; Margreiter, J.; Willeit, J.; Berek, A.; Schmutzhard, E.; Mutz, N.J. Polyneuropathies in critically ill patients: A prospective
evaluation. Intensiv. Care Med. 1996, 22, 849–855. [CrossRef]
32. De Jonghe, B.; Cook, D.; Sharshar, T.; Lefaucheur, J.-P.; Carlet, J.; Outin, H. Acquired neuromuscular disorders in critically ill
patients: A systematic review. Intensiv. Care Med. 1998, 24, 1242–1250. [CrossRef] [PubMed]
33. Perner, A.; Gordon, A.; De Backer, D.; Dimopoulos, G.; Russell, J.A.; Lipman, J.; Jensen, J.U.S.; Myburgh, J.; Singer, M.;
Bellomo, R.; et al. Sepsis: Frontiers in diagnosis, resuscitation and antibiotic therapy. Intensiv. Care Med. 2016, 42, 1958–1969.
[CrossRef] [PubMed]
34. Sakr, Y.; Jaschinski, U.; Wittebole, X.; Szakmany, T.; Lipman, J.; Ñamendys-Silva, S.A.; Martin-Loeches, I.; Leone, M.; Lupu, M.-N.;
Vincent, J.-L.; et al. Sepsis in Intensive Care Unit Patients: Worldwide Data From the Intensive Care over Nations Audit. Open
Forum Infect. Dis. 2018, 5, ofy313. [CrossRef] [PubMed]
35. Vincent, J.-L.; on behalf of the ICON and SOAP investigators; Lefrant, J.-Y.; Kotfis, K.; Nanchal, R.; Martin-Loeches, I.;
Wittebole, X.; Sakka, S.G.; Pickkers, P.; Moreno, R.; et al. Comparison of European ICU patients in 2012 (ICON) versus
2002 (SOAP). Intensiv. Care Med. 2018, 44, 337–344. [CrossRef] [PubMed]
36. Medrinal, C.; Prieur, G.; Bonnevie, T.; Gravier, F.-E.; Mayard, D.; Desmalles, E.; Smondack, P.; Lamia, B.; Combret, Y.; Fossat, G.
Muscle weakness, functional capacities and recovery for COVID-19 ICU survivors. BMC Anesthesiol. 2021, 21, 64. [CrossRef]
37. Van Aerde, N.; Berghe, G.V.D.; Wilmer, A.; Gosselink, R.; Hermans, G. Intensive care unit acquired muscle weakness in COVID-19
patients. Intensiv. Care Med. 2020, 46, 2083–2085. [CrossRef]
38. Berger, D.; Bloechlinger, S.; Von Haehling, S.; Doehner, W.; Takala, J.; Z’Graggen, W.J.; Schefold, J.C. Dysfunction of respiratory
muscles in critically ill patients on the intensive care unit. J. Cachex- Sarcopenia Muscle 2016, 7, 403–412. [CrossRef]
39. Wollersheim, T.; Woehlecke, J.; Krebs, M.; Hamati, J.; Lodka, D.; Luther-Schroeder, A.; Langhans, C.; Haas, K.; Radtke, T.;
Kleber, C.; et al. Dynamics of myosin degradation in intensive care unit-acquired weakness during severe critical illness. Intensiv.
Care Med. 2014, 40, 528–538. [CrossRef]
40. Ochala, J.; Larsson, L. Effects of a preferential myosin loss on Ca2+activation of force generation in single human skeletal muscle
fibres. Exp. Physiol. 2008, 93, 486–495. [CrossRef]
41. Bierbrauer, J.; Koch, S.; Olbricht, C.; Hamati, J.; Lodka, D.; Schneider, J.; Luther-Schröder, A.; Kleber, C.; Faust, K.;
Wiesener, S.; et al. Early type II fiber atrophy in intensive care unit patients with nonexcitable muscle membrane. Crit. Care Med.
2012, 40, 647–650. [CrossRef]
42. Weber-Carstens, S.; Schneider, J.; Wollersheim, T.; Assmann, A.; Bierbrauer, J.; Marg, A.; Al Hasani, H.; Chadt, A.; Wenzel, K.;
Koch, S.; et al. Critical Illness Myopathy and GLUT4. Am. J. Respir. Crit. Care Med. 2013, 187, 387–396. [CrossRef] [PubMed]
43. Langhans, C.; Weber-Carstens, S.; Schmidt, F.; Hamati, J.; Kny, M.; Zhu, X.; Wollersheim, T.; Koch, S.; Krebs, M.;
Schulz, H.; et al. Inflammation-Induced Acute Phase Response in Skeletal Muscle and Critical Illness Myopathy. PLoS
ONE 2014, 9, e92048. [CrossRef] [PubMed]
44. Solomon, V.; Goldberg, A.L. Importance of the ATP-Ubiquitin-Proteasome Pathway in the Degradation of Soluble and Myofibrillar
Proteins in Rabbit Muscle Extracts. J. Biol. Chem. 1996, 271, 26690–26697. [CrossRef]
Biomolecules 2021, 11, 1327 29 of 42
45. Cohen, S.; Nathan, J.A.; Goldberg, A.L. Muscle wasting in disease: Molecular mechanisms and promising therapies. Nat. Rev.
Drug Discov. 2015, 14, 58–74. [CrossRef]
46. Gregorio, C.C.; Antin, P. To the heart of myofibril assembly. Trends Cell Biol. 2000, 10, 355–362. [CrossRef]
47. Çetin, G.; Klafack, S.; Studencka-Turski, M.; Krüger, E.; Ebstein, F. The Ubiquitin–Proteasome System in Immune Cells. Biomol.
2021, 11, 60. [CrossRef]
48. Swatek, K.N.; Komander, D. Ubiquitin modifications. Cell Res. 2016, 26, 399–422. [CrossRef]
49. Hurley, J.H.; Lee, S.; Prag, G. Ubiquitin-binding domains. Biochem. J. 2006, 399, 361–372. [CrossRef] [PubMed]
50. Chen, X.; Htet, Z.M.; López-Alfonzo, E.; Martin, A.; Walters, K.J. Proteasome interaction with ubiquitinated substrates: From
mechanisms to therapies. FEBS J. 2020. [CrossRef] [PubMed]
51. Heink, S.; Ludwig, D.; Kloetzel, P.-M.; Krüger, E. From The Cover: IFN-Induced immune adaptation of the proteasome system is
an accelerated and transient response. Proc. Natl. Acad. Sci. USA 2005, 102, 9241–9246. [CrossRef] [PubMed]
52. Seifert, U.; Bialy, L.P.; Ebstein, F.; Bech-Otschir, D.; Voigt, A.; Schröter, F.; Prozorovski, T.; Lange, N.; Steffen, J.; Rieger, M.; et al.
Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress. Cell 2010, 142, 613–624. [CrossRef]
53. Niewerth, D.; Kaspers, G.J.; Assaraf, Y.G.; van Meerloo, J.; Kirk, C.J.; Anderl, J.; Blank, J.L.; van de Ven, P.M.; Zweegman, S.;
Jansen, G.; et al. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in
human hematological cell lines. J. Hematol. Oncol. 2014, 7, 7. [CrossRef]
54. SijtsP, E.J.A.M.; Kloetzel, P.-M. The role of the proteasome in the generation of MHC class I ligands and immune responses. Cell.
Mol. Life Sci. 2011, 68, 1491–1502. [CrossRef]
55. Yewdell, J.W.; Antón, L.C.; Bennink, J.R. Defective ribosomal products (DRiPs): A major source of antigenic peptides for MHC
class I molecules? J. Immunol. 1996, 157, 1823–1826.
56. Yewdell, J.W.; Hollý, J. DRiPs get molecular. Curr. Opin. Immunol. 2020, 64, 130–136. [CrossRef]
57. Rock, K.L.; Farfan-Arribas, D.; Colbert, J.D.; Goldberg, A.L. Re-examining class-I presentation and the DRiP hypothesis. Trends
Immunol. 2014, 35, 144–152. [CrossRef]
58. Guillaume, B.; Stroobant, V.; Bousquet, M.-P.; Colau, D.; Chapiro, J.; Parmentier, N.; Dalet, A.; Eynde, B.J.V.D. Analysis of
the Processing of Seven Human Tumor Antigens by Intermediate Proteasomes. J. Immunol. 2012, 189, 3538–3547. [CrossRef]
[PubMed]
59. Gohlke, S.; Kloβ, A.; Tsokos, M.; Textoris-Taube, K.; Keller, C.; Kloetzel, P.-M.; Dahlmann, B. Adult human liver contains
intermediate-type proteasomes with different enzymatic properties. Ann. Hepatol. 2014, 13, 429–438. [CrossRef]
60. Dahlmann, B. Mammalian proteasome subtypes: Their diversity in structure and function. Arch. Biochem. Biophys. 2016,
591, 132–140. [CrossRef] [PubMed]
61. Rousseau, A.; Bertolotti, A. Regulation of proteasome assembly and activity in health and disease. Nat. Rev. Mol. Cell Biol. 2018,
19, 697–712. [CrossRef] [PubMed]
62. Ebstein, F.; Kloetzel, P.-M.; Krüger, E.; Seifert, U.; Krueger, E. Emerging roles of immunoproteasomes beyond MHC class I antigen
processing. Cell. Mol. Life Sci. 2012, 69, 2543–2558. [CrossRef] [PubMed]
63. Ebstein, F.; Voigt, A.; Lange, N.; Warnatsch, A.; Schröter, F.; Prozorovski, T.; Kuckelkorn, U.; Aktas, O.; Seifert, U.; Kloetzel, P.-M.;
et al. Immunoproteasomes Are Important for Proteostasis in Immune Responses. Cell 2013, 152, 935–937. [CrossRef]
64. Murata, S.; Yashiroda, H.; Tanaka, K. Molecular mechanisms of proteasome assembly. Nat. Rev. Mol. Cell Biol. 2009, 10, 104–115.
[CrossRef] [PubMed]
65. Brehm, A.; Liu, Y.; Sheikh, A.; Marrero, B.; Omoyinmi, E.; Zhou, Q.; Montealegre, G.; Biancotto, A.; Reinhardt, A.;
De Jesus, A.A.; et al. Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN
production. J. Clin. Investig. 2015, 125, 4196–4211. [CrossRef]
66. Radhakrishnan, S.; Lee, C.S.; Young, P.; Beskow, A.; Chan, J.Y.; Deshaies, R.J. Transcription Factor Nrf1 Mediates the Proteasome
Recovery Pathway after Proteasome Inhibition in Mammalian Cells. Mol. Cell 2010, 38, 17–28. [CrossRef]
67. Xie, Y.; Varshavsky, A. RPN4 is a ligand, substrate, and transcriptional regulator of the 26S proteasome: A negative feedback
circuit. Proc. Natl. Acad. Sci. 2001, 98, 3056–3061. [CrossRef]
68. Lehrbach, N.; Ruvkun, G. Proteasome dysfunction triggers activation of SKN-1A/Nrf1 by the aspartic protease DDI-1. eLife 2016,
5, e17721. [CrossRef]
69. Grimberg, K.B.; Beskow, A.; Lundin, D.; Davis, M.M.; Young, P. Basic Leucine Zipper Protein Cnc-C Is a Substrate and
Transcriptional Regulator of the Drosophila 26S Proteasome. Mol. Cell. Biol. 2011, 31, 897–909. [CrossRef]
70. Kim, H.M.; Han, J.W.; Chan, J.Y. Nuclear Factor Erythroid-2 Like 1 (NFE2L1): Structure, function and regulation. Gene 2016, 584,
17–25. [CrossRef]
71. Chan, J.Y.; Kwong, M.; Lu, R.; Chang, J.; Wang, B.; Yen, T.; Kan, Y.W. Targeted disruption of the ubiquitous CNC-bZIP transcription
factor, Nrf-1, results in anemia and embryonic lethality in mice. EMBO J. 1998, 17, 1779–1787. [CrossRef]
72. Wang, W.; Chan, J.Y. Nrf1 Is Targeted to the Endoplasmic Reticulum Membrane by an N-terminal Transmembrane Domain.
J. Biol. Chem. 2006, 281, 19676–19687. [CrossRef] [PubMed]
73. Zhang, Y.; Crouch, D.H.; Yamamoto, M.; Hayes, J.D. Negative regulation of the Nrf1 transcription factor by its N-terminal domain
is independent of Keap1: Nrf1, but not Nrf2, is targeted to the endoplasmic reticulum. Biochem. J. 2006, 399, 373–385. [CrossRef]
[PubMed]
Biomolecules 2021, 11, 1327 30 of 42
74. Radhakrishnan, S.; Besten, W.D.; Deshaies, R.J. p97-dependent retrotranslocation and proteolytic processing govern formation of
active Nrf1 upon proteasome inhibition. eLife 2014, 3, e01856. [CrossRef]
75. Northrop, A.; Byers, H.A.; Radhakrishnan, S.K. Regulation of NRF1, a master transcription factor of proteasome genes: Implica-
tions for cancer and neurodegeneration. Mol. Biol. Cell 2020, 31, 2158–2163. [CrossRef] [PubMed]
76. Steffen, J.; Seeger, M.; Koch, A.; Krueger, E. Proteasomal Degradation Is Transcriptionally Controlled by TCF11 via an ERAD-
Dependent Feedback Loop. Mol. Cell 2010, 40, 147–158. [CrossRef] [PubMed]
77. Sotzny, F.; Schormann, E.; Kühlewindt, I.; Koch, A.; Brehm, A.; Goldbach-Mansky, R.; Gilling, K.E.; Krüger, E. TCF11/Nrf1-
Mediated Induction of Proteasome Expression Prevents Cytotoxicity by Rotenone. Antioxidants Redox Signal. 2016, 25, 870–885.
[CrossRef] [PubMed]
78. Tomlin, F.M.; Gerling-Driessen, U.I.M.; Liu, Y.-C.; Flynn, R.A.; Vangala, J.R.; Lentz, C.S.; Clauder-Muenster, S.; Jakob, P.;
Mueller, W.F.; Ordoñez-Rueda, D.; et al. Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome
Inhibitor Cytotoxicity. ACS Central Sci. 2017, 3, 1143–1155. [CrossRef] [PubMed]
79. Lehrbach, N.; Breen, P.C.; Ruvkun, G. Protein Sequence Editing of SKN-1A/Nrf1 by Peptide:N-Glycanase Controls Proteasome
Gene Expression. Cell 2019, 177, 737–750.e15. [CrossRef]
80. Zhang, Y.; Li, S.; Xiang, Y.; Qiu, L.; Zhao, H.; Hayes, J. The selective post-translational processing of transcription factor Nrf1
yields distinct isoforms that dictate its ability to differentially regulate gene expression. Sci. Rep. 2015, 5, 12983. [CrossRef]
81. Sha, Z.; Goldberg, A.L. Proteasome-Mediated Processing of Nrf1 Is Essential for Coordinate Induction of All Proteasome Subunits
and p97. Curr. Biol. 2014, 24, 1573–1583. [CrossRef]
82. Vangala, J.R.; Sotzny, F.; Krueger, E.; Deshaies, R.; Radhakrishnan, S.K. Nrf1 can be processed and activated in a proteasome-
independent manner. Curr. Biol. 2016, 26, R834–R835. [CrossRef]
83. Nowak, K.; Taubert, R.M.; Haberecht, S.; Venz, S.; Krüger, E. Inhibition of calpain-1 stabilizes TCF11/Nrf1 but does not affect its
activation in response to proteasome inhibition. Biosci. Rep. 2018, 38, BSR20180393. [CrossRef]
84. Koizumi, S.; Irie, T.; Hirayama, S.; Sakurai, Y.; Yashiroda, H.; Naguro, I.; Ichijo, H.; Hamazaki, J.; Murata, S. The aspartyl protease
DDI2 activates Nrf1 to compensate for proteasome dysfunction. eLife 2016, 5, e18357. [CrossRef] [PubMed]
85. Yip, M.C.J.; Bodnar, N.O.; Rapoport, T.A. Ddi1 is a ubiquitin-dependent protease. Proc. Natl. Acad. Sci. 2020, 117, 7776–7781.
[CrossRef]
86. Dirac-Svejstrup, A.B.; Walker, J.; Faull, P.; Encheva, V.; Akimov, V.; Puglia, M.; Perkins, D.; Kümper, S.; Hunjan, S.S.;
Blagoev, B.; et al. DDI2 Is a Ubiquitin-Directed Endoprotease Responsible for Cleavage of Transcription Factor NRF1. Mol. Cell
2020, 79, 332–341.e7. [CrossRef] [PubMed]
87. Kwak, M.-K.; Wakabayashi, N.; Greenlaw, J.L.; Yamamoto, M.; Kensler, T.W. Antioxidants Enhance Mammalian Proteasome
Expression through the Keap1-Nrf2 Signaling Pathway. Mol. Cell. Biol. 2003, 23, 8786–8794. [CrossRef]
88. Arlt, A.; Bauer, I.; Schafmayer, C.; Tepel, J.; Müerköster, S.S.; Brosch, M.; Röder, C.; Kalthoff, H.; Hampe, J.; Moyer, M.P.; et al.
Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of
nuclear factor E2-related factor 2 (Nrf2). Oncogene 2009, 28, 3983–3996. [CrossRef] [PubMed]
89. Furuya, N.; Ikeda, S.-I.; Sato, S.; Soma, S.; Ezaki, J.; Trejo, J.A.O.; Takeda-Ezaki, M.; Fujimura, T.; Arikawa-Hirasawa, E.;
Tada, N.; et al. PARK2/Parkin-mediated mitochondrial clearance contributes to proteasome activation during slow-twitch muscle
atrophy via NFE2L1 nuclear translocation. Autophagy 2014, 10, 631–641. [CrossRef]
90. Baumann, C.W.; Liu, H.M.; Thompson, L.V. Denervation-Induced Activation of the Ubiquitin-Proteasome System Reduces
Skeletal Muscle Quantity Not Quality. PLoS ONE 2016, 11, e0160839. [CrossRef]
91. Liu, H.M.; Ferrington, D.; Baumann, C.W.; Thompson, L.V. Denervation-Induced Activation of the Standard Proteasome and
Immunoproteasome. PLoS ONE 2016, 11, e0166831. [CrossRef]
92. Kobayashi, A. Roles of NRF3 in the Hallmarks of Cancer: Proteasomal Inactivation of Tumor Suppressors. Cancers 2020, 12, 2681.
[CrossRef] [PubMed]
93. Xu, H.; Fu, J.; Ha, S.-W.; Ju, D.; Zheng, J.; Li, L.; Xie, Y. The CCAAT box-binding transcription factor NF-Y regulates basal
expression of human proteasome genes. Biochim. et Biophys. Acta (BBA)-Bioenerg. 2012, 1823, 818–825. [CrossRef] [PubMed]
94. Ehmsen, J.T.; Höke, A. Cellular and molecular features of neurogenic skeletal muscle atrophy. Exp. Neurol. 2020, 331, 113379.
[CrossRef] [PubMed]
95. Liu, Y.; Qiao, F.; Leiferman, P.C.; Ross, A.; Schlenker, E.H.; Wang, H. FOXOs modulate proteasome activity in human-induced
pluripotent stem cells of Huntington’s disease and their derived neural cells. Hum. Mol. Genet. 2017, 26, 4416–4428. [CrossRef]
[PubMed]
96. Vangala, J.R.; Dudem, S.; Jain, N.; Kalivendi, S.V. Regulation of PSMB5 Protein and β Subunits of Mammalian Proteasome by
Constitutively Activated Signal Transducer and Activator of Transcription 3 (STAT3). J. Biol. Chem. 2014, 289, 12612–12622.
[CrossRef] [PubMed]
97. Koizumi, S.; Hamazaki, J.; Murata, S. Transcriptional regulation of the 26S proteasome by Nrf1. Proc. Jpn. Acad. Ser. B 2018,
94, 325–336. [CrossRef]
98. Vilchez, D.; Boyer, L.; Morantte, I.; Lutz, M.; Merkwirth, C.; Joyce, D.; Spencer, B.; Page, L.; Masliah, E.; Berggren, W.T.; et al.
Increased proteasome activity in human embryonic stem cells is regulated by PSMD11. Nat. Cell Biol. 2012, 489, 304–308.
[CrossRef] [PubMed]
Biomolecules 2021, 11, 1327 31 of 42
99. Zhang, Y.; Manning, B.D. mTORC1 signaling activates NRF1 to increase cellular proteasome levels. Cell Cycle 2015, 14, 2011–2017.
[CrossRef]
100. Aki, M.; Shimbara, N.; Takashina, M.; Akiyama, K.; Kagawa, S.; Tamura, T.; Tanahashi, N.; Yoshimura, T.; Tanaka, K.; Ichihara, A.
Interferon-γ Induces Different Subunit Organizations and Functional Diversity of Proteasomes1. J. Biochem. 1994, 115, 257–269.
[CrossRef]
101. Loukissa, A.; Cardozo, C.; Altschuller-Felberg, C.; Nelson, J.E. Control of lmp7 expression in human endothelial cells by cytokines
regulating cellular and humoral immunity. Cytokine 2000, 12, 1326–1330. [CrossRef]
102. Haller, K.; Seki, K.; Wei, C.; Castelli, C.; Rivoltini, L.; Kiessling, R.; Levitskaya, J. Tumor necrosis factor-α induces coordinated
changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell
surface. Blood 2001, 98, 1108–1115. [CrossRef]
103. Callahan, M.K.; Wohlfert, E.A.; Ménoret, A.; Srivastava, P.K. Heat shock up-regulates lmp2 and lmp7 and enhances presentation
of immunoproteasome-dependent epitopes. J. Immunol. 2006, 177, 8393–8399. [CrossRef] [PubMed]
104. Husom, A.D.; Peters, E.A.; Kolling, E.A.; Fugere, N.A.; Thompson, L.V.; Ferrington, D. Altered proteasome function and subunit
composition in aged muscle. Arch. Biochem. Biophys. 2004, 421, 67–76. [CrossRef] [PubMed]
105. Díaz-Hernández, M.; Hernández, F.; Martín-Aparicio, E.; Gómez-Ramos, P.; Morán, M.A.; Castaño, J.G.; Ferrer, I.; Avila, J.;
Lucas, J.J. Neuronal Induction of the Immunoproteasome in Huntington’s Disease. J. Neurosci. 2003, 23, 11653–11661. [CrossRef]
[PubMed]
106. Ferrer, I.; Rovira, M.B.; Guerra, M.L.S.; Rey, M.J.; Costa-Jussá, F. Neuropathology and Pathogenesis of Encephalitis following
Amyloid β Immunization in Alzheimer’s Disease. Brain Pathol. 2004, 14, 11–20. [CrossRef]
107. Shin, E.-C.; Seifert, U.; Kato, T.; Rice, C.M.; Feinstone, S.M.; Kloetzel, P.-M.; Rehermann, B. Virus-induced type I IFN stimulates
generation of immunoproteasomes at the site of infection. J. Clin. Investig. 2006, 116, 3006–3014. [CrossRef] [PubMed]
108. Freudenburg, W.; Gautam, M.; Chakraborty, P.; James, J.; Richards, J.; Salvatori, A.S.; Baldwin, A.; Schriewer, J.; Buller, R.M.L.;
Corbett, J.A.; et al. Immunoproteasome Activation During Early Antiviral Response in Mouse Pancreatic β-cells: New Insights
into Auto-antigen Generation in Type I Diabetes? J. Clin. Cell. Immunol. 2013, 4, 1–5. [CrossRef]
109. Chatterjee-Kishore, M.; Wright, K.L.; Ting, J.P.-Y.; Stark, G.R. How Stat1 mediates constitutive gene expression: A complex of
unphosphorylated Stat1 and IRF1 supports transcription of the LMP2 gene. EMBO J. 2000, 19, 4111–4122. [CrossRef]
110. Gautel, M.; Djinovic-Carugo, K. The sarcomeric cytoskeleton: From molecules to motion. J. Exp. Biol. 2016, 219, 135–145.
[CrossRef]
111. Rottbauer, W.; Wessels, G.; Dahme, T.; Just, S.; Trano, N.; Hassel, D.; Burns, C.G.; Katus, H.A.; Fishman, M.C. Cardiac Myosin
Light Chain-2. Circ. Res. 2006, 99, 323–331. [CrossRef]
112. Yang, Q.; Sanbe, A.; Osinska, H.; Hewett, T.E.; Klevitsky, R.; Robbins, J. A mouse model of myosin binding protein C human
familial hypertrophic cardiomyopathy. J. Clin. Investig. 1998, 102, 1292–1300. [CrossRef] [PubMed]
113. Agnetti, G.; Herrmann, H.; Cohen, S. New roles for desmin in the maintenance of muscle homeostasis. FEBS J. 2021. [CrossRef]
[PubMed]
114. Cohen, S.; Zhai, B.; Gygi, S.P.; Goldberg, A.L. Ubiquitylation by Trim32 causes coupled loss of desmin, Z-bands, and thin filaments
in muscle atrophy. J. Cell Biol. 2012, 198, 575–589. [CrossRef]
115. Kramerova, I.; Kudryashova, E.; Venkatraman, G.; Spencer, M.J. Calpain 3 participates in sarcomere remodeling by acting
upstream of the ubiquitin–proteasome pathway. Hum. Mol. Genet. 2005, 14, 2125–2134. [CrossRef]
116. Du, J.; Wang, X.; Miereles, C.; Bailey, J.L.; Debigaré, R.; Zheng, B.; Price, S.R.; Mitch, W.E. Activation of caspase-3 is an initial step
triggering accelerated muscle proteolysis in catabolic conditions. J. Clin. Investig. 2004, 113, 115–123. [CrossRef]
117. Cohen, S. Role of calpains in promoting desmin filaments depolymerization and muscle atrophy. Biochim. et Biophys. Acta
(BBA)-Bioenerg. 2020, 1867, 118788. [CrossRef]
118. Tidball, J.G.; Spencer, M.J. Expression of a calpastatin transgene slows muscle wasting and obviates changes in myosin isoform
expression during murine muscle disuse. J. Physiol. 2002, 545, 819–828. [CrossRef]
119. Smith, I.J.; Lecker, S.H.; Hasselgren, P.-O. Calpain activity and muscle wasting in sepsis. Am. J. Physiol. Metab. 2008,
295, E762–E771. [CrossRef]
120. Aweida, D.; Rudesky, I.; Volodin, A.; Shimko, E.; Cohen, S. GSK3-β promotes calpain-1–mediated desmin filament depolymeriza-
tion and myofibril loss in atrophy. J. Cell Biol. 2018, 217, 3698–3714. [CrossRef] [PubMed]
121. Guroff, G. A Neutral, Calcium-activated Proteinase from the Soluble Fraction of Rat Brain. J. Biol. Chem. 1964, 239, 149–155.
[CrossRef]
122. Goll, D.E.; Thompson, V.F.; Li, H.; Wei, W.; Cong, J. The Calpain System. Physiol. Rev. 2003, 83, 731–801. [CrossRef] [PubMed]
123. Baudry, M. Calpain-1 and Calpain-2 in the Brain: Dr. Jekill and Mr Hyde? Curr. Neuropharmacol. 2019, 17, 823–829. [CrossRef]
[PubMed]
124. Richard, I.; Broux, O.; Allamand, V.; Fougerousse, F.; Chiannilkulchai, N.; Bourg, N.; Brenguier, L.; Devaud, C.; Pasturaud, P.;
Roudaut, C.; et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995,
81, 27–40. [CrossRef]
125. Richard, I.; Roudaut, C.; Marchand, S.; Baghdiguian, S.; Herasse, M.; Stockholm, D.; Ono, Y.; Suel, L.; Bourg, N.; Sorimachi, H.;
et al. Loss of Calpain 3 Proteolytic Activity Leads to Muscular Dystrophy and to Apoptosis-Associated Iκbα/Nuclear Factor κb
Pathway Perturbation in Mice. J. Cell Biol. 2000, 151, 1583–1590. [CrossRef] [PubMed]
Biomolecules 2021, 11, 1327 32 of 42
126. Bartoli, M.; Richard, I. Calpains in Muscle Wasting Review. Available online: https://reader.elsevier.com/reader/sd/pii/S135
7272505000208?token=D09B11C9F65BEEE80C9FAF13B2FE629C9B52EEF445E37CDC6C16FDE7B3206F6EC9CEF731B1DD185
AD08A9BFD0372F1CF&originRegion=eu-west-1&originCreation=20210504092316 (accessed on 4 May 2021).
127. Sorimachi, H.; Mamitsuka, H.; Ono, Y. Understanding the substrate specificity of conventional calpains. Biol. Chem. 2012,
393, 853–871. [CrossRef]
128. Ono, Y.; Saido, T.C.; Sorimachi, H. Calpain research for drug discovery: Challenges and potential. Nat. Rev. Drug Discov. 2016,
15, 854–876. [CrossRef]
129. Shenkman, B.S.; Belova, S.P.; Lomonosova, Y.N.; Kostrominova, T.Y.; Nemirovskaya, T.L. Calpain-dependent regulation of the
skeletal muscle atrophy following unloading. Arch. Biochem. Biophys. 2015, 584, 36–41. [CrossRef]
130. Smith, I.J.; Dodd, S.L. Calpain activation causes a proteasome-dependent increase in protein degradation and inhibits the Akt
signalling pathway in rat diaphragm muscle. Exp. Physiol. 2007, 92, 561–573. [CrossRef]
131. Fareed, M.U.; Evenson, A.R.; Wei, W.; Menconi, M.; Poylin, V.; Petkova, V.; Pignol, B.; Hasselgren, P.-O. Treatment of rats with
calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expression. Am. J.
Physiol. Integr. Comp. Physiol. 2006, 290, R1589–R1597. [CrossRef]
132. Costelli, P.; Reffo, P.; Penna, F.; Autelli, R.; Bonelli, G.; Baccino, F.M. Ca2+-dependent proteolysis in muscle wasting. Int. J. Biochem.
Cell Biol. 2005, 37, 2134–2146. [CrossRef] [PubMed]
133. Furuno, K.; Goldberg, A.L.; Hasselgren, P.O.; Zamir, O.; James, J.H.; Fischer, J.E.; Hall-Angerås, M.; Angerås, U.; Benson, D.;
Ballard, F.J.; et al. The activation of protein degradation in muscle by Ca2+ or muscle injury does not involve a lysosomal
mechanism. Biochem. J. 1986, 237, 859–864. [CrossRef] [PubMed]
134. Baracos, V.; Greenberg, R.E.; Goldberg, A.L. Influence of calcium and other divalent cations on protein turnover in rat skeletal
muscle. Am. J. Physiol. Metab. 1986, 250, E702–E710. [CrossRef]
135. Menconi, M.J.; Wei, W.; Yang, H.; Wray, C.J.; Hasselgren, P.-O. Treatment of cultured myotubes with the calcium ionophore
A23187 increases proteasome activity via a CaMK II-caspase-calpain–dependent mechanism. Surg. 2004, 136, 135–142. [CrossRef]
136. Volodin, A.; Kosti, I.; Goldberg, A.L.; Cohen, S. Myofibril breakdown during atrophy is a delayed response requiring the
transcription factor PAX4 and desmin depolymerization. Proc. Natl. Acad. Sci. USA 2017, 114, E1375–E1384. [CrossRef] [PubMed]
137. Bodine, S.C.; Latres, E.; Baumhueter, S.; Lai, V.K.-M.; Nunez, L.; Clarke, B.A.; Poueymirou, W.T.; Panaro, F.J.; Na, E.; Dharmarajan,
K.; et al. Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy. Science 2001, 294, 1704–1708. [CrossRef]
138. Gomes, M.D.; Lecker, S.H.; Jagoe, R.T.; Navon, A.; Goldberg, A.L. Atrogin-1, a muscle-specific F-box protein highly expressed
during muscle atrophy. Proc. Natl. Acad. Sci. USA 2001, 98, 14440–14445. [CrossRef] [PubMed]
139. Wray, C.J.; Mammen, J.M.; Hershko, D.D.; Hasselgren, P.-O. Sepsis upregulates the gene expression of multiple ubiquitin ligases
in skeletal muscle. Int. J. Biochem. Cell Biol. 2003, 35, 698–705. [CrossRef]
140. Sandri, M.; Sandri, C.; Gilbert, A.; Skurk, C.; Calabria, E.; Picard, A.; Walsh, K.; Schiaffino, S.; Lecker, S.H.; Goldberg, A.L. Foxo
Transcription Factors Induce the Atrophy-Related Ubiquitin Ligase Atrogin-1 and Cause Skeletal Muscle Atrophy. Cell 2004,
117, 399–412. [CrossRef]
141. Lecker, S.H.; Jagoe, R.T.; Gilbert, A.; Gomes, M.; Baracos, V.; Bailey, J.; Price, S.R.; Mitch, W.E.; Goldberg, A.L. Multiple types of
skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 2003, 18, 39–51. [CrossRef] [PubMed]
142. Baehr, L.M.; Furlow, J.D.; Bodine, S.C. Muscle sparing in muscle RING finger 1 null mice: Response to synthetic glucocorticoids.
J. Physiol. 2011, 589, 4759–4776. [CrossRef] [PubMed]
143. Koyama, S.; Hata, S.; Witt, C.C.; Ono, Y.; Lerche, S.; Ojima, K.; Chiba, T.; Doi, N.; Kitamura, F.; Tanaka, K.; et al. Muscle
RING-Finger Protein-1 (MuRF1) as a Connector of Muscle Energy Metabolism and Protein Synthesis. J. Mol. Biol. 2008,
376, 1224–1236. [CrossRef]
144. Labeit, S.; Kohl, C.H.; Witt, C.C.; Labeit, D.; Jung, J.; Granzier, H. Modulation of Muscle Atrophy, Fatigue and MLC Phospho-
rylation by MuRF1 as Indicated by Hindlimb Suspension Studies on MuRF1-KO Mice. J. Biomed. Biotechnol. 2010, 2010, 1–9.
[CrossRef] [PubMed]
145. Nguyen, T.; Bowen, T.S.; Augstein, A.; Schauer, A.; Gasch, A.; Linke, A.; Labeit, S.; Adams, V. Expression of MuRF1 or MuRF2 is
essential for the induction of skeletal muscle atrophy and dysfunction in a murine pulmonary hypertension model. Skelet. Muscle
2020, 10, 1–10. [CrossRef] [PubMed]
146. Centner, T.; Yano, J.; Kimura, E.; McElhinny, A.S.; Pelin, K.; Witt, C.C.; Bang, M.-L.; Trombitas, K.; Granzier, H.; Gregorio, C.C.;
et al. Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. J. Mol. Biol. 2001,
306, 717–726. [CrossRef] [PubMed]
147. Pizon, V.; Iakovenko, A.; van der Ven, P.; Kelly, R.; Fatu, C.; Fürst, D.O.; Karsenti, E.; Gautel, M. Transient association of titin and
myosin with microtubules in nascent myofibrils directed by the MURF2 RING-finger protein. J. Cell Sci. 2002, 115, 4469–4482.
[CrossRef]
148. Spencer, J.A.; Eliazer, S.; Ilaria, R.L.; Richardson, J.A.; Olson, E.N. Regulation of Microtubule Dynamics and Myogenic Differentia-
tion by Murf, a Striated Muscle Ring-Finger Protein. J. Cell Biol. 2000, 150, 771–784. [CrossRef]
149. Cohen, S.; Brault, J.; Gygi, S.P.; Glass, D.J.; Valenzuela, D.M.; Gartner, C.; Latres, E.; Goldberg, A.L. During muscle atrophy, thick,
but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. 2009, 185, 1083–1095. [CrossRef]
150. Witt, S.H.; Granzier, H.; Witt, C.C.; Labeit, S. MURF-1 and MURF-2 Target a Specific Subset of Myofibrillar Proteins Redundantly:
Towards Understanding MURF-dependent Muscle Ubiquitination. J. Mol. Biol. 2005, 350, 713–722. [CrossRef]
Biomolecules 2021, 11, 1327 33 of 42
151. Fielitz, J.; Kim, M.-S.; Shelton, J.M.; Latif, S.; Spencer, J.A.; Glass, D.J.; Richardson, J.A.; Bassel-Duby, R.; Olson, E.N. Myosin
accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. J. Clin. Investig. 2007,
117, 2486–2495. [CrossRef]
152. Kedar, V.; McDonough, H.; Arya, R.; Li, H.-H.; Rockman, H.A.; Patterson, C. Muscle-specific RING finger 1 is a bona fide
ubiquitin ligase that degrades cardiac troponin I. Proc. Natl. Acad. Sci. USA 2004, 101, 18135–18140. [CrossRef]
153. Lodka, D.; Pahuja, A.; Geers-Knörr, C.; Scheibe, R.J.; Nowak, M.; Hamati, J.; Köhncke, C.; Purfürst, B.; Kanashova, T.; Schmidt, S.;
et al. Muscle RING-finger 2 and 3 maintain striated-muscle structure and function. J. Cachex-Sarcopenia Muscle 2015, 7, 165–180.
[CrossRef] [PubMed]
154. Bodine, S.C.; Baehr, L.M. Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1. Am. J. Physiol.
Metab. 2014, 307, E469–E484. [CrossRef] [PubMed]
155. Hirner, S.; Krohne, C.; Schuster, A.; Hoffmann, S.; Witt, S.; Erber, R.; Sticht, C.; Gasch, A.; Labeit, S.; Labeit, D. MuRF1-dependent
Regulation of Systemic Carbohydrate Metabolism as Revealed from Transgenic Mouse Studies. J. Mol. Biol. 2008, 379, 666–677.
[CrossRef] [PubMed]
156. Nowak, M.; Suenkel, B.; Porras, P.; Migotti, R.; Schmidt, F.; Kny, M.; Zhu, X.; Wanker, E.E.; Dittmar, G.; Fielitz, J.; et al. DCAF8, a
novel MuRF1 interaction partner, promotes muscle atrophy. J. Cell Sci. 2019, 132, 132. [CrossRef]
157. Duda, D.M.; Scott, D.C.; Calabrese, M.F.; Zimmerman, E.S.; Zheng, N.; Schulman, B.A. Structural regulation of cullin-RING
ubiquitin ligase complexes. Curr. Opin. Struct. Biol. 2011, 21, 257–264. [CrossRef]
158. Angers, S.; Li, T.; Yi, X.; MacCoss, M.J.; Moon, R.T.; Zheng, N. Molecular architecture and assembly of the DDB1–CUL4A ubiquitin
ligase machinery. Nat. Cell Biol. 2006, 443, 590–593. [CrossRef] [PubMed]
159. Tintignac, L.A.; Lagirand, J.; Batonnet, S.; Sirri, V.; Leibovitch, M.P.; Leibovitch, S.A. Degradation of MyoD Mediated by the SCF
(MAFbx) Ubiquitin Ligase. J. Biol. Chem. 2005, 280, 2847–2856. [CrossRef]
160. Lagirand-Cantaloube, J.; Offner, N.; Csibi, A.; Leibovitch, M.P.; Batonnet-Pichon, S.; Tintignac, L.A.; Segura, C.T.; Leibovitch, S.
The initiation factor eIF3-f is a major target for Atrogin1/MAFbx function in skeletal muscle atrophy. EMBO J. 2008, 27, 1266–1276.
[CrossRef]
161. Lokireddy, S.; Wijesoma, I.W.; Sze, S.K.; McFarlane, C.; Kambadur, R.; Sharma, M. Identification of atrogin-1-targeted proteins
during the myostatin-induced skeletal muscle wasting. Am. J. Physiol. Physiol. 2012, 303, C512–C529. [CrossRef]
162. Friedrich, O.; Reid, M.B.; Berghe, G.V.D.; Vanhorebeek, I.; Hermans, G.; Rich, M.M.; Larsson, L. The Sick and the Weak:
Neuropathies/Myopathies in the Critically Ill. Physiol. Rev. 2015, 95, 1025–1109. [CrossRef] [PubMed]
163. Constantin, D.; McCullough, J.; Mahajan, R.P.; Greenhaff, P.L. Novel events in the molecular regulation of muscle mass in critically
ill patients. J. Physiol. 2011, 589, 3883–3895. [CrossRef] [PubMed]
164. Klaude, M.; Fredriksson, K.; Tjäder, I.; Hammarqvist, F.; Ahlman, B.; Rooyackers, O.; Wernerman, J. Proteasome proteolytic
activity in skeletal muscle is increased in patients with sepsis. Clin. Sci. 2007, 112, 499–506. [CrossRef] [PubMed]
165. Llano-Diez, M.; Fury, W.; Okamoto, H.; Bai, Y.; Gromada, J.; Larsson, L. RNA-sequencing reveals altered skeletal muscle
contraction, E3 ligases, autophagy, apoptosis, and chaperone expression in patients with critical illness myopathy. Skelet. Muscle
2019, 9, 9. [CrossRef] [PubMed]
166. Schmidt, F.; Kny, M.; Zhu, X.; Wollersheim, T.; Persicke, K.; Langhans, C.; Lodka, D.; Kleber, C.; Weber-Carstens, S.; Fielitz, J.
The E3 ubiquitin ligase TRIM62 and inflammation-induced skeletal muscle atrophy. Crit. Care 2014, 18, 545. [CrossRef]
167. Bawa, S.; Piccirillo, R.; Geisbrecht, E. TRIM32: A Multifunctional Protein Involved in Muscle Homeostasis, Glucose Metabolism,
and Tumorigenesis. Biomol. 2021, 11, 408. [CrossRef]
168. Reymond, A.; Meroni, G.; Fantozzi, A.; Merla, G.; Cairo, S.; Luzi, L.; Riganelli, D.; Zanaria, E.; Messali, S.; Cainarca, S.; et al.
The tripartite motif family identifies cell compartments. EMBO J. 2001, 20, 2140–2151. [CrossRef]
169. Cohen, S.; Lee, D.; Zhai, B.; Gygi, S.P.; Goldberg, A.L. Trim32 reduces PI3K–Akt–FoxO signaling in muscle atrophy by promoting
plakoglobin–PI3K dissociation. J. Cell Biol. 2014, 204, 747–758. [CrossRef]
170. Frosk, P.; Del Bigio, M.R.; Wrogemann, K.; Greenberg, C.R. Hutterite brothers both affected with two forms of limb girdle
muscular dystrophy: LGMD2H and LGMD2I. Eur. J. Hum. Genet. 2005, 13, 978–982. [CrossRef]
171. Assereto, S.; Piccirillo, R.; Baratto, S.; Scudieri, P.; Fiorillo, C.; Massacesi, M.; Traverso, M.; Galietta, L.J.; Bruno, C.;
Minetti, C.; et al. The ubiquitin ligase tripartite-motif-protein 32 is induced in Duchenne muscular dystrophy. Lab. Investig. 2016,
96, 862–871. [CrossRef]
172. Sosa-Pineda, B.; Chowdhury, K.; Torres, M.; Oliver, G.; Gruss, P. The Pax4 gene is essential for differentiation of insulin-producing
β cells in the mammalian pancreas. Nat. Cell Biol. 1997, 386, 399–402. [CrossRef]
173. Shimajiri, Y.; Sanke, T.; Furuta, H.; Hanabusa, T.; Nakagawa, T.; Fujitani, Y.; Kajimoto, Y.; Takasu, N.; Nanjo, K. A missense
mutation of Pax4 gene (R121W) is associated with type 2 diabetes in Japanese. Diabetes 2001, 50, 2864–2869. [CrossRef] [PubMed]
174. Mauvais-Jarvis, F.; Smith, S.B.; Le May, C.; Leal, S.M.; Gautier, J.-F.; Molokhia, M.; Riveline, J.-P.; Rajan, A.S.; Kevorkian, J.-P.;
Zhang, S.; et al. PAX4 gene variations predispose to ketosis-prone diabetes. Hum. Mol. Genet. 2004, 13, 3151–3159. [CrossRef]
[PubMed]
175. Ye, Y.; Tang, W.K.; Zhang, T.; Xia, D. A Mighty “Protein Extractor” of the Cell: Structure and Function of the p97/CDC48 ATPase.
Front. Mol. Biosci. 2017, 4, 39. [CrossRef]
176. Piccirillo, R.; Goldberg, A.L. The p97/VCP ATPase is critical in muscle atrophy and the accelerated degradation of muscle
proteins. EMBO J. 2012, 31, 3334–3350. [CrossRef]
Biomolecules 2021, 11, 1327 34 of 42
177. Koncarevic, A.; Jackman, R.W.; Kandarian, S.C. The ubiquitin-protein ligase Nedd4 targets Notch1 in skeletal muscle and
distinguishes the subset of atrophies caused by reduced muscle tension. FASEB J. 2006, 21, 427–437. [CrossRef]
178. Stevenson, E.J.; Giresi, P.G.; Koncarevic, A.; Kandarian, S.C. Global analysis of gene expression patterns during disuse atrophy in
rat skeletal muscle. J. Physiol. 2003, 551, 33–48. [CrossRef]
179. Dupont-Versteegden, E.E.; Fluckey, J.D.; Knox, M.; Gaddy, D.; Peterson, C.A. Effect of flywheel-based resistance exercise on
processes contributing to muscle atrophy during unloading in adult rats. J. Appl. Physiol. 2006, 101, 202–212. [CrossRef]
180. Batt, J.; Bain, J.; Goncalves, J.; Michalski, B.; Plant, P.; Fahnestock, M.; Woodgett, J. Differential gene expression profiling of short
and long term denervated muscle. FASEB J. 2005, 20, 115–117. [CrossRef]
181. Persaud, A.; Alberts, P.; Mari, S.; Tong, J.; Murchie, R.; Maspero, E.; Safi, F.; Moran, M.F.; Polo, S.; Rotin, D. Tyrosine phosphoryla-
tion of NEDD4 activates its ubiquitin ligase activity. Sci. Signal. 2014, 7, ra95. [CrossRef] [PubMed]
182. Attali, I.; Tobelaim, W.S.; Persaud, A.; Motamedchaboki, K.; Simpson-Lavy, K.J.; Mashahreh, B.; Levin-Kravets, O.; Keren-Kaplan,
T.; Pilzer, I.; Kupiec, M.; et al. Ubiquitylation-dependent oligomerization regulates activity of Nedd4 ligases. EMBO J. 2017,
36, 425–440. [CrossRef]
183. Cao, X.R.; Lill, N.L.; Boase, N.; Shi, P.P.; Croucher, D.; Shan, H.; Qu, J.; Sweezer, E.M.; Place, T.; Kirby, P.A.; et al. Nedd4 Controls
Animal Growth by Regulating IGF-1 Signaling. Sci. Signal. 2008, 1, ra5. [CrossRef] [PubMed]
184. Nagpal, P.; Plant, P.J.; Correa, J.; Bain, A.; Takeda, M.; Kawabe, H.; Rotin, D.; Bain, J.R.; Batt, J.A.E. The Ubiquitin Ligase Nedd4-1
Participates in Denervation-Induced Skeletal Muscle Atrophy in Mice. PLoS ONE 2012, 7, e46427. [CrossRef]
185. Lamothe, B.; Besse, A.; Campos, A.D.; Webster, W.K.; Wu, H.; Darnay, B.G. Site-specific Lys-63-linked Tumor Necrosis Factor
Receptor-associated Factor 6 Auto-ubiquitination Is a Critical Determinant of IκB Kinase Activation. J. Biol. Chem. 2007,
282, 4102–4112. [CrossRef] [PubMed]
186. Paul, P.K.; Gupta, S.K.; Bhatnagar, S.; Panguluri, S.K.; Darnay, B.G.; Choi, Y.; Kumar, A. Targeted ablation of TRAF6 inhibits
skeletal muscle wasting in mice. J. Cell Biol. 2010, 191, 1395–1411. [CrossRef]
187. Milan, G.; Romanello, V.; Pescatore, F.; Armani, A.; Paik, J.-H.; Frasson, L.; Seydel, A.; Zhao, J.; Abraham, R.; Goldberg, A.L.; et al.
Regulation of autophagy and the ubiquitin–proteasome system by the FoxO transcriptional network during muscle atrophy. Nat.
Commun. 2015, 6, 6670. [CrossRef]
188. Wing, S.S. Deubiquitinases in skeletal muscle atrophy. Int. J. Biochem. Cell Biol. 2013, 45, 2130–2135. [CrossRef] [PubMed]
189. Peris-Moreno, D.; Cussonneau, L.; Combaret, L.; Polge, C.; Taillandier, D. Ubiquitin Ligases at the Heart of Skeletal Muscle
Atrophy Control. Molecules 2021, 26, 407. [CrossRef]
190. Tuttle, C.S.; Thang, L.A.; Maier, A.B. Markers of inflammation and their association with muscle strength and mass: A systematic
review and meta-analysis. Ageing Res. Rev. 2020, 64, 101185. [CrossRef] [PubMed]
191. Yamaki, T.; Wu, C.-L.; Gustin, M.; Lim, J.; Jackman, R.W.; Kandarian, S.C. Rel A/p65 is required for cytokine-induced myotube
atrophy. Am. J. Physiol. Physiol. 2012, 303, C135–42. [CrossRef]
192. Zhang, L.; Pan, J.; Dong, Y.; Tweardy, D.J.; Dong, Y.; Garibotto, G.; Mitch, W.E. Stat3 Activation Links a C/EBPδ to Myostatin
Pathway to Stimulate Loss of Muscle Mass. Cell Metab. 2013, 18, 368–379. [CrossRef]
193. Pedersen, B.K. Muscle as a Secretory Organ. Compr. Physiol. 2013, 3, 1337–1362. [CrossRef]
194. Hahn, A.; Kny, M.; Pablo-Tortola, C.; Todiras, M.; Willenbrock, M.; Schmidt, S.; Schmoeckel, K.; Jorde, I.; Nowak, M.; Jarosch,
E.; et al. Serum amyloid A1 mediates myotube atrophy via Toll-like receptors. J. Cachex-Sarcopenia Muscle 2020, 11, 103–119.
[CrossRef]
195. Huang, N.; Kny, M.; Riediger, F.; Busch, K.; Schmidt, S.; Luft, F.C.; Slevogt, H.; Fielitz, J. Deletion of Nlrp3 protects from
inflammation-induced skeletal muscle atrophy. Intensiv. Care Med. Exp. 2017, 5, 1–15. [CrossRef]
196. Lang, C.H.; Silvis, C.; Deshpande, N.; Nystrom, G.; Frost, R.A. Endotoxin Stimulates In Vivo Expression of Inflammatory
Cytokines Tumor Necrosis Factor Alpha, Interleukin-1beta, -6, and High-Mobility-Group Protein-1 in Skeletal Muscle. Shock.
2003, 19, 538–546. [CrossRef]
197. Torti, F.M.; Dieckmann, B.; Beutler, B.; Cerami, A.; Ringold, G.M. A macrophage factor inhibits adipocyte gene expression: An
in vitro model of cachexia. Science 1985, 229, 867–869. [CrossRef] [PubMed]
198. Hasselgren, P.-O.; Fischer, J.E. Muscle Cachexia: Current Concepts of Intracellular Mechanisms and Molecular Regulation. Ann.
Surg. 2001, 233, 9–17. [CrossRef] [PubMed]
199. Han, Y.; Weinman, S.; Boldogh, I.; Walker, R.K.; Brasier, A.R. Tumor Necrosis Factor-α-inducible IκBα Proteolysis Mediated by
Cytosolic m-Calpain. J. Biol. Chem. 1999, 274, 787–794. [CrossRef] [PubMed]
200. Li, Y.-P.; Reid, M.B. NF-κB mediates the protein loss induced by TNF-α in differentiated skeletal muscle myotubes. Am. J. Physiol.
Integr. Comp. Physiol. 2000, 279, R1165–R1170. [CrossRef] [PubMed]
201. Patel, H.J.; Patel, B.M. TNF-α and cancer cachexia: Molecular insights and clinical implications. Life Sci. 2017, 170, 56–63.
[CrossRef]
202. Kadowaki, M.; Kanazawa, T. Amino acids as regulators of proteolysis. J. Nutr. 2003, 133, 2052S–2056S. [CrossRef] [PubMed]
203. Winkelman, C.; Johnson, K.D.; Gordon, N. Associations Between Muscle-Related Cytokines and Selected Patient Outcomes in the
ICU. Biol. Res. Nurs. 2015, 17, 125–134. [CrossRef] [PubMed]
204. Witteveen, E.; Wieske, L.; Van Der Poll, T.; Van Der Schaaf, M.; Van Schaik, I.N.; Schultz, M.J.; Verhamme, C.; Horn, J. Increased
Early Systemic Inflammation in ICU-Acquired Weakness; A Prospective Observational Cohort Study. Crit. Care Med. 2017,
45, 972–979. [CrossRef] [PubMed]
Biomolecules 2021, 11, 1327 35 of 42
205. Zamir, O.; Hasselgren, P.-O.; Kunkel, S.L.; Frederick, J.; Higashiguchi, T.; Fischer, J.E. Evidence That Tumor Necrosis Factor
Participates in the Regulation of Muscle Proteolysis During Sepsis. Arch. Surg. 1992, 127, 170–174. [CrossRef] [PubMed]
206. Li, Y.-P.; Chen, Y.; John, J.; Moylan, J.S.; Jin, B.; Mann, D.; Reid, M.B. TNF-α acts via p38 MAPK to stimulate expression of the
ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J. 2004, 19, 362–370. [CrossRef] [PubMed]
207. De Larichaudy, J.; Zufferli, A.; Serra, F.; Isidori, A.M.; Naro, F.; Dessalle, K.; Desgeorges, M.; Piraud, M.; Cheillan, D.; Vidal, H.;
et al. TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism. Skelet. Muscle 2012, 2, 2. [CrossRef]
208. Sharma, B.; Dabur, R. Role of Pro-inflammatory Cytokines in Regulation of Skeletal Muscle Metabolism: A Systematic Review.
Curr. Med. Chem. 2020, 27, 2161–2188. [CrossRef]
209. Micheau, O.; Tschopp, J. Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes. Cell 2003,
114, 181–190. [CrossRef]
210. Schiaffino, S.; Mammucari, C. Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: Insights from genetic models.
Skelet. Muscle 2011, 1, 4. [CrossRef] [PubMed]
211. Reid, M.B.; Li, Y.-P. Tumor necrosis factor-α and muscle wasting: A cellular perspective. Respir. Res. 2001, 2, 269–272. [CrossRef]
212. Tierney, M.T.; Aydogdu, T.; Sala, D.; Malecova, B.; Gatto, S.; Puri, P.L.; Latella, L.; Sacco, A. STAT3 signaling controls satellite cell
expansion and skeletal muscle repair. Nat. Med. 2014, 20, 1182–1186. [CrossRef]
213. Hoene, M.; Runge, H.; Häring, H.U.; Schleicher, E.D.; Weigert, C. Interleukin-6 promotes myogenic differentiation of mouse
skeletal muscle cells: Role of the STAT3 pathway. Am. J. Physiol. Physiol. 2013, 304, C128–C136. [CrossRef]
214. Bonetto, A.; Aydogdu, T.; Jin, X.; Zhang, Z.; Zhan, R.; Puzis, L.; Koniaris, L.G.; Zimmers, T.A. JAK/STAT3 pathway inhibi-
tion blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am. J. Physiol. Metab. 2012,
303, E410–E421. [CrossRef] [PubMed]
215. Tilg, H.; Dinarello, C.A.; Mier, J.W. IL-6 and APPs: Anti-inflammatory and immunosuppressive mediators. Immunol. Today 1997,
18, 428–432. [CrossRef]
216. Goodman, M.N. Interleukin-6 Induces Skeletal Muscle Protein Breakdown in Rats. Exp. Biol. Med. 1994, 205, 182–185. [CrossRef]
[PubMed]
217. Ebisui, C.; Tsujinaka, T.; Morimoto, T.; Kan, K.; Iijima, S.; Yano, M.; Kominami, E.; Tanaka, K.; Monden, M. Interleukin-6
Induces Proteolysis by Activating Intracellular Proteases (Cathepsins B and L, Proteasome) in C2C12 Myotubes. Clin. Sci. 1995,
89, 431–439. [CrossRef]
218. Haddad, F.; Zaldivar, F.; Cooper, D.M.; Adams, G.R. IL-6-induced skeletal muscle atrophy. J. Appl. Physiol. 2005, 98, 911–917.
[CrossRef] [PubMed]
219. White, J.P.; Puppa, M.J.; Gao, S.; Sato, S.; Welle, S.L.; Carson, J.A. Muscle mTORC1 suppression by IL-6 during cancer cachexia:
A role for AMPK. Am. J. Physiol. Metab. 2013, 304, E1042–E1052. [CrossRef]
220. García-Martínez, C.; López-Soriano, F.J.; Argilés, J.M. Interleukin-6 does not activate protein breakdown in rat skeletal muscle.
Cancer Lett. 1994, 76, 1–4. [CrossRef]
221. Heinrich, P.C.; Behrmann, I.; Müller-Newen, G.; Schaper, F.; Graeve, L. Interleukin-6-type cytokine signalling through the
gp130/Jak/STAT pathway1. Biochem. J. 1998, 334, 297–314. [CrossRef]
222. Rose-John, S. IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6. Int. J.
Biol. Sci. 2012, 8, 1237–1247. [CrossRef]
223. Tanaka, T.; Narazaki, M.; Kishimoto, T. IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harb. Perspect. Biol. 2014,
6, a016295. [CrossRef] [PubMed]
224. Seto, D.N.; Kandarian, S.C.; Jackman, R.W. A Key Role for Leukemia Inhibitory Factor in C26 Cancer Cachexia. J. Biol. Chem.
2015, 290, 19976–19986. [CrossRef]
225. Darnell, J.E.; Kerr, I.M.; Stark, G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular
signaling proteins. Science 1994, 264, 1415–1421. [CrossRef] [PubMed]
226. Wen, Z.; Zhong, Z.; Darnell, J.E. Maximal activation of transcription by statl and stat3 requires both tyrosine and serine
phosphorylation. Cell 1995, 82, 241–250. [CrossRef]
227. Babon, J.J.; Kershaw, N.; Murphy, J.; Varghese, L.N.; Laktyushin, A.; Young, S.N.; Lucet, I.S.; Norton, R.S.; Nicola, N.A. Suppression
of Cytokine Signaling by SOCS3: Characterization of the Mode of Inhibition and the Basis of Its Specificity. Immunity 2012,
36, 239–250. [CrossRef] [PubMed]
228. Rui, L.; Yuan, M.; Frantz, D.; Shoelson, S.; White, M.F. SOCS-1 and SOCS-3 Block Insulin Signaling by Ubiquitin-mediated
Degradation of IRS1 and IRS2. J. Biol. Chem. 2002, 277, 42394–42398. [CrossRef]
229. Rommel, C.; Bodine, S.; Clarke, B.A.; Rossman, R.; Nunez, L.; Stitt, T.N.; Yancopoulos, G.D.; Glass, D.J. Mediation of IGF-1-
induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 2001, 3, 1009–1013.
[CrossRef]
230. Yoshida, T.; Delafontaine, P. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells 2020,
9, 1970. [CrossRef]
231. Belizário, J.E.; Fontes-Oliveira, C.C.; Borges, J.P.; Kashiabara, J.A.; Vannier, E. Skeletal muscle wasting and renewal: A pivotal role
of myokine IL-6. SpringerPlus 2016, 5, 1–15. [CrossRef]
Biomolecules 2021, 11, 1327 36 of 42
232. Weber-Carstens, S.; Deja, M.; Koch, S.; Spranger, J.; Bubser, F.; Wernecke, K.D.; Spies, C.D.; Spuler, S.; Keh, D. Risk factors in
critical illness myopathy during the early course of critical illness: A prospective observational study. Crit. Care 2010, 14, R119.
[CrossRef] [PubMed]
233. Dinarello, C.A. Interleukin-1β. Crit. Care Med. 2005, 33, S460–S462. [CrossRef] [PubMed]
234. Pruitt, J.H.; Copeland, E.M.; Moldawer, L.L. Interleukin-1 and interleukin-1 antagonism in sepsis, systemic inflammatory response
syndrome, and septic shock. Shock 1995, 3, 235–251. [CrossRef]
235. Van Deuren, M. Kinetics of tumour necrosis factor-alpha, soluble tumour necrosis factor receptors, interleukin 1-beta and its
receptor antagonist during serious infections. Eur. J. Clin. Microbiol. Infect. Dis. 1994, 13, S12–S16. [CrossRef]
236. Zamir, O.; Hasselgren, P.-O.; Von Allmen, D.; Fischer, J.E. The effect of interleukin-1α and the glucocorticoid receptor blocker RU
38486 on total and myofibrillar protein breakdown in skeletal muscle. J. Surg. Res. 1991, 50, 579–583. [CrossRef]
237. Cooney, R.N.; Maish, G.O.; Gilpin, T.; Shumate, M.L.; Lang, C.H.; Vary, T.C. Mechanism of IL-1 induced inhibition of protein
synthesis in skeletal muscle. Shock 1999, 11, 235–241. [CrossRef]
238. Zamir, O.; O’Brien, W.; Thompson, R.; Bloedow, D.C.; Fischer, J.E.; Hasselgren, P.-O. Reduced muscle protein breakdown in septic
rats following treatment with interleukin-1 receptor antagonist. Int. J. Biochem. 1994, 26, 943–950. [CrossRef]
239. Cooney, R.; Owens, E.; Jurasinski, C.; Gray, K.; Vannice, J.; Vary, T. Interleukin-1 receptor antagonist prevents sepsis-induced
inhibition of protein synthesis. Am. J. Physiol. Metab. 1994, 267, E636–E641. [CrossRef]
240. Afonina, I.S.; Müller, C.; Martin, S.; Beyaert, R. Proteolytic Processing of Interleukin-1 Family Cytokines: Variations on a Common
Theme. Immunity 2015, 42, 991–1004. [CrossRef] [PubMed]
241. Groß, O.; Thomas, C.J.; Guarda, G.; Tschopp, J. The inflammasome: An integrated view. Immunol. Rev. 2011, 243, 136–151.
[CrossRef]
242. Lamkanfi, M.; Dixit, V.M. Inflammasomes and Their Roles in Health and Disease. Annu. Rev. Cell Dev. Biol. 2012, 28, 137–161.
[CrossRef] [PubMed]
243. Hotchkiss, R.S.; Karl, I.E. The Pathophysiology and Treatment of Sepsis. N. Engl. J. Med. 2003, 348, 138–150. [CrossRef]
244. Schroder, K.; Tschopp, J. The Inflammasomes. Cell 2010, 140, 821–832. [CrossRef] [PubMed]
245. Schroder, K.; Zhou, R.; Tschopp, J. The NLRP3 Inflammasome: A Sensor for Metabolic Danger? Science 2010, 327, 296–300.
[CrossRef] [PubMed]
246. Rawat, R.; Cohen, T.V.; Ampong, B.; Francia, D.; Henriques-Pons, A.; Hoffman, E.P.; Nagaraju, K. Inflammasome Up-Regulation
and Activation in Dysferlin-Deficient Skeletal Muscle. Am. J. Pathol. 2010, 176, 2891–2900. [CrossRef] [PubMed]
247. Brigelius-Flohé, R.; Banning, A.; Kny, M.; Böl, G.-F. Redox events in interleukin-1 signaling. Arch. Biochem. Biophys. 2004,
423, 66–73. [CrossRef]
248. Li, W.; Moylan, J.S.; Chambers, M.A.; Smith, J.; Reid, M.B. Interleukin-1 stimulates catabolism in C2C12 myotubes. Am. J. Physiol.
Physiol. 2009, 297, C706–C714. [CrossRef]
249. Llovera, M.; Carbó, N.; Lopez-Soriano, J.; Martinez, C.G.; Busquets, S.; Alvarez, B.; Agell, N.; Costelli, P.; López-Soriano, F.J.;
Celada, A.; et al. Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett. 1998, 133, 83–87.
[CrossRef]
250. Kalbitz, M.; Fattahi, F.; Grailer, J.J.; Jajou, L.; Malan, E.A.; Zetoune, F.S.; Huber-Lang, M.; Russell, M.W.; Ward, P.A. Complement-
induced activation of the cardiac NLRP3 inflammasome in sepsis. FASEB J. 2016, 30, 3997–4006. [CrossRef]
251. Busch, K.; Kny, M.; Huang, N.; Klassert, T.E.; Stock, M.; Hahn, A.; Graeger, S.; Todiras, M.; Schmidt, S.; Chamling, B.; et al.
Inhibition of the NLRP3/IL-1β Axis Protects against Sepsis-Induced Cardiomyopathy. J. Cachexia Sarcopenia Muscle 2021.
[CrossRef]
252. Luo, Y.-P.; Jiang, L.; Kang, K.; Fei, D.-S.; Meng, X.; Nan, C.-C.; Pan, S.-H.; Zhao, M.-R. Hemin inhibits NLRP3 inflammasome
activation in sepsis-induced acute lung injury, involving heme oxygenase-1. Int. Immunopharmacol. 2014, 20, 24–32. [CrossRef]
253. Liu, Y.; Jing, Y.-Y.; Zeng, C.-Y.; Li, C.-G.; Xu, L.-H.; Yan, L.; Bai, W.-J.; Zha, Q.-B.; Ouyang, D.-Y.; He, X.-H. Scutellarin Suppresses
NLRP3 Inflammasome Activation in Macrophages and Protects Mice against Bacterial Sepsis. Front. Pharmacol. 2018, 8, 975.
[CrossRef]
254. Zhang, W.; Xu, X.; Kao, R.; Mele, T.; Kvietys, P.; Martin, C.M.; Rui, T. Cardiac Fibroblasts Contribute to Myocardial Dysfunction in
Mice with Sepsis: The Role of NLRP3 Inflammasome Activation. PLoS ONE 2014, 9, e107639. [CrossRef]
255. Shakoory, B.; Carcillo, J.A.; Chatham, W.W.; Amdur, R.L.; Zhao, H.; Dinarello, C.A.; Cron, R.Q.; Opal, S.M. Interleukin-1 Receptor
Blockade Is Associated with Reduced Mortality in Sepsis Patients with Features of Macrophage Activation Syndrome. Reanalysis
of a Prior Phase III Trial. Crit. Care Med. 2016, 44, 275–281. [CrossRef] [PubMed]
256. Jr, G.H.S. Serum amyloid A—A review. Mol. Med. 2018, 24, 1–27. [CrossRef]
257. Uhlar, C.M.; Whitehead, A.S. Serum amyloid A, the major vertebrate acute-phase reactant. JBIC J. Biol. Inorg. Chem. 1999, 265,
501–523. [CrossRef] [PubMed]
258. Passey, S.L.; Bozinovski, S.; Vlahos, R.; Anderson, G.P.; Hansen, M.J. Serum Amyloid A Induces Toll-Like Receptor 2-Dependent
Inflammatory Cytokine Expression and Atrophy in C2C12 Skeletal Muscle Myotubes. PLoS ONE 2016, 11, e0146882. [CrossRef]
[PubMed]
259. Garcia-Obregon, S.; Azkargorta, M.; Seijas, I.; Pilar-Orive, J.; Borrego, F.; Elortza, F.; Boyano, M.D.; Astigarraga, I. Identification of
a panel of serum protein markers in early stage of sepsis and its validation in a cohort of patients. J. Microbiol. Immunol. Infect.
2018, 51, 465–472. [CrossRef]
Biomolecules 2021, 11, 1327 37 of 42
260. Gutfeld, O. Expression of Serum Amyloid A, in Normal, Dysplastic, and Neoplastic Human Colonic Mucosa: Implication for a
Role in Colonic Tumorigenesis. J. Histochem. Cytochem. 2006, 54, 63–73. [CrossRef]
261. Urieli-Shoval, S.; Finci-Yeheskel, Z.; Dishon, S.; Galinsky, D.; Linke, R.P.; Ariel, I.; Levin, M.; Ben-Shachar, I.; Prus, D. Expression of
Serum Amyloid A in Human Ovarian Epithelial Tumors: Implication for a Role in Ovarian Tumorigenesis. J. Histochem. Cytochem.
2010, 58, 1015–1023. [CrossRef] [PubMed]
262. Bonetto, A.; Aydogdu, T.; Kunzevitzky, N.; Guttridge, D.C.; Khuri, S.; Koniaris, L.G.; Zimmers, T.A. STAT3 Activation in Skeletal
Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia. PLoS ONE 2011, 6, e22538. [CrossRef]
263. Zhang, L.; Du, J.; Hu, Z.; Han, G.; Delafontaine, P.; Garcia, G.; Mitch, W.E. IL-6 and Serum Amyloid A Synergy Mediates
Angiotensin II–Induced Muscle Wasting. J. Am. Soc. Nephrol. 2009, 20, 604–612. [CrossRef]
264. Niemi, K.; Teirilä, L.; Lappalainen, J.; Rajamäki, K.; Baumann, M.; Öörni, K.; Wolff, H.; Kovanen, P.T.; Matikainen, S.; Eklund, K.K.
Serum Amyloid A Activates the NLRP3 Inflammasome via P2X7 Receptor and a Cathepsin B-Sensitive Pathway. J. Immunol.
2011, 186, 6119–6128. [CrossRef] [PubMed]
265. Baranova, I.N.; Bocharov, A.V.; Vishnyakova, T.G.; Kurlander, R.; Chen, Z.; Fu, D.; Arias, I.M.; Csako, G.; Patterson, A.P.;
Eggerman, T.L. CD36 Is a Novel Serum Amyloid A (SAA) Receptor Mediating SAA Binding and SAA-induced Signaling in
Human and Rodent Cells. J. Biol. Chem. 2010, 285, 8492–8506. [CrossRef] [PubMed]
266. Chen, M.; Zhou, H.; Cheng, N.; Qian, F.; Ye, R.D. Serum amyloid A1 isoforms display different efficacy at Toll-like receptor 2 and
formyl peptide receptor 2. Immunobiology 2014, 219, 916–923. [CrossRef] [PubMed]
267. Cheng, N.; He, R.; Tian, J.; Ye, P.P.; Ye, R.D. Cutting Edge: TLR2 Is a Functional Receptor for Acute-Phase Serum Amyloid A. J.
Immunol. 2008, 181, 22–26. [CrossRef]
268. Bhatnagar, S. The TWEAK-Fn14 System: Breaking the Silence of Cytokine-Induced Skeletal Muscle Wasting. Curr. Mol. Med.
2012, 12, 3–13. [CrossRef]
269. Dogra, C.; Changotra, H.; Wedhas, N.; Qin, X.; Wergedal, J.E.; Kumar, A. TNF-related weak inducer of apoptosis (TWEAK) is a
potent skeletal muscle-wasting cytokine. FASEB J. 2007, 21, 1857–1869. [CrossRef]
270. Bhatnagar, S.; Mittal, A.; Gupta, S.K.; Kumar, A. TWEAK causes myotube atrophy through coordinated activation of ubiquitin-
proteasome system, autophagy, and caspases. J. Cell. Physiol. 2012, 227, 1042–1051. [CrossRef]
271. Marie, C.; Cavaillon, J.-M.; Losser, M.-R. Elevated Levels of Circulating Transforming Growth Factor-β 1 in Patients with the
Sepsis Syndrome. Ann. Intern. Med. 1996, 125, 520–521. [CrossRef]
272. Schulte, W.; Bernhagen, J.; Bucala, R. Cytokines in Sepsis: Potent Immunoregulators and Potential Therapeutic Targets—An
Updated View. Mediat. Inflamm. 2013, 2013, 1–16. [CrossRef] [PubMed]
273. Blobe, G.C.; Schiemann, W.P.; Lodish, H.F. Role of Transforming Growth Factor β in Human Disease. N. Engl. J. Med. 2000, 342,
1350–1358. [CrossRef]
274. Bogdan, C.; Nathan, C. Modulation of Macrophage Function by Transforming Growth Factor? Interleukin-4, and Interleukin-10.
Ann. N. Y. Acad. Sci. 1993, 685, 713–739. [CrossRef] [PubMed]
275. Turner, M.; Chantry, D.; Katsikis, P.; Berge, A.; Brennan, F.M.; Feldmann, M. Induction of the interleukin 1 receptor antagonist
protein by transforming growth factor-β. Eur. J. Immunol. 1991, 21, 1635–1639. [CrossRef]
276. Narola, J.; Pandey, S.; Glick, A.; Chen, Y.-W. Conditional Expression of TGF-β1 in Skeletal Muscles Causes Endomysial Fibrosis
and Myofibers Atrophy. PLoS ONE 2013, 8, e79356. [CrossRef]
277. Mendias, C.L.; Bs, J.P.G.; Davis, C.S.; Bromley, C.W.; Bs, C.S.D.; Brooks, S. Transforming growth factor-beta induces skeletal
muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve 2011, 45, 55–59. [CrossRef]
278. Wang, Y.; Pessin, J.E. Mechanisms for fiber-type specificity of skeletal muscle atrophy. Curr. Opin. Clin. Nutr. Metab. Care 2013, 16,
243–250. [CrossRef]
279. Burks, T.N.; Cohn, R.D. Role of TGF-β signaling in inherited and acquired myopathies. Skelet. Muscle 2011, 1, 19. [CrossRef]
280. Ohsawa, Y.; Okada, T.; Nishimatsu, S.-I.; Ishizaki, M.; Suga, T.; Fujino, M.; Murakami, T.; Uchino, M.; Tsuchida, K.; Noji, S.;
et al. An inhibitor of transforming growth factor beta type I receptor ameliorates muscle atrophy in a mouse model of caveolin
3-deficient muscular dystrophy. Lab. Investig. 2012, 92, 1100–1114. [CrossRef] [PubMed]
281. Bernasconi, P.; Di Blasi, C.; Mora, M.; Morandi, L.; Galbiati, S.; Confalonieri, P.; Cornelio, F.; Mantegazza, R. Transforming growth
factor-β1 and fibrosis in congenital muscular dystrophies. Neuromuscul. Disord. 1999, 9, 28–33. [CrossRef]
282. Weiss, A.; Attisano, L. The TGFbeta Superfamily Signaling Pathway. Wiley Interdiscip. Rev. Dev. Biol. 2013, 2, 47–63. [CrossRef]
283. Shi, Y.; Massagué, J. Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus. Cell 2003, 113, 685–700. [CrossRef]
284. Zhang, Y.E. Non-Smad Signaling Pathways of the TGF-β Family. Cold Spring Harb. Perspect. Biol. 2016, 9, a022129. [CrossRef]
285. Lee, J.H.; Jun, H.-S. Role of Myokines in Regulating Skeletal Muscle Mass and Function. Front. Physiol. 2019, 10, 42. [CrossRef]
286. Egerman, M.A.; Cadena, S.M.; Gilbert, J.A.; Meyer, A.; Nelson, H.N.; Swalley, S.E.; Mallozzi, C.; Jacobi, C.; Jennings, L.L.; Clay, I.;
et al. GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration. Cell Metab. 2015, 22, 164–174. [CrossRef]
287. Trendelenburg, A.U.; Meyer, A.; Rohner, D.; Boyle, J.; Hatakeyama, S.; Glass, D.J. Myostatin reduces Akt/TORC1/p70S6K
signaling, inhibiting myoblast differentiation and myotube size. Am. J. Physiol. Physiol. 2009, 296, C1258–C1270. [CrossRef]
[PubMed]
288. McPherron, A.; Lawler, A.M.; Lee, S.-J. Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member. Nat.
Cell Biol. 1997, 387, 83–90. [CrossRef] [PubMed]
Biomolecules 2021, 11, 1327 38 of 42
289. George, I.; Bish, L.T.; Kamalakkannan, G.; Petrilli, C.; Oz, M.C.; Naka, Y.; Sweeney, H.L.; Maybaum, S. Myostatin activation in
patients with advanced heart failure and after mechanical unloading. Eur. J. Hear. Fail. 2010, 12, 444–453. [CrossRef] [PubMed]
290. Qin, H.; Chan, M.W.; Liyanarachchi, S.; Balch, C.; Potter, D.; Souriraj, I.J.; Cheng, A.S.; Agosto-Perez, F.J.; Nikonova, E.V.; Yan, P.S.;
et al. An integrative ChIP-chip and gene expression profiling to model SMAD regulatory modules. BMC Syst. Biol. 2009, 3, 73.
[CrossRef]
291. Amirouche, A.; Durieux, A.-C.; Banzet, S.; Koulmann, N.; Bonnefoy, R.; Mouret, C.; Bigard, X.; Peinnequin, A.; Freyssenet, D.
Down-Regulation of Akt/Mammalian Target of Rapamycin Signaling Pathway in Response to Myostatin Overexpression in
Skeletal Muscle. Endocrinology 2009, 150, 286–294. [CrossRef] [PubMed]
292. El Shafey, N.; Guesnon, M.; Simon, F.; Deprez, E.; Cosette, J.; Stockholm, D.; Scherman, D.; Bigey, P.; Kichler, A. Inhibition of the
myostatin/Smad signaling pathway by short decorin-derived peptides. Exp. Cell Res. 2016, 341, 187–195. [CrossRef]
293. Costelli, P.; Muscaritoli, M.; Bonetto, A.; Penna, F.; Reffo, P.; Bossola, M.; Bonelli, G.; Doglietto, G.B.; Baccino, F.M.; Fanelli, F.R.
Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur. J. Clin. Investig. 2008, 38, 531–538. [CrossRef]
294. Morén, A.; Imamura, T.; Miyazono, K.; Heldin, C.-H.; Moustakas, A. Degradation of the Tumor Suppressor Smad4 by WW and
HECT Domain Ubiquitin Ligases. J. Biol. Chem. 2005, 280, 22115–22123. [CrossRef]
295. Ebisawa, T.; Fukuchi, M.; Murakami, G.; Chiba, T.; Tanaka, K.; Imamura, T.; Miyazono, K. Smurf1 Interacts with Transforming
Growth Factor-β Type I Receptor through Smad7 and Induces Receptor Degradation. J. Biol. Chem. 2001, 276, 12477–12480.
[CrossRef]
296. Roh, J.D.; Hobson, R.; Chaudhari, V.; Quintero, P.; Yeri, A.; Benson, M.; Xiao, C.; Zlotoff, D.; Bezzerides, V.; Houstis, N.; et al.
Activin type II receptor signaling in cardiac aging and heart failure. Sci. Transl. Med. 2019, 11, eaau8680. [CrossRef]
297. Bollinger, L.; Witczak, C.A.; Houmard, J.A.; Brault, J.J. SMAD3 augments FoxO3-induced MuRF-1 promoter activity in a
DNA-binding-dependent manner. Am. J. Physiol. Physiol. 2014, 307, C278–C287. [CrossRef]
298. Latres, E.; Mastaitis, J.; Fury, W.; Miloscio, L.; Trejos, J.; Pangilinan, J.; Okamoto, H.; Cavino, K.; Na, E.; Papatheodorou, A.; et al.
Activin A more prominently regulates muscle mass in primates than does GDF8. Nat. Commun. 2017, 8, 15153. [CrossRef]
[PubMed]
299. Ding, H.; Zhang, G.; Sin, K.W.T.; Liu, Z.; Lin, R.-K.; Li, M.; Li, Y.-P. Activin A induces skeletal muscle catabolism via p38β
mitogen-activated protein kinase. J. Cachex-Sarcopenia Muscle 2016, 8, 202–212. [CrossRef] [PubMed]
300. Ma, Z.-Y.; Zhong, Z.-G.; Qiu, M.-Y.; Zhong, Y.-H.; Zhang, W.-X. TGF-β1 activates the canonical NF-κB signaling to promote cell
survival and proliferation in dystrophic muscle fibroblasts in vitro. Biochem. Biophys. Res. Commun. 2016, 471, 576–581. [CrossRef]
[PubMed]
301. Sartori, R.; Schirwis, E.; Blaauw, B.; Bortolanza, S.; Zhao, J.; Enzo, E.; Stantzou, A.; Mouisel, E.; Toniolo, L.; Ferry, A.; et al. BMP
signaling controls muscle mass. Nat. Genet. 2013, 45, 1309–1318. [CrossRef]
302. Sartori, R.; Gregorevic, P.; Sandri, M. TGFβ and BMP signaling in skeletal muscle: Potential significance for muscle-related
disease. Trends Endocrinol. Metab. 2014, 25, 464–471. [CrossRef]
303. Saxton, R.A.; Sabatini, D.M. mTOR Signaling in Growth, Metabolism, and Disease. Cell 2017, 168, 960–976. [CrossRef] [PubMed]
304. Cai, D.; Frantz, J.; Tawa, N.E.; Melendez, P.A.; Oh, B.-C.; Lidov, H.G.; Hasselgren, P.-O.; Frontera, W.R.; Lee, J.; Glass, D.J.; et al.
IKKβ/NF-κB Activation Causes Severe Muscle Wasting in Mice. Cell 2004, 119, 285–298. [CrossRef] [PubMed]
305. Mourkioti, F.; Kratsios, P.; Luedde, T.; Song, Y.-H.; Delafontaine, P.; Adami, R.; Parente, V.; Bottinelli, R.; Pasparakis, M.;
Rosenthal, N. Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J. Clin.
Investig. 2006, 116, 2945–2954. [CrossRef] [PubMed]
306. Hunter, R.B.; Kandarian, S.C. Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. J. Clin. Investig.
2004, 114, 1504–1511. [CrossRef] [PubMed]
307. Oeckinghaus, A.; Ghosh, S. The NF- B Family of Transcription Factors and Its Regulation. Cold Spring Harb. Perspect. Biol. 2009, 1,
a000034. [CrossRef]
308. Ladner, K.J.; Caligiuri, M.A.; Guttridge, D.C. Tumor Necrosis Factor-regulated Biphasic Activation of NF-κB Is Required for
Cytokine-induced Loss of Skeletal Muscle Gene Products. J. Biol. Chem. 2003, 278, 2294–2303. [CrossRef]
309. Li, Q.; Verma, I.M. NF-κB regulation in the immune system. Nat. Rev. Immunol. 2002, 2, 725–734. [CrossRef] [PubMed]
310. Coux, O.; Goldberg, A.L. Enzymes Catalyzing Ubiquitination and Proteolytic Processing of the p105 Precursor of Nuclear Factor
κB1. J. Biol. Chem. 1998, 273, 8820–8828. [CrossRef] [PubMed]
311. Palombella, V.J.; Rando, O.; Goldberg, A.L.; Maniatis, T. The ubiquitinproteasome pathway is required for processing the NF-κB1
precursor protein and the activation of NF-κB. Cell 1994, 78, 773–785. [CrossRef]
312. Heusch, M.; Lin, L.; Geleziunas, R.; Greene, W.C. The generation of nfkb2 p52: Mechanism and efficiency. Oncogene 1999, 18,
6201–6208. [CrossRef]
313. Ghosh, S.; Karin, M. Missing Pieces in the NF-κB Puzzle. Cell 2002, 109, S81–S96. [CrossRef]
314. Sun, S.-C.; Chang, J.-H.; Jin, J. Regulation of nuclear factor-κB in autoimmunity. Trends Immunol. 2013, 34, 282–289. [CrossRef]
[PubMed]
315. Sun, S.-C. The non-canonical NF-κB pathway in immunity and inflammation. Nat. Rev. Immunol. 2017, 17, 545–558. [CrossRef]
[PubMed]
Biomolecules 2021, 11, 1327 39 of 42
316. Deng, L.; Wang, C.; Spencer, E.; Yang, L.; Braun, A.; You, J.; Slaughter, C.; Pickart, C.; Chen, Z.J. Activation of the IκB Kinase
Complex by TRAF6 Requires a Dimeric Ubiquitin-Conjugating Enzyme Complex and a Unique Polyubiquitin Chain. Cell 2000,
103, 351–361. [CrossRef]
317. Chen, Z.J. Ubiquitin signalling in the NF-κB pathway. Nat. Cell Biol. 2005, 7, 758–765. [CrossRef] [PubMed]
318. Brun, J.; Gray, D.A. Targeting the ubiquitin proteasome pathway for the treatment of septic shock in patients. Crit. Care 2009, 13,
311. [CrossRef]
319. Granado, M.; Martín, A.I.; Priego, T.; López-Calderón, A.; Villanúa, M.A. Tumour necrosis factor blockade did not prevent the
increase of muscular muscle RING finger-1 and muscle atrophy F-box in arthritic rats. J. Endocrinol. 2006, 191, 319–326. [CrossRef]
320. Kawamura, I.; Morishita, R.; Tomita, N.; Lacey, E.; Aketa, M.; Tsujimoto, S.; Manda, T.; Tomoi, M.; Kida, I.; Higaki, J.; et al.
Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model. Gene Ther. 1999,
6, 91–97. [CrossRef]
321. Traenckner, E.; Wilk, S.; Baeuerle, P. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphory-
lated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J. 1994, 13, 5433–5441. [CrossRef]
322. Beehler, B.C.; Sleph, P.G.; Benmassaoud, L.; Grover, G.J. Reduction of Skeletal Muscle Atrophy by a Proteasome Inhibitor in a Rat
Model of Denervation. Exp. Biol. Med. 2006, 231, 335–341. [CrossRef]
323. Moresi, V.; Adamo, S.; Berghella, L. The JAK/STAT Pathway in Skeletal Muscle Pathophysiology. Front. Physiol. 2019, 10, 500.
[CrossRef]
324. Schindler, C.; Levy, D.; Decker, T. JAK-STAT Signaling: From Interferons to Cytokines. J. Biol. Chem. 2007, 282, 20059–20063.
[CrossRef] [PubMed]
325. Silva, K.A.S.; Dong, J.; Dong, Y.; Dong, Y.; Schor, N.; Tweardy, D.J.; Zhang, L.; Mitch, W.E. Inhibition of Stat3 Activation Suppresses
Caspase-3 and the Ubiquitin-Proteasome System, Leading to Preservation of Muscle Mass in Cancer Cachexia. J. Biol. Chem. 2015,
290, 11177–11187. [CrossRef] [PubMed]
326. Oh, H.-M.; Yu, C.-R.; Dambuza, I.; Marrero, B.; Egwuagu, C.E. STAT3 Protein Interacts with Class O Forkhead Transcription
Factors in the Cytoplasm and Regulates Nuclear/Cytoplasmic Localization of FoxO1 and FoxO3a Proteins in CD4+ T Cells.
J. Biol. Chem. 2012, 287, 30436–30443. [CrossRef]
327. Kesanakurti, D.; Chetty, C.; Maddirela, D.R.; Gujrati, M.; Rao, J.S. Essential role of cooperative NF-κB and Stat3 recruitment to
ICAM-1 intronic consensus elements in the regulation of radiation-induced invasion and migration in glioma. Oncogene 2012, 32,
5144–5155. [CrossRef] [PubMed]
328. Zhang, W.; Liu, H.T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002, 12, 9–18.
[CrossRef]
329. Kramer, H.F.; Goodyear, L.J. Exercise, MAPK, and NF-κB signaling in skeletal muscle. J. Appl. Physiol. 2007, 103, 388–395.
[CrossRef]
330. Suelves, M.; Lluis, F.; Ruiz, V.; Nebreda, A.R.; Muñoz-Cánoves, P. Phosphorylation of MRF4 transactivation domain by p38
mediates repression of specific myogenic genes. EMBO J. 2004, 23, 365–375. [CrossRef]
331. Liu, X.; Manzano, G.; Lovett, D.H.; Kim, H.T. Role of AP-1 and RE-1 binding sites in matrix metalloproteinase-2 transcriptional
regulation in skeletal muscle atrophy. Biochem. Biophys. Res. Commun. 2010, 396, 219–223. [CrossRef]
332. Penna, F.; Costamagna, D.; Fanzani, A.; Bonelli, G.; Baccino, F.M.; Costelli, P. Muscle Wasting and Impaired Myogenesis in Tumor
Bearing Mice Are Prevented by ERK Inhibition. PLoS ONE 2010, 5, e13604. [CrossRef]
333. Stitt, T.N.; Drujan, D.; Clarke, B.A.; Panaro, F.; Timofeyva, Y.; Kline, W.O.; Gonzalez, M.; Yancopoulos, G.D.; Glass, D.J. The IGF-
1/PI3K/Akt Pathway Prevents Expression of Muscle Atrophy-Induced Ubiquitin Ligases by Inhibiting FOXO Transcription
Factors. Mol. Cell 2004, 14, 395–403. [CrossRef]
334. Raffaello, A.; Milan, G.; Masiero, E.; Carnio, S.; Lee, D.; Lanfranchi, G.; Goldberg, A.L.; Sandri, M. JunB transcription factor
maintains skeletal muscle mass and promotes hypertrophy. J. Cell Biol. 2010, 191, 101–113. [CrossRef] [PubMed]
335. Moresi, V.; Williams, A.H.; Meadows, E.; Flynn, J.M.; Potthoff, M.; McAnally, J.; Shelton, J.M.; Backs, J.; Klein, W.H.; Richardson,
J.A.; et al. Myogenin and Class II HDACs Control Neurogenic Muscle Atrophy by Inducing E3 Ubiquitin Ligases. Cell 2010,
143, 35–45. [CrossRef]
336. Du Bois, P.; Tortola, C.P.; Lodka, D.; Kny, M.; Schmidt, F.; Song, K.; Schmidt, S.; Bassel-Duby, R.; Olson, E.N.; Fielitz, J. Angiotensin
II Induces Skeletal Muscle Atrophy by Activating TFEB-Mediated MuRF1 Expression. Circ. Res. 2015, 117, 424–436. [CrossRef]
337. Tortola, C.P.; Fielitz, B.; Li, Y.; Rüdebusch, J.; Luft, F.C.; Fielitz, J. Activation of Tripartite Motif Containing 63 Expression by
Transcription Factor EB and Transcription Factor Binding to Immunoglobulin Heavy Chain Enhancer 3 Is Regulated by Protein
Kinase D and Class IIa Histone Deacetylases. Front. Physiol. 2021, 11, 550506. [CrossRef] [PubMed]
338. Coleman, M.E.; DeMayo, F.; Yin, K.C.; Lee, H.M.; Geske, R.; Montgomery, C.; Schwartz, R.J. Myogenic Vector Expression of
Insulin-like Growth Factor I Stimulates Muscle Cell Differentiation and Myofiber Hypertrophy in Transgenic Mice. J. Biol. Chem.
1995, 270, 12109–12116. [CrossRef]
339. Musaro, A.; McCullagh, K.; Paul, A.; Houghton, L.; Dobrowolny, G.; Molinaro, M.; Barton, E.R.; Sweeney, H.L.; Rosenthal, N.
Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat. Genet. 2001,
27, 195–200. [CrossRef]
340. Matsui, T.; Nagoshi, T.; Rosenzweig, A. Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival. Cell Cycle
2003, 2, 219–222. [CrossRef]
Biomolecules 2021, 11, 1327 40 of 42
341. Andjelkovic, M.; Alessi, D.; Meier, R.; Fernandez, A.; Lamb, N.J.C.; Frech, M.; Cron, P.; Cohen, P.; Lucocq, J.; Hemmings, B.A. Role
of Translocation in the Activation and Function of Protein Kinase B. J. Biol. Chem. 1997, 272, 31515–31524. [CrossRef] [PubMed]
342. Vivanco, I.; Sawyers, C.L. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2, 489–501.
[CrossRef]
343. Jefferson, L.S.; Fabian, J.R.; Kimball, S.R. Glycogen synthase kinase-3 is the predominant insulin-regulated eukaryotic initiation
factor 2B kinase in skeletal muscle. Int. J. Biochem. Cell Biol. 1999, 31, 191–200. [CrossRef]
344. Gingras, A.-C.; Raught, B.; Sonenberg, N. eIF4 Initiation Factors: Effectors of mRNA Recruitment to Ribosomes and Regulators of
Translation. Annu. Rev. Biochem. 1999, 68, 913–963. [CrossRef] [PubMed]
345. Hay, N. Interplay between FOXO, TOR, and Akt. Biochim. et Biophys. Acta (BBA)-Bioenerg. 2011, 1813, 1965–1970. [CrossRef]
346. Pallafacchina, G.; Calabria, E.; Serrano, A.L.; Kalhovde, J.M.; Schiaffino, S. A protein kinase B-dependent and rapamycin-sensitive
pathway controls skeletal muscle growth but not fiber type specification. Proc. Natl. Acad. Sci. USA 2002, 99, 9213–9218.
[CrossRef] [PubMed]
347. Lin, T.-A.; Lawrence, C.L., Jr. Control of the Translational Regulators PHAS-I and PHAS-II by Insulin and cAMP in 3T3-L1
Adipocytes. J. Biol. Chem. 1996, 271, 30199–30204. [CrossRef]
348. Schiaffino, S.; Dyar, K.; Ciciliot, S.; Blaauw, B.; Sandri, M. Mechanisms regulating skeletal muscle growth and atrophy. FEBS J.
2013, 280, 4294–4314. [CrossRef]
349. Sacheck, J.M.; Ohtsuka, A.; McLary, S.C.; Goldberg, A.L. IGF-I stimulates muscle growth by suppressing protein breakdown and
expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am. J. Physiol. Metab. 2004, 287, E591–E601. [CrossRef]
350. Goldbraikh, D.; Neufeld, D.; Eid-Mutlak, Y.; Lasry, I.; Gilda, J.E.; Parnis, A.; Cohen, S. USP 1 deubiquitinates Akt to inhibit PI
3K-Akt-FoxO signaling in muscle during prolonged starvation. EMBO Rep. 2020, 21, e48791. [CrossRef]
351. dos Santos, C.; Hussain, S.N.A.; Mathur, S.; Picard, M.; Herridge, M.; Correa, J.; Bain, A.; Guo, Y.; Advani, A.; Advani, S.L.; et al.
Mechanisms of Chronic Muscle Wasting and Dysfunction after an Intensive Care Unit Stay. A Pilot Study. Am. J. Respir. Crit. Care
Med. 2016, 194, 821–830. [CrossRef]
352. Rocheteau, P.; Chatre, L.; Briand, D.; Mebarki, M.; Jouvion, G.; Bardon, J.; Crochemore, C.; Serrani, P.; Lecci, P.P.; Latil, M.; et al.
Sepsis induces long-term metabolic and mitochondrial muscle stem cell dysfunction amenable by mesenchymal stem cell therapy.
Nat. Commun. 2015, 6, 10145. [CrossRef] [PubMed]
353. Walsh, C.J.; Batt, J.; Herridge, M.S.; Mathur, S.; Bader, G.D.; Hu, P.; Dos Santos, C.C. Transcriptomic analysis reveals abnormal
muscle repair and remodeling in survivors of critical illness with sustained weakness. Sci. Rep. 2016, 6, 29334. [CrossRef]
[PubMed]
354. Relaix, F.; Zammit, P.S. Satellite cells are essential for skeletal muscle regeneration: The cell on the edge returns centre stage.
Development 2012, 139, 2845–2856. [CrossRef] [PubMed]
355. Mauro, A. SATELLITE CELL OF SKELETAL MUSCLE FIBERS. J. Cell Biol. 1961, 9, 493–495. [CrossRef] [PubMed]
356. Bentzinger, C.F.; Wang, Y.X.; Rudnicki, M.A. Building Muscle: Molecular Regulation of Myogenesis. Cold Spring Harb. Perspect.
Biol. 2012, 4, a008342. [CrossRef]
357. Millay, D.P.; O’Rourke, J.R.; Sutherland, L.B.; Bezprozvannaya, S.; Shelton, J.M.; Bassel-Duby, R.; Olson, E.N. Myomaker is a
membrane activator of myoblast fusion and muscle formation. Nat. Cell Biol. 2013, 499, 301–305. [CrossRef] [PubMed]
358. Quinn, M.E.; Goh, Q.; Kurosaka, M.; Gamage, D.G.; Petrany, M.J.; Prasad, V.; Millay, D.P. Myomerger induces fusion of
non-fusogenic cells and is required for skeletal muscle development. Nat. Commun. 2017, 8, 15665. [CrossRef]
359. Schiaffino, S.; Rossi, A.C.; Smerdu, V.; Leinwand, L.A.; Reggiani, C. Developmental myosins: Expression patterns and functional
significance. Skelet. Muscle 2015, 5, 1–14. [CrossRef]
360. Chargé, S.B.P.; Rudnicki, M. Cellular and Molecular Regulation of Muscle Regeneration. Physiol. Rev. 2004, 84, 209–238. [CrossRef]
361. Massague, J.; Cheifetz, S.; Endo, T.; Nadal-Ginard, B. Type beta transforming growth factor is an inhibitor of myogenic
differentiation. Proc. Natl. Acad. Sci. USA 1986, 83, 8206–8210. [CrossRef]
362. Elkina, Y.; Von Haehling, S.; Anker, S.D.; Springer, J. The role of myostatin in muscle wasting: An overview. J. Cachexia Sarcopenia
Muscle 2011, 2, 143–151. [CrossRef] [PubMed]
363. Link, B.A.; Nishi, R. Opposing Effects of Activin A and Follistatin on Developing Skeletal Muscle Cells. Exp. Cell Res. 1997, 233,
350–362. [CrossRef] [PubMed]
364. Droguett, R.; Cabello-Verrugio, C.; Santander, C.; Brandan, E. TGF-β receptors, in a Smad-independent manner, are required for
terminal skeletal muscle differentiation. Exp. Cell Res. 2010, 316, 2487–2503. [CrossRef]
365. Filvaroff, E.; Ebner, R.; Derynck, R. Inhibition of myogenic differentiation in myoblasts expressing a truncated type II TGF-beta
receptor. Development 1994, 120, 1085–1095. [CrossRef] [PubMed]
366. Zhu, X.; Kny, M.; Schmidt, F.; Hahn, A.; Wollersheim, T.; Kleber, C.; Weber-Carstens, S.; Fielitz, J. Secreted Frizzled-Related
Protein 2 and Inflammation-Induced Skeletal Muscle Atrophy. Crit. Care Med. 2017, 45, e169–e183. [CrossRef]
367. Di Giovanni, S.; Molon, A.; Broccolini, A.; Melcon, G.; Mirabella, M.; Hoffman, E.P.; Servidei, S. Constitutive activation of MAPK
cascade in acute quadriplegic myopathy. Ann. Neurol. 2004, 55, 195–206. [CrossRef]
368. Kitajima, Y.; Suzuki, N.; Nunomiya, A.; Osana, S.; Yoshioka, K.; Tashiro, Y.; Takahashi, R.; Ono, Y.; Aoki, M.; Nagatomi, R.
The Ubiquitin-Proteasome System Is Indispensable for the Maintenance of Muscle Stem Cells. Stem Cell Rep. 2018, 11, 1523–1538.
[CrossRef]
Biomolecules 2021, 11, 1327 41 of 42
369. Lecker, S.H.; Solomon, V.; Mitch, W.E.; Goldberg, A.L. Muscle Protein Breakdown and the Critical Role of the Ubiquitin-
Proteasome Pathway in Normal and Disease States. J. Nutr. 1999, 129, 227S–237S. [CrossRef]
370. Tawa, N.E.; Odessey, R.; Goldberg, A.L. Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal
muscles. J. Clin. Investig. 1997, 100, 197–203. [CrossRef]
371. Fang, C.H.; Wang, J.J.; Hobler, S.; Li, B.G.; Fischer, J.E.; Hasselgren, P.O. Proteasome Blockers Inhibit Protein Breakdown in
Skeletal Muscle after Burn Injury in Rats. Clin. Sci. Lond. Engl. 1979 1998, 95, 225–233.
372. Hobler, S.C.; Tiao, G.; Fischer, J.E.; Monaco, J.; Hasselgren, P.-O. Sepsis-induced increase in muscle proteolysis is blocked by
specific proteasome inhibitors. Am. J. Physiol. Integr. Comp. Physiol. 1998, 274, R30–R37. [CrossRef]
373. Fischer, D.; Gang, G.; Pritts, T.; Hasselgren, P.-O. Sepsis-Induced Muscle Proteolysis Is Prevented by a Proteasome Inhibitor in
Vivo. Biochem. Biophys. Res. Commun. 2000, 270, 215–221. [CrossRef]
374. KadlČíková, J.; HoleČek, M.; Šafránek, R.; Tilšer, I.; Kessler, B.M. Effects of proteasome inhibitors MG132, ZL3VS and
AdaAhx3L3VS on protein metabolism in septic rats. Int. J. Exp. Pathol. 2004, 85, 365–371. [CrossRef]
375. Šafránek, R.; Ishibashi, N.; Oka, Y.; Ozasa, H.; Shirouzu, K.; Holeček, M. Modulation of inflammatory response in sepsis by
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